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Abstract 
The potential for chemoprevention of breast cancer depends on the benefits being 
achieved at reasonable cost. This study assesses the economics of chemoprevention of 
breast cancer with tamoxifen within the context of the International Breast Cancer 
Intervention Study (IBIS) and published data on outcomes. 
Anonymised trial data are used to measure direct resource costs based on the pattern 
of service delivery in the IBIS clinics. Changes in morbidity are measured as the 
differences in use of resources for hospital visits, procedures undertaken in hospital, 
use of prescribed medications and visits to GPs between women in the 2 arms of IBIS. 
Changes in quality of life are assessed using the SF 36. Information on the personal 
costs to the women themselves was gained through a postal questionnaire. 
A sensitivity analysis assesses the effects on cost effectiveness of alternative 
assumptions about the duration of the protective effect of tamoxifen (5,10 or 15 years) 
beyond the treatment period. Other alternative assumptions explored include different 
models of service delivery, differences in personal costs to the women themselves and 
in their risk status. 
Tamoxifen chemoprophylaxis for breast cancer has a cost of less than £5000 per 
discounted life year gained for women at high risk for the disease assuming that the 
protective effect persists for at least 10 years. This result is sensitive to the risk status 
of the women since the number needed to treat (NNT) would be high for women at 
low absolute risk of breast cancer. The model of service delivery is also important. No 
significant differences in morbidity between the groups were found. Hospital visits for 
benign breast disease or gynaecological symptoms and the use of beta blockers may 
merit further investigation. There appear to be no effects on quality of life. 
Chemoprevention of breast cancer could be delivered through general practice with 
minimal specialist support. The potential may be limited because of the need to target 
women at high risk in order to make efficient use of resources for this common 
condition. 
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The economics and policy implications of tamoxifen chemoprophylaxis for breast 
cancer. 
Introduction 
This thesis is concerned with the economics and policy implications of use of the drug 
tamoxifen to prevent breast cancer in women at high risk for the disease. The work 
has been developed alongside the International Breast Cancer Intervention Study 
(IBIS) 1' Results from other chemoprevention studies are also used particularly the 
NSABP P-12. 
Economic analysis requires detailed information about the effects of an intervention 
on survival and general health as well as information about changes in resource use 
arising directly from the intervention and for the target population. In this case it will 
include the resource consequences of delivering a service for tarnoxifen 
chemoprophylaxis, possible changes in health care resources due to side effects of the 
intervention and resource implications for the women themselves both in terms of 
changes in personal costs incurred or in quality of life. In order to inform the policy 
implications an understanding of acceptability and likely uptake among the target 
population is also needed as well as comparative information on alternative means of 
reducing mortality and morbidity from breast cancer. 
The information needed on the efficacy of the intervention has been based on target 
assumptions developed within IBIS and from the findings of NSABP P-1. Detailed 
information on use of hospital services and medications has been taken from the data 
collected from women enrolled in IBIS. The information has been used to develop 
methodologies for understanding the resource consequences of changes in morbidity 
for women taking prophylactic tamoxifen. 
Other specific studies used to inform the economic analysis include detailed 
measurements of the resources used in delivering the intervention based on the 
models adopted within IBIS centres and a study of the resource consequences for the 
women themselves. This latter study was carried out by means of a questionnaire sent 
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to women enrolled in IBIS. Information was collected on the costs of IBIS to the 
women themselves, on quality of life and on use of primary care services. 
It was not possible to use unblinded information from IBIS since the trial has not yet 
completed. It was however possible to obtain data sets separated into 2 anonymised 
groups. This enabled understanding of the significance of any differences in resource 
use between the 2 groups. Conclusions have been drawn about the key factors 
affecting the cost effectiveness of tamoxifen prophylaxis and its likely range given 
currently available information. Once the trial has been concluded the methodology 
and approach developed here can be used to conclude the economic analysis. 
Information to inform policy has been developed from a detailed review of the 
published literature on the aetiology of breast cancer and the impact of current 
therapeutic interventions. A discussion of the potential for primary prevention with 
dietary intervention is also included. 
IBIS is continuing to recruit towards its target of 7,000 women with the aim of 
providing crucial information on the impact of tamoxifen on both incidence and 
mortality from breast cancer. As a consequence it may also be possible to address 
questions concerning the characteristics of the women most likely to benefit from 
prophylactic tamoxifen and the nature of tumours which do arise. Such information 
would contribute to more detailed understanding of the cost effectiveness of the 
intervention for women at different levels of risk of breast cancer. As part of the 
continuing data collection further information will be available on the use of 
medications and hospital services by women in IBIS. This will contribute to the 
analysis of resource consequences of changes in morbidity for women taking long 
term tamoxifen enabling refinement of current estimates. Detailed information will 
also be available on serious adverse consequences of the drug and specific side 
effects. 
Breast cancer is a major public health problem. It is the most frequent malignancy 
and the leading cause of death from cancer for women over the age of 35 in the UK as 
well as the rest of Western Europe and North America3. The major known risk factors 
associated with breast cancer include reproductive factors and family history4. Since 
these are not easily amenable to modification by behavioural or lifestyle interventions 
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the emphasis for reducing the burden of mortality and morbidity from breast cancer 
has focused on early detection and treatment, and palliation of advanced disease. 
Until recently, the impact of therapeutic interventions on population mortality from 
breast cancer in England and Wales has been slight with mortality rates continuing to 
rise. The steady upward trend in mortality from breast cancer is however beginning 
to reverse as more systematic efforts are made to implement effective diagnostic and 
therapeutic interventions and with possible changes in the distribution of risk factors 
in younger cohorts in the population 5,6 
Interest in chemoprevention of breast cancer has been stimulated by good evidence of 
a decrease in contralateral breast cancer incidence following use of tamoxifen in 
adjuvant therapy and the increasing understanding about the role of available 
oestrogen and other growth factors in the aetiology of breast cancer7. A number of 
trials are underway to investigate the impact of use of tamoxifen on incidence and 
mortality from breast cancer in women at high risk for the disease Z, 8'ß. Risk 
assessments are based on family history or a summary score of reproductive factors. 
The largest of these trials, NSABP P-1 has published findings of a reduction in 
incidence of about 50% for women at increased risk of breast cancer. Though these 
results have not been replicated in smaller trials published subsequently, the findings 
from NSABP P-i do seem to be robust. They are internally valid and are consistent 
with findings by the Early Breast Cancer Triallists Collaborative Group7of a 
preventive effect of tamoxifen, reducing by 47% the incidence of cancer, in the 
contralateral breast for women taking adjuvant tamoxifen. The lack of confirmatory 
results in the smaller trials may be due to a younger population, to poor compliance in 
one of the studies and to differences in the risk profile of the populations recruited'. 
None of the trials provide reliable data on mortality. There are various possible 
outcomes associated with tamoxifen chemoprophylaxis for breast cancer. These 
include delaying or preventing the onset of disease and in reducing mortality from 
breast cancer. Reductions in the incidence of disease or a delay in the appearance of 
breast cancer may not be associated with a survival benefit though there may be a 
benefit in terms of shortening morbidity associated with the disease. It is likely 
however that the relationship between the benefit derived from breast cancer 
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chemoprevention and the cost of the intervention will be sensitive to variations in a 
number of parameters. These will include the magnitude and duration of the 
intervention, reduction in risk of breast cancer and breast cancer mortality rates. The 
outcome cost per life years gained estimated in this thesis will be sensitive to breast 
cancer free life years. The emphasis on mortality in deriving an appropriate outcome 
measure allows comparison with other studies of cost effectiveness. At this stage 
empirical information is available only on incidence. Long term follow up will be 
needed in fully determining the value of this intervention in relation to alternative 
health outcomes. 
Published breast cancer chemoprevention trials have to date provided some 
information on the side effects of long term use of tamoxifen in healthy women 
though none has quantified the potential benefits of the intervention in relation to the 
risks of increased morbidity or mortality from other conditions or the economic costs 
of the intervention. Even where tamoxifen chemoprophylaxis for breast cancer is 
shown to be effective it may not be cost effective particularly if associated with 
increased resource use required to manage side effects or because of possible changes 
to quality of life. Indeed the cost of targeting an eligible population and administering 
prophylactic tamoxifen may be substantial. A small proportion of the total population 
is at high risk of breast cancer yet the number of women at increased risk is large with 
the possibility of profound effects on the use of health care resources. 
As discussed earlier, the main focus of this study is to determine the cost effectiveness 
of tamoxifen chemoprophylaxis for breast cancer and to understand how important 
the main costs are in offsetting the potential benefits of the intervention. Preliminary 
studies have suggested that a reduction of less than 1% in quality of life could offset 
potential survival gains10. Other commentaries on this subject have concluded that 
there may be only a small potential gain in survival in relation to adverse effects such 
as increased risk of thromboembolism and endometrial cancer" or a substantial 
overall cost of service delivery where the acquisition costs of tamoxifen are high'2"3. 
Without a full cost effectiveness analysis it remains unclear at what level of use 
tamoxifen chemoprophylaxis could produce sufficient benefit to cover the cost of 
service delivery or indeed generate cost savings within the health service. 
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The information needed for the cost effectiveness analysis covers three broad 
categories of resource use. Firstly, there are the costs involved in delivering a service 
for prophylactic tamoxifen. This includes the costs of identifying and targeting 
women with sufficient risk of breast cancer to be eligible for prophylaxis and the cost 
of running clinics for administering the drug and for monitoring and follow up. 
Secondly there may be resource implications arising from changes in the pattern of 
use of health services because of adverse or indeed beneficial effects of long term use 
of tamoxifen. This requires information on changes in the use of hospital services, 
visits to general practitioners and use of medications by women taking tamoxifen. 
Thirdly information is needed on the costs incurred by the women themselves in 
attending clinics or health centres to receive tamoxifen or for a follow up visit. These 
personal costs include the cost of travel, the cost of time off work and other costs 
involved as well as changes in the quality of life of women taking long term 
tamoxifen. 
Collecting information on resource use within the context of a randomised trial is of 
considerable value since data can be compared directly between the 2 arms of the 
trial. For the cost effectiveness analysis, information collected from women recruited 
to IBIS on the use of resources is combined with standard unit costs for elements of 
service delivery, treatment, drug use or for the women's personal costs in order to 
estimate the marginal costs of tamoxifen chemoprophylaxis for breast cancer. The 
costs are applied to the resources used differently between the 2 arms of the trial using 
Healthcare Resource Groups (HRGs) 14 for the pattern of use of health services 
including the cost of mammography, the British National Formulary (BNF) 15 for use 
of medications - including the cost of tamoxifen in the UK and staffing costs 
principally for the assessment of service delivery. The cost of breast cancer is 
estimated from an analysis of resource use based on the findings of the Thames 
Cancer Registry (TCR) Audit of Breast Cancer in North Thames 16. For each category 
of resource use comparison is made for the purpose of validating the data where 
possible with routine sources of information for the general population. 
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Because as yet there is no reliable information on the impact of tamoxifen 
chemoprophylaxis on mortality the initial assessment of cost effectiveness is based on 
cost per breast cancer prevented. A more useful measure for comparison with other 
cost effectiveness studies is the cost per life year gained. For this analysis net 
incidence is estimated from the results of NSABP P-1 for the potential impact of 
tamoxifen chemoprophylaxis within a cohort of women at high risk for breast cancer. 
Projections of survival benefits are included in the sensitivity analysis. The effects of 
discounting future costs and benefits are examined using a baseline discount rate of 
5%. This was chosen over higher rates to avoid unduly minimising the impact of a 
l preventive intervention 7' 1 s't 9 
The impact of changes in a number of aspects of resource use on cost effectiveness is 
also assessed in the sensitivity analysis. They include the cost of service delivery, the 
risk status of the women, changes in morbidity and the personal costs borne by the 
women themselves. 
The detailed analysis presented here is unique in studies of breast cancer 
chemoprophylaxis since it provides an examination of the resource consequences of 
changes in morbidity for women taking tamoxifen prophylaxis and measures both 
changes in quality of life and personal costs of the intervention to the women 
themselves. The findings have important implications for the use of breast cancer 
chemoprevention with tamoxifen or its derivatives. 
A full understanding of the potential role of tamoxifen chemoprophylaxis for reducing 
the burden of breast cancer must be considered against the background of current 
interventions for reducing mortality and morbidity from breast cancer and within the 
context of changing trends in incidence and mortality. These aspects of the study are 
considered in Chapter 1 with further discussion made in Chapter 7 within the context 
of the conclusions on cost effectiveness of tamoxifen chemoprophylaxis. 
Chapter 2 reviews the evidence underpinning the rationale for tamoxifen as an agent 
for chemoprevention of breast cancer assessing also the potential side effects of the 
drug based on evidence mainly from adjuvant studies though including some work 
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from prevention trials. Chapters 3,4,5 and 6 analyse the resource use involved in 
tamoxifen chemoprophylaxis needed for the cost effectiveness analysis. 
Chapter 3 sets out findings from a study of the costs of service delivery for tamoxifen 
chemoprophylaxis based on the model of delivery used within IBIS but discussing 
also other possible options for safe and effective service delivery including care in 
general practice. Chapters 4 and 5 provide an analysis of the resource consequences 
of changes in the morbidity of women taking tamoxifen chemoprophylaxis measured 
through changes in use of hospital services and use of medications respectively. 
Chapter 6 sets out the results from the study of health status and quality of life for 
women in the 2 arms of IBIS and includes the results of the analysis of personal costs 
borne by the women themselves. 
Finally, in chapter 7 the costs of tamoxifen chemoprophylaxis including the costs of 
service delivery, the costs of morbidity and the personal costs to the women 
themselves are combined and set alongside information on effectiveness derived from 
IBIS and from the NSABP P-1 study to produce a consolidated estimate for cost 
effectiveness. 
Much of the information used in this thesis is derived from collaboration with 
Professor Jack Cusick and his team at the International Breast Cancer Intervention 
Study (IBIS). In Chapter 3 details of the pattern of work and models of service 
delivery were developed entirely by the author through site visits and interviews with 
study co-ordinators in each centre. In Chapters 4 and 5 information for the economic 
analysis of tamoxifen chemoprophylaxis for breast cancer was derived from data 
collected within the protocol for IBIS designed and run by Professor Jack Cusick and 
others at the Imperial Cancer Research Fund (ICRF). The questions used to elucidate 
resource use within the study - those concerned with the rate of use of hospital 
services and the use of medications by women recruited to the trial - were added to 
the trial protocol with the help of Professor Charles Normand at the London School of 
Hygiene and Tropical Medicine. Extraction of data needed for the analysis was 
undertaken by Dr Rob Edwards, senior statistician responsible for data collection in 
IBIS. Accuracy and validation of the data used, its analysis and the conclusions 
drawn are entirely the responsibility of the author. The author developed the self- 
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completed questionnaire used in Chapter 5 to gather information concerning the 
quality of life and personal costs of IBIS to the women themselves. Clare O'neill the 
co-ordinator of IBIS also contributed questions to the questionnaire seeking views 
from the women on their personal involvement in IBIS, their understanding of breast 
self care and satisfaction with services for breast cancer. Analysis and discussion of 
these latter questions is not included in this thesis. The questionnaire was piloted in 
collaboration with Clare O'neill, mailed to the women in the study from the IBIS 
office with data entry completed by the IBIS data clerks. The analysis and 
conclusions drawn were the responsibility of the author. Chapter 7 draws on 
information developed by the Thames Cancer Registry Audit of Breast Cancer in 
order to derive an estimate of the current average cost of breast cancer care for use in 
estimating cost effectiveness of tamoxifen chemoprophylaxis. Drafts of the thesis 
were commented on by the advisory panel including Dr Jack Cusick at ICRF, 
Professor Klim Mcpherson and Professor Charles Normand at the London School of 
Hygiene and Tropical Medicine. 
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Chapter One 
Background and Literature Review 
The context for chemoprevention: Trends in incidence and mortality 
This chapter sets out the context for tamoxifen chemoprophylaxis of breast cancer. 
The possible impact of a preventive intervention for women at high risk for breast 
cancer is assessed against the background of recent trends in incidence and mortality 
of the disease. The scope for prevention is compared with current options for reducing 
mortality and morbidity from breast cancer. These include treatment of early breast 
cancer, interventions used in treating advanced disease and findings from the 
population based mammography screening programme. The prospects for primary 
prevention are included focussing particularly on the limited evidence available of a 
possible role for dietary fat. 
The crude mortality from breast cancer for England and Wales (1996) is 70 per 
100,000 women. There are about 25,000 new cases of breast cancer per year in 
England and Wales and 12,000 deaths20. A reduction in mortality of 35% from breast 
cancer as heralded for chemoprevention by some authors would have substantial 
public health significance potentially reducing the death rate to around 40 per 100,000 
per year preventing more than 5000 deaths per year'. Such a broad scale 
improvement is unlikely from tamoxifen chemoprophylaxis however since the 
intervention is aimed at high risk women in the age range 40-65 while over 60% of 
breast cancer deaths are in women aged 65 and over. ' Moreover a reduction in breast 
cancer mortality in the younger age range may have the effect of delaying rather than 
preventing mortality overall. 
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Trends in mortality 
Figure 1 shows the changes in mortality from breast cancer for women in 5-year age 
bands including death rates up until 1996 from 1979. The data on which the chart is 
based are shown in Table 1. Reduction in mortality can be seen in women in the 
middle age range particularly from age 45-49 up until aged 60-64 where the 
downward trend appeared later from the mid 1980s. The trend is also evident though 
not as striking in women aged 65-69 and 70-74. 
Figure 1 
Change in Breast Cancer Mortality Rates over Time 
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Data in Figure 1. from Breast cancer Deaths in England and Wales in 5-year age bands from 1979- 
1996 (using ICD9 code no 174). Published by ONS Mortality Statistics Section. Population figures 
for England and Wales ONS20. 
Table 1. BREAST CANCER DEATH RATES per 100,000 
1 15 year age bands 
Time Period 35- 
39 
40- 
44 
45- 
49 
50- 
54 
55-59 60- 
64 
65- 
69 
70- 
74 
75-79 80-84 85plus 
1979-1981 15 31 55 77 92 106 116 130 152 187 253 
1982-1984 15 30 53 78 97 105 122 137 157 191 280 
1982-1984 15 29 51 76 94 115 123 146 170 216 280 
1988-1990 15 29 50 72 94 109 128 143 170 216 322 
1991-1993 13 27 45 68 85 103 120 138 170 222 311 
1994-1996 13 25 42 64 77 90 109 130 154 201 271 
The rate of decline in mortality in the UK has been less than that seen in the recent 
downward trends or levelling of previously upward trends seen in many other 
countries world-wide particularly Australia, Austria, Canada, FRG, Greece, The 
Netherlands, Sweden, Switzerland and the USA'- Mortality from breast cancer in the 
UK remains the highest amongst comparable countries in Western Europe, USA, 
Australia and New Zealand. The decline in overall mortality in England and Wales 
began around 1985 following declines in the early 1980s in many comparable 
Western European countries'. An overall increase in mortality from breast cancer 
began in the post war years but was predominantly in the 50-54 year olds with 
increases in mortality for women aged 60-64 not occurring until the 1960s or the 
1970s for older women. By the mid 1970s, mortality had begun to fall in women 
under 50 but was still rising in those over 60. For women aged 55-69 mortality rose 
from about 83 per 100,000 in the early 1960s to level off at around 107 per 100,000 in 
the mid 1980s. Though changing very little during the late 1980s mortality in this age 
group fell steeply after 1990 and in 1994 was 12 % lower than in 1987. 
For women aged 40-59 the decline in breast cancer mortality has been linked to 
increased fertility during the post war years. Beral has suggested that the reduction in 
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mortality is due to a change in the risk profile for women because the average age at 
first birth and the proportion of childless women declined after the Second World 
Warb. Other authors have concluded that the trends may also be due to improvements 
in survival because of earlier detection of tumours'`' and better treatment regimen'`'. 
The extent to which the decline in mortality has been the result of the introduction of 
mammographic screening in 1987 is still the subject of much debate. Quinn' 
concluded in an analysis of trends in breast cancer incidence and mortality until 1994 
that the reduction in mortality is unlikely to be due to screening. 
The decline in breast cancer mortality in many developed countries appears at least in 
part to be due to birth cohort effects or period effects°. Average mortality patterns 
conceal trends in different age cohorts of women23. In order to assess this effect the 
data in Table 1 and Figure 1 were recalculated to show mortality by birth cohort from 
women born in 1912-1916 to 1952-56 from age 40-44 to age 85-89. The results are 
shown in Figure 2. 
Figure 2. Mortality rate (per 100,000) by birth cohort 
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An upward trend in mortality continued for women until the birth cohorts born in the 
1930s for the age groups 40-54. These women would have experienced their peak 
fertility in the 50s and 60s not delaying child bearing unlike earlier cohorts who were 
reaching their 20s and 30s in the war years. A peak in trends in mortality is seen for 
women aged 55-59 born in earlier birth cohorts (1925-1929) and for women aged 60- 
64 for birth cohorts born in the 1920s. Younger women aged from 40-44 to 50-54 
born in the 1930s see a reduction in mortality at an average of 20%. Similar 
reductions are seen in the older age groups though these appear earlier from birth 
cohorts 1925-1929 for women aged 55-59 and from birth cohorts 1920-1924 for 
women aged 60-64. 
These data are consistent with the hypothesis that widespread improvements in 
treatment for breast cancer rather than the screening programme underlie recent 
reductions in mortality. The effects are consistent across all age groups and not seen 
only in the screened age groups. The drug tamoxifen was introduced into breast 
cancer treatment regimen in 1973 and has been shown in successive large-scale 
studies to increase survival for women of all ages24. The rate of reduction in mortality 
found in randomised controlled trials is around 50%. This is higher than the 20% 
shown across all age groups in the figure above but is consistent when allowing for 
the possibility of undertreatment of older. A meta-analysis emphasising the 
' importance of treating younger women with tamoxifen was not published until 1998. 
A screening effect might be expected to appear some 5-7 years after the development 
of the programme for women who were first screened aged 50-54 in 1987 but the 
downward trend in breast cancer mortality began well before the development of the 
screening programme and is not significantly higher in the older age groups. Finally a 
screening effect may well delay the development of breast cancer, yet the downward 
trend is seen in all age groups. 
The overall impact of the reduction in breast cancer mortality shown in Figure 2 is an 
average reduction for younger women under 50 of 21.5%, for women aged 50-64 of 
around 33% and for women over 65 of around 12 %. For women in the age group 
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targeted for tamoxifen prophylaxis (45-64) the reduction in breast cancer mortality 
rates since the mid 1980s represents about 1000 breast cancer deaths prevented per 
year (assuming a rate of around 84 per 100,000 and 12,000 deaths per year for this age 
group in the mid 1980s compared with a rate of around 68 per 100,000 in the most 
recent figures). 
Chemoprevention with tamoxifen by contrast would be targeted at only a proportion 
of these women though the mortality reduction is estimated to be greater. Comparing 
the same population with the rates prevailing in the mid 80s and assuming that 
chemoprevention is targeted towards one third of all women with an efficacy of 
around 33%25.26 the numbers of breast cancer deaths prevented might be less than half 
of those actually seen from changing trends in breast cancer mortality. Clearly the 
costs in terms of the disbenefits of the intervention need to be considered carefully in 
fully evaluating the effect. The potential for enhancing the downward trend in breast 
cancer mortality is considerable. Careful analysis will be needed to fully evaluate the 
effect against the current improving trends in breast cancer mortality and the further 
potential for more appropriate application of adjuvant tamoxifen. 
Trends in Incidence 
The incidence of breast cancer in the female population in the UK increased by about 
2% each year from the late 1950s to the late 1980s. From 1988, after the introduction 
of the screening programme the annual rate of increase more than doubled to nearly 
4.5% until 1991; there was virtually no change in incidence between 1991 and 1992. 
In 1992 the age standardised incidence of breast cancer in women in England and 
Wales was 102 per 100,0000 about a 40% increase from 74 per 100,0000 in 197427. 
Age specific incidence rates for breast cancer rise rapidly with age though unlike other 
common cancers the rate of increase declines after age 50 around the age of the 
menopause. Currently approximately one in 14 women in the UK will develop breast 
cancer by age 75. A similar pattern in incidence of breast cancer is seen in other 
Western European countries28. 
18 
Table 2 shows the lifetime risk of breast cancer (Cumulative incidence (%)) in 1992 
for the most recent data available, in 1987 at the time of the development of the NHS 
Breast Screening Programme and in 1982 prior to the introduction of the breast 
screening programme. 
Table 2: Lifetime risk of Breast Cancer (cumulative incidence) in 1982 and 1992. 
Rate per annum Rate over 5 years Cumulative 
Incidence 
per 100,000 per 100,000 (%) 
Age group 1982 1992 1982 1992 1982 1992 
30- 25 30 125 150 0.1 0.2 
35- 50 50 250 250 0.4 0.4 
40- 100 100 500 500 0.9 0.9 
45- 150 175 750 875 1.6 1.8 
50- 150 240 750 1200 2.4 3 
55- 175 250 875 1250 3.3 4.2 
60- 190 265 950 1325 4.2 5.6 
65- 200 265 1000 1325 5.2 6.9 
70- 220 270 1100 1350 6.3 8.2 
75- 225 300 1125 1500 7.4 9.7 
80- 250 300 1250 1500 8.7 11.2 
85- 300 330 1500 1650 10.2 12.9 
90- 310 360 1550 1800 11.7 14.7 
95- 320 400 1600 2000 13.3 16.7 
Based on A ge specific incidence rates per 100,000 
The table shows the lifetime probability of acquiring breast cancer for women in each 
age category according to life expectancy. For women aged 30 the life expectancy is 
83 years. Reading against the 80- category shows that the probability of acquiring 
breast cancer has risen from 8.7% (1 in 11) in 1982 to 11.2% (1 in 9)in 1992. If the 
women lives longer then the rate increases to 12.9% (1 in 8) by age 85 assuming that 
the 1992 incidence rates continue throughout her lifetime. 
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The impact of the NHS Breast Cancer Screening Programme on registration rates can 
be seen clearly in Figure 3. Age specific incidence rates for breast cancer are plotted 
for cohorts of women by 5 year age groups. 
Figure 3. 
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The increase in the incidence rate of registration of breast cancer since the 
development of the NHS Breast Screening Programme can be seen for women aged 
50-64 - the screened age group. Incidence figures are often difficult to ascertain 
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because of problems due to reporting error. Nevertheless the changed trend 
demonstrated here is likely to be due directly to early detection by the breast screening 
programme rather than a true increase in breast cancer risk. 
Treatment effectiveness for early breast cancer: systemic therapy 
Evidence for reducing rates of death and recurrence from early breast cancer with 
systemic adjuvant therapies including use of tamoxifen, ovarian ablation, 
chemotherapy (and polychemotherapy) and immunotherapy - comes from two 
extensive publications by the Early Breast Cancer Triallists Collaboration. The first 
publication reviewed 133 randomised trials involving 75,000 women with information 
on follow up to 10 years after treatment24. The second overview is concerned 
primarily with the role of tamoxifen and is derived from 55 randomised trials 
involving almost 37,000 women'. 
In the first publication, significant reductions of 17% (SD 2) in the relative risk of 
death and annual rates of recurrence are seen for adjuvant treatment with the drug 
tamoxifen, of 25% (SD 7) for ovarian ablation for women below age 50 and of 16% 
(SD 3) by polychemotherapy (chemotherapy with more than one drug for more than 
one month) but not by ovarian ablation at older ages or by immunotherapy. Direct 
comparisons show that for women aged between 50-69 combined chemotherapy and 
tamoxifen is significantly better than chemotherapy alone for recurrence and mortality 
(p<0.00001) and for tamoxifen alone for recurrence (p<0.000001). Estimates suggest 
a reduction in the risk of death of around 30% (SD 4) for combined chemo-endocrine 
therapy for women in the 50-69 age group. The proportional risk reduction will be 
about the same for node positive and node negative women though the absolute 
improvement in 10 year survival is twice as high for node positive women because of 
their relatively poorer prognosis. 
For women under 50 only 2 treatments have clearly significant effects. These are a 
27% reduction in the relative risk of death following chemotherapy (SD 6) and a 28% 
reduction following ovarian ablation (SD 9). Indirect comparisons alone showed a 
21 
significant benefit from combining chemotherapy and ovarian ablation. Both direct 
and indirect randomised comparisons showed polychemotherapy to be significantly 
better than single agent chemotherapy at any age; polychemotherapy has a greater 
impact on the risk of death for younger women, a 25% (SD 5) reduction in the relative 
risk of death for women under 50 compared with a 12% (SD 4) reduction in relative 
risk for women over 50). 
The effects of tamoxifen appear to be cumulative. Most of the regimen included in the 
studies were for a median of 2 years for tamoxifen and 1 year for polychemotherapy 
yet significant differences in survival between treated and control groups were found 
at both 5 and 10 years. The collaboration demonstrated a highly significant trend 
towards a greater therapeutic effect for longer-term use of tamoxifen although the 
directly randomised comparisons of different tamoxifen duration indicate only a non- 
significant difference in favour of long term therapy. These results were confirmed by 
the second overview which found that in oestrogen receptor women or in those where 
the oestrogen receptor status was unknown for women treated with tamoxifen for one, 
two or five years the reduction in the rate of recurrence was 21%, 29% and 47% 
respectively. The reduction in contralateral tumours was 13%, 26% and 47% and the 
reduction in mortality was 12%, 17% and 26%. The number needed to treat (NNT) to 
prevent recurrence for women treated with tamoxifen for five years was eight. Further 
evidence also emerged in the second overview on the benefits for younger women of 
about five years of tamoxifen adjuvant therapy with an absolute reduction in 
recurrence rates as a first event of 14%. 
It is important also to note in these studies that the incidence of endometrial cancer 
was shown to double after 1-2 years of tamoxifen use and to increase four fold in 
trials of five years or more of tamoxifen. The absolute reduction in the risk of 
contralateral breast cancer is however about twice as large as the increase in the 
incidence of endometrial cancer. There was no apparent increase in the incidence of 
any other cancer although ascertainment of death was not complete. Overall there 
was a relative reduction in the risk of death from all causes for women in the 
intervention group compared with control (rr=0.99 SD 0.05). 
22 
Treatment of Advanced Disease 
There are no standard therapies for second or third line treatment for patients with 
refractory disease or with anthracycline resistant metastatic breast cancer or for 
patients with high-risk presentations of early disease. Yet, given the prevalence of the 
condition and the poor prognosis for newly diagnosed women with extensive axillary 
node involvement and late stage disease in general there is a good deal of interest in 
developing new drugs to improve outcome. 
Claims are made for the efficacy of some agents such as docetaxel (taxotere) as a 
unique agent in the treatment of metastatic breast cancer and use of this drug is 
increasing. The evidence for efficacy of the drug is mostly from case series (so called 
phase 2 studies) designed to test the likely magnitude of response of the drug and to 
monitor the side effects and a limited number of randomised controlled - phase 3 
drug trials. A review of phase 2 studies report a total of 317 patients observed in 8 
different studies throughout Europe, North America and Japan'-9. Excluding the 
Japanese study which had 85 people entered and offered a lower dose of docetaxel 
than in the majority of the other studies, the mean number of women observed was 33. 
The range of response to treatment in these studies lies between 39 and 57% with 
docetaxel used as first line therapy in four studies and second line chemotherapy in 
three studies. Few patients achieve complete response in any of the studies. 
Complete response is defined as the disappearance of all clinical evidence of tumour 
by physical examination or imaging studies for a minimum of four weeks. Most 
reports are of partial response defined as broadly a 50% reduction in the sum of the bi 
- perpendicular diameters of all neoplastic lesions for at least four weeks. 
Phase 2 studies are not controlled studies; response rates, mean duration of response 
and survival rates can only be compared within the study among patients who 
responded and those who did not. Many of these case series report a high number of 
patients experiencing significant side effects or progressive disease leading them to 
withdraw from treatment; a large proportion of patients also experience dose 
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reduction. The results of the phase 2 studies are broadly similar and a more detailed 
examination of the two most recent is considered below. 
In two Phase 2 studies30'3' from North America published in the last three years 
patients with metastatic breast disease treated with docetaxel as second and first line 
therapy respectively achieved remission in 53% and 54% of cases. In the patients 
treated first line there was complete response in two (5%) out of the 37 patients 
treated and a partial response in 18 (49%) patients. The median response duration 
was 26 weeks, excluding four patients who withdrew from the study while in response 
in order to receive high dose chemotherapy. In the study of second line therapy 18 
out of 35 patients achieved a partial response. The median response duration was 7.5 
months (30 weeks) with an overall survival for responding patients of 13.5 months. 
The median overall survival rate was nine months for all patients entered into the 
study. No information is given in either paper to compare the outcome with the 
median survival of patients treated on standard palliative therapy 
Of the toxicity reported, neutropenia is the most usual dose-limiting problem. In the 
first of the studies described above 31 out of 35 patients are reported to have had 
neutropenia 18 of which were complicated by fever mostly requiring intravenous 
antibiotic; eight of these patients also contracted significant infections, one patient 
died. In the second study 35 out of the 37 patients experienced neutropenia and 
leukopenia and there were 19 episodes of febrile neutropenia. Infection was 
documented in six of these patients. One patient with neutropenia developed 
mucositis with gastrointestinal haemorrhage and died. Myelosuppression and alopecia 
are also usual while nausea and vomiting are less so. A high proportion of patients in 
both studies (33 out of 35 and 30 out of 37 respectively) experienced fluid retention. 
In the latter study 30% of patients withdrew because of this toxicity. The aetiology of 
fluid retention for patients taking this drug is poorly understood and may limit 
implementation. 
A randomised phase 3 trial completed on a sample of 392 patients in N. America32 
found a significant improvement in response rate for patients with anthracycline 
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resistant disease randomised to receive docetaxel compared with those on Mitomycin 
C plus Vinblastin. Response rates in the docetaxel group compared with standard 
therapy were 30% compared with 11.6%, time to progression was 19 vs 11 weeks and 
overall survival was 11.4 months compared with 8.7 months. 
Costs involved in administering docetaxel are significant since a high proportion of 
patients will experience significant side effects, some of which require in patient 
hospital treatment. Moreover, anticipated sensitivity reactions are treated in advance 
with steroids or antihistamines. Treatment costs alone to achieve the three months 
survival benefit rate reported in the phase 3 randomised trial per patient benefiting 
would be around £50,000 since the data suggest an NNT of 5.4 and costs per patients 
for the drug alone are around £9,000.32"' 32/2 
Bone Marrow and Peripheral Blood Stem Cell Transplantation for Breast 
Cancer 
The partial success of adjuvant chemotherapy in the treatment of metastatic disease 
alongside evidence for a dose response effect of chemotherapy in both early stage 
disease and in patients with metastatic disease provides the clinical rationale for 
research using intensive high dose therapy (including myeloablative chemo and 
radiotherapy treatments together with progenitor cell transplantation) in patients with 
high risk presentations of early stage disease. Moreover, the toxicity associated with 
high dose therapy has been substantial and has constituted a considerable barrier to its 
use for women with breast cancer. More recently, however, advances in treatment 
have reduced the mortality (to below 5%) and morbidity of treatment enabling greater 
experimentation with intensive therapy and the prospect of widespread use of active 
treatment in advanced disease. High response rates have been found in some series 
though the duration of the effect has been limited. 
To date there have been only three randomised trials of high dose therapy compared 
with conventional chemotherapy including a total of 197 patients. One of these trials 
used high dose chemotherapy with hematopoetic rescue as a primary treatment. In 
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the other two trials initial chemotherapy had been given though in one of these studies 
only nine patients were randomised restricting meaningful analysis. This latter small 
study reported a significant benefit for patients on conventional therapy though 
presented little information on survival and stopped early because of poor recruitment. 
The remaining trial found a significantly increased odds ratio for survival in the 
experimental arm. 
A review of high dose therapy33 suggested that the limited evidence from randomised 
trials is inconsistent. The trial reporting a benefit when treating patients with primary 
disease may be confounded by tamoxifen given as maintenance therapy to patients 
responding to high dose regimen. Patients receiving conventional chemotherapy 
were less likely to respond to treatment and so fewer also received tamoxifen. 
Moreover patients in the control arm had a lower survival rate than expected by 
comparison with other series. The trial showing an advantage for patients on 
conventional chemotherapy also showed a significantly higher survival rate for 
patients given high dose therapy. The results in this case may well have been affected 
by patients in the conventional arm crossing over to receive high dose therapy at the 
time of recurrence. Clearly further studies are needed before treatments of this kind 
can have any role in conventional care of breast cancer. 
Cost effectiveness of treatment for early breast cancer 
Few studies are available to assess fully the cost effectiveness of current interventions 
in breast cancer. Results from the overviewsdiscussed above were however used to 
estimate the comparative costs involved in following alternative treatment regimes in 
adjuvant therapy for early breast cancer. The costs were applied to the standard 
cyclophosphamide, methotrexate and flouracil regimen (CMF)34 for chemotherapy 
and for antiemetics, administration costs, supplies, blood cell counts and medical time 
and were compared in relation to the benefits (numbers needed to treat) with the 
addition of tamoxifen for both two and five year regimen. The costs are based on 
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estimates of standard polychemotherapy and tamoxifen and include antiemetics, other 
supplies, blood cell counts and doctor time. 
The results for women treated in the USA show that systemic therapy is highly cost 
effective. The costs per life saved at ten years in early breast cancer ranges from 
around $17,000 for women at all ages in the highest risk category to over $50,000 for 
women at any age at a lower risk of death. Where the duration of treatment is 
increased or where combined therapies are used costs increase substantially. The cost 
of treatment with tamoxifen is less in the UK now that patent restrictions no longer 
apply to the drug. Costs of tamoxifen in the UK are around £30/patient per year and 
of standard polychemotherapy around £300 for a single cycle of treatment. 
The cost effectiveness of adjuvant therapy is proportional to the individual risk. Cost 
per QALY estimates for women under 50, for example vary with oestrogen status 
from $12,000 for node negative oestrogen receptor positive breast cancer to $4000 
and $6,000 for node positive breast cancer in pre and postmenopausal women 
respectively. For postmenopausal women with node negative breast cancer cost per 
QALY estimates vary from $28,000 - 36,00035 The Early Breast Cancer Triallists 
Collaboration' concluded that the treatment of low risk patients was as effective and 
that the addition of combined therapies offered moderate additions in life expectancy. 
Yet these strategies are unlikely to be as cost effective as targeting and treating 
women in higher risk categories. Similar effects would be seen with the effect of dose 
where increased or changed regimen may increase costs considerably for small 
reductions in mortality or risk of recurrence. Very little information is available on 
the impact of changes in quality of life for alternative treatment regimen in breast 
cancer care yet this may affect the balance of costs and benefits quite considerably. 
Most estimates of the cost effectiveness of treatment options are made on the basis of 
mortality reduction alone. 
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Quality of care 
As discussed earlier the incidence of breast cancer in the UK though high is 
comparable to that of other western European countries yet the mortality rate has 
remained consistently higher. Studies in the UK continue to show variations in the 
management of patients with breast cancer despite adjustments for case mix both in 
the North East and South East of England36'3'; variations in health outcome between 
Health Authorities have also been well documented38. The Eurocare study39 providing 
the largest set of population based estimates of cancer survival in 12 European 
countries shows considerable variation in age adjusted survival for women diagnosed 
with breast cancer using data from 30 cancer registries between 1978 - 1985. In 
particular the study found that women in England and Wales faced lower prospects 
for survival than women in most other comparable countries. Compared with 62% 5- 
year survival for women in England and Wales, only 2 other of the countries studied, 
Estonia and Poland, had poorer survival rates. Survival in Scotland ranked 8th equal 
with a survival rate of around 65%. The authors claim that with implementation of 
effective practice throughout the UK further reductions in mortality of at least 10% 
could be achieved. 
Although guidelines for optimal management of breast cancer are now available""' 
variations in management and use of poorly evaluated treatments persist across the 
UK42. The average 5-year relative survival rate for breast cancer in England and Wales 
remains between 60 and 65% and the median survival is just over 8 years43. Data 
from the Scottish cancer registries analysing survival rates among 34,107 women with 
breast cancer diagnoses between 1968 and 1987 did show improvements in 5 year 
survival rates particularly for women under 55 (10%) compared with women aged 55- 
64 and 65-74 (9% and 6% respectively)'. Gillis and Hole44 argue that this was due to 
a range of therapeutic advances including more widespread use of chemotherapy and 
radiotherapy, the emergence of multidisciplinary breast cancer teams and increasing 
specialisation of breast cancer surgeons as well as the introduction of tamoxifen. 
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A more recent audit from the Scottish Cancer Therapy Network suggest that 
improvements in the quality of care are possible where patients have access to breast 
specialists45. Between 1987 and 1993 the proportion of patients having surgery to the 
axilla had increased and the proportion of patients receiving systemic adjuvant 
treatment had increased. The 5-year survival was 9% higher and the 10-year rate 8% 
higher for patients treated by specialist surgeons than those treated by general 
surgeons. When the results were adjusted to account for the case mix of patients in 
the different centres the reduction in the risk of dying for patients in specialist centres 
increased to 16%. The benefits of specialist care were found across all subgroups 
examined including patient's age, the size and stage of tumours and patients from 
different socio-economic groups16 
Breast Screening 
The NHS Breast Screening Programme (NHS BSP) became fully operational in the 
UK in 1988 following publication of the Forrest Report47. which recommended 
routine mammography screening every 3 years for women aged 50-65. The policy 
was adopted by the NHS and led to the development of 99 screening units throughout 
the UK operating a mobile screening service with a computerised call recall system 
for the relevant age group at an estimated cost of £38m. Women are called via their 
GP once every 3 years; results are usually posted within 2 weeks of screening. 
Women with positive or equivocal results are recalled for assessment to the breast- 
screening unit. Diagnostic assessment of non-palpable lesions is carried out using 
triple assessment: clinical examination, further mammography and core biopsy or fine 
needle aspiration, the latter is more usual for palpable lesions. 
The rationale for the programme was based on a number of trials particularly those 
published from Sweden which showed a beneficial effect of screening mammography 
especially in the 50-64 age group°ß. An overview of the Swedish trials49 undertaken in 
two counties and three cities and including 156,111 women in the invited group 
compared with 125,866 in the control group showed an estimated overall reduction in 
mortality of 24%; this was 6%, 28% and 34% in the age groups 40-49,50-59 and 60- 
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69 respectively. The cost effectiveness estimates for the programme were based on 
single medio lateral oblique view mammography and a target uptake of 70% 
The NHS Breast Screening Programme is now in its 3rd round. Uptake rates are 
variable throughout the country though the overall rate of 72% uptake achieved in 
1990-93 has been exceeded with uptake rates of 77.4% in 1994-5. Regionally the 
uptake varies from just under 70% in the Thames Regions to over 80% in East Anglia, 
Oxford and Wessex50. The programme has exceeded the early cost estimates which 
now stand at nearer £45m/years'. Increased expenditure will be needed with the 
demographic increase of women in eligible age groups. 
Subsequent trials of breast screening efficacy have however been equivocal in 
supporting the early estimates of mortality reduction though an overview found a 30% 
reduction in mortality for women in the screened age groups. The cost of the 
programme has risen substantially and a full evaluation is urgently needed to tackle 
the controversy about the value of mammography screening compared with 
alternative means for reducing mortality from breast cancer. The impact of the 
programme in the UK is low since screen detected cases still comprise around 50% of 
breast cancers detected in total for women in the screened age groups. As fewer than 
40% of all breast cancers registered occur in the eligible age range this may limit the 
impact of the programme to the possible early diagnosis of only 20% of cases". 
Proposals to increase the impact of the programme such as reducing the interval for 
screening, extending the programme to cover younger women or removing the upper 
age limit need to be assessed against the impact of the current programme on overall 
mortality53"s4 Changing or extending the programme to target women at high risk of 
breast cancer because of family history has also been proposedss 
Many of the criteria set out by the WHO56 for the validity of screening programmes 
are met by screening for breast cancer: there is an early recognisable stage, 
mammography is a suitable screening method and appears to be acceptable to women, 
facilities for diagnosing and treating abnormal findings are available and can be 
monitored. Breast cancer is an important disease being responsible for a considerable 
30 
number of years of life lost since it affects women in middle age and early detection 
may lead to a more favourable prognosis. The natural history of breast cancer is still, 
however, not sufficiently well understood and it is possible that the treatment given in 
the early stage of the disease is not more effective than after the clinical diagnosis of 
symptomatic disease. Early detection will lead to an apparent improvement in 
survival because of lead-time bias but may not produce real reductions in mortality. 
The compelling public policy questions concerning the effectiveness of age based 
mammography screening for breast cancer are whether the costs involved are justified 
in terms of reduced population morbidity and mortality from breast cancer. Measures 
of the effectiveness of screening programmes should include evidence of changes in 
population mortality as well as improvements in case survival. 
Published estimates of the effectiveness of breast cancer screening programmes are 
available from nine randomised clinical trials of mammography in six countries. The 
recent trialsas. a9. s7 were not significant though a meta analysis did show a statistically 
significant relative risk reduction of 25-30% in mortality due to breast cancer for 
women over 50. " There was no effect was shown for women under 50. There is 
considerable debate in the interpretation of this result in terms of the expected 
absolute benefit for women in continuing with the screening programme and the cost 
per life saved in comparison with other health care interventions. 
As might be expected there are a number of differences in the characteristics of the 
trials such as the uptake rates and the ratio of benign to malignant tumours detected. 
The policy of different countries also varies with regard to screening intervals, follow 
up, type of mammography used and the weighting given to issues such as costs 
involved in further investigation and treatment and the personal costs of travelling as 
well as reduced availability for work and incidental expenses. 
A recent editorial reviewing all of the published trials of screening effectiveness 
suggests that the absolute benefits of breast cancer screening are small ranging from 
mortality reduction of 0.05 - 0.14p58. The number of women who need to be 
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screened to save one life ranges from around 7,000 to 63,000 in the screening trials. A 
number of authors' highlight that insufficient attention is given to the problem of false 
positives. About 1 in 20 women have a screening abnormality -a positive or 
suspicious result -but only between 1 in 5 and 1 in 14 will have cancer. These 
positive or suspicious lesions lead to considerable often quite invasive unnecessary 
further investigation and surgery. Secondly a negative result does not mean the 
absence of cancer since 10 -15% of early lesions are missed by screening. Finally for 
the majority of women in whom breast cancer is diagnosed by screening the outcome 
is unchanged59. 
Other authors have argued that screening is both effective and cost effective 
comparing favourably with other health care interventions such as renal dialysis. 
Estimates of the cost per death prevented range from £25,000 -£100,000 for UK 
women60. The lower range depends on detection rates of around 0.2% which is higher 
than the 0.06% found for example in the 1985 SNBH study61. Based on these studies 
cost per year of life saved is estimated to be around £5000; this compares with 
haemodialysis at £20,000 per year of life saved. Moreover some authors argue that 
the rate of inappropriate biopsies and other interventions in the NHS are far lower 
than might be expected from an analysis of practice in the USA where the pressure to 
intervene leads to substantially higher average costs. The benign: malignant ratio is 
now lower than the 4: 1 expected in the Forrest report with some centres reporting 
1: 462. 
Changing the age range 
Recent guidance from the NHS Executive allowed women over 65 to opt to continue 
attending for 3 yearly screening mammography though they will not be included in 
the call recall system. The uptake among older women is currently the subject of 
evaluation. It has been estimated that extending the age range of the programme may 
offer an incremental increase in deaths from breast cancer prevented at a cost, which 
is, lower than that implicit in the current programme63. The current NHS breast- 
screening programme does not currently target women at highest risk for breast cancer 
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and studies have shown an advantage for women up to age 75. Mortality from breast 
cancer may well decline if there is systematic screening of women in older age groups 
though increased anxiety could also be a significant consequence of advancing the 
lead time for diagnosis in this age group. 
Incremental cost estimates from the current NHS BSP are £25,142 per death 
prevented, or £2,525 per life year saved. Extending the age range to 69 years offers 
an incremental cost per death prevented of £21,376 or £2,990 per life year saved 
whereas reducing the screening interval changes the incremental cost per death 
prevented to £39,431or cost per life year saved £3,545; both options improve the 
efficiency of the current breast screening programme. 
All the arguments in favour of screening younger women are derived indirectly from 
studies that show no advantage in the original analysis. Only one of the eight 
randomised-controlled trials was designed to study the effect in pre - menopausal 
women' Meta analysis showed a non significant reduction of 10-15% in women 
under 4065. In the UK, mortality from breast cancer in this age group is around 
30/100,000 suggesting that at least 1,000 women would have to be screened for 16 
years before saving a single life. Detectability of small lesions is more difficult in the 
younger breast because of the density of the tissue. Reduction in mortality for 
increased cost are unlikely to compare favourably with that possible for older women 
although it could be argued that the increase in life years gained would be 
considerable. 
Targeting women who are most at risk of breast cancer may be the most effective way 
to improve the predictive value of screening and to lower the false positive rate. 
Between 5 and 20% of women with breast cancer have an increased relative risk 
because of family history or reproductive factors. A proportion of these will have the 
highly penetrant cancer susceptibility gene such as BRCA1 or a familial cancer 
syndrome. High risk women have most to gain in reduced anxiety and earlier 
detection; this group will experience higher absolute benefit especially younger 
women where the potential years of life saved are considerable66 
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As discussed earlier, an evaluation of the trends in incidence in the UKS following the 
development of the screening programme show the increases that were expected in the 
prevalence round. From 1979 to 1987 the rate of increase in incidence was 
approximately 2% per year to 86/100,000. After the introduction of the screening 
programme the annual rate of increase more than doubled to nearly 4.5% each year to 
102/100,000. The greatest increase is seen in the screened age group (women aged 
50-64). Incidence rates rose and exceeded those seen in the elderly unscreened 
population (women over 65). As early as 1990 incidence in 60-64 year olds exceeded 
that of 80-84 year olds. Incidence in age groups not invited to the screening 
programme fluctuated only slightly throughout this period. Recorded incidence is 
expected to return to pre-screening levels in the screened age group after the 
prevalence round, except for women in the age group 50 -52 who will always be in a 
prevalence round. 
The impact of the screening programme can also be seen in the proportion of tumours 
that were small and node negative. Mortality has also changed quite markedly since 
the beginning of the screening programme though is unlikely to be attributable mainly 
to it. For women between 55-69 a steep rise in age standardised mortality after the war 
continued until the late 80s when it fell sharply until in 1994 it was 12% lower than in 
1987. Any effect of the screening programme on mortality is unlikely to be seen until 
at least 7 years after the prevalence round. None of the screening trials show a 
reduction in mortality around the period of the prevalence round. 
Further evaluation of the programme is needed to address the potential for reducing 
morbidity for patients with earlier diagnosis of cancer prior to metastasis and the costs 
of care associated with earlier diagnosis. In developing a true assessment of 
population benefit the programme must demonstrate benefits in cost per life saved 
which exceed those seen with alternative means of reducing mortality and morbidity 
from breast cancer. The benefits of refocusing the programme to cover women at 
highest risk including older women and women with risk factors due to family history 
or reproductive history are made in comparison with the outcome from the current 
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programme though not in terms of alternative means of reducing mortality. At 
present estimates of the cost effectiveness of adjuvant therapy exceed those for breast 
screening by almost five fold. 
Risk of breast cancer and the potential for primary prevention. 
Breast cancer risk factors 
Epidemiological evidence supports the hypothesis that ovarian hormones are strongly 
implicated in the aetiology of breast cancer67. Early menarche, late menopause and 
nulliparity are associated with increased risk. The incidence of breast cancer is 
reduced by oophorectomy or by induced menopause with radiation. Experimental 
evidence with mice shows that ovarian function or stimulation with oestrogen is 
required for tumour development68. The risk increases with length of exposure - the 
earlier the intervention to reduce ovarian function the greater the reduction in risk. 
Oestrogen alone and with progestogen induces cell division and is of considerable 
interest in the pathogenesis of breast cancer. Other endogenous hormones such as 
prolactin and androgens may also be involved though further research is needed to 
fully elucidate their possible role. 
Family history increases the probability of breast cancer. Women with an affected 
first degree relative have a 2-3 fold increased risk and those with an affected second 
degree relative have a two fold increased risk. Risks are even further raised if two 
first degree relatives are involved or if the first degree relative has bilateral breast 
cancer or if the cancer was diagnosed before age 4069 
Overall only around 5% of women with a family history of breast cancer have a breast 
cancer gene; young age at breast cancer of a first degree relative is the strongest 
indicator of genetic susceptibility. Other risk factors directly associated with 
endogenous oestrogens include reproductive factors. Late age at first full term 
pregnancy (30 years of age or more) and nulliparity increase risk and high parity 
decreases risk in women aged over 5070. 
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Obesity, which increases risk of breast cancer in postmenopausal women, is thought 
to be linked to a hormonal mechanism. Case series and laboratory studies have shown 
that obese women have higher levels of serum oestrogen than non-obese women. This 
is because of greater metabolisation of androstenedione to oestrogen in adipose cells70. 
The extent to which body mass is implicated as a predictor of breast cancer is 
however complicated since overweight may reduce the risk of breast cancer in pre - 
menopausal women and the timing of weight change as well as the distribution of fat 
may also predict increased risk of breast cancer". In pre-menopausal women extended 
breast feeding may, through suppressing oestrogen production, confer a protective 
effect on the risk of breast cancer but the evidence for this is not strong72. 
A meta-analysis of 27 epidemiological studies of the effect of oral contraceptives on 
breast cancer risk suggests that risks may be increased by about 20% for younger, 
nulliparous women and for long term use73. Likewise, hormone replacement therapy is 
only associated with an increased risk of breast cancer after five years of use and the 
beneficial effect on the cardiovascular system and on a reduced risk of osteoporosis 
may also outweigh the adverse effects on breast cancer risk74. 
Other known risk factors which are more amenable to change are chiefly associated 
with diet75 and exercise76; alcohol use has also been implicated. A meta - analysis of 
50 studies looking at the relationship between alcohol intake and breast cancer risk 
suggested a small positive association; around a 25% increase in risk with the 
equivalent of two drinks (two units of alcohol) per day". Other studies78 including a 
more recent review of the literature79 concluded that causality had by no means been 
demonstrated and that several factors modify the relationship including age, weight 
and use of exogenous oestrogen. There are a number of measurement problems in 
estimating alcohol use, difficulties in detecting small relative risks and errors in 
confounding. Widespread changes in the use of alcohol are unlikely to have a 
significant effect on the profile of breast cancer especially since the publication of 
trials showing the beneficial effect of alcohol on HDL cholesterol and the 
corresponding reduction in cardiovascular risk. 
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Physical activity in adolescence and among young adults has been shown to reduce 
the risk of breast cancer in premenopausal and perimenopausal women. Risk 
reductions may well be hormonally mediated since physical activity delays the onset 
of menarche and decreases the number of ovulatory cycles80. Studies suggest that the 
effect of physical activity is independent of body size - though is difficult to separate 
from the effect of activity on excess body masse'. 
A great many studies have been reported which seek to explore the relationship 
between dietary fat and breast cancer. There is considerable debate about any 
possible association and the potential for primary prevention through dietary 
intervention. Consideration is given to this in a separate section below. A number of 
epidemiological studies have suggested that carotenoids in fruit and vegetables have a 
protective effect on breast cancer risk". Other studies of specific nutrients include 
vitamin A from animal sources83. Both vitamin A and carotenoids have 
anticarcinogenic effects in laboratory experiments. Little confirmatory information is 
available. 
A great deal of concern has been raised in the literature about the possible effects of 
environmental pollutants on breast cancer risk84. Some authors have suggested that 
women with breast cancer have higher levels of organochlorines in their serum though 
others have shown no association. Electromagnetic fields and ionising radiation have 
also been investigated. Electromagnetic fields are currently under review though the 
more intensive exposure through use of electric blankets is not implicated85. High 
dose ionising radiation to the chest does increase breast cancer risk at the level of dose 
required for radiotherapy86. 
Country of birth has a marked effect on risk of breast cancer and wide variations in 
incidence rates suggest there is scope for improving rates world-wide. Rates are 
higher in developed than in developing countries except for Japan where the rates are 
half those of N. America and N. Europe though they are increasing. Where women 
migrate, their breast cancer rates over two or three generations assume a pattern more 
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similar to the host country suggesting that the determinants of breast cancer risk are 
more likely to be environmental than genetic87. 
Scope for primary prevention 
For women identified at high risk increased surveillance through screening 
mammography and clinical examination is available for early diagnosis. Bilateral 
mastectomy8° and oophorectomy are highly effective and may be a practical option for 
women in high risk groups particularly those with significant family history or 
positive identification of breast cancer genes; doubt does remain however even with 
these radical procedures particularly over long term psychological sequelae and the 
prospect of tumours developing in the chest wall. Gene therapy may eventually be 
possible. For women using exogenous hormones some modification of contraceptive 
method may be possible after long term use and women taking HRT for longer than 
five years may wish to balance continued use and the potential for increased risk of 
breast cancer with possible reduced risk of osteoporosis and cardiovascular disease. 
Well known risk factors explain a large proportion of breast cancer incidence yet there 
are substantial gaps in knowledge about how they might be modified to reduce the 
risk of breast cancer. Risk factors concerned with family history are thought to be 
related to or mediated by endogenous hormones and so are assumed to be not 
amenable to change. Yet breast carcinogenesis and the development of disease are 
equally complex processes and have been subject to a great many clinical trials. 
Prevention trials have raised greater ethical concerns. 
In cancer prevention trials a great many healthy women would need to be involved to 
detect an effect since breast cancer occurs at a rate of between 0.5 and 0.8% in the age 
group which is likely to be targeted for prevention. An intervention period of several 
years is likely to be needed to achieve the required endpoint and any trial would 
involve considerable cost in order to achieve the power needed to detect an effect. 
Such considerations may have contributed to the dearth of cancer prevention trials 
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though it is surprising that even for risk factors which could be modified through 
lifestyle change such as obesity, changes in alcohol intake or contraceptive use our 
understanding of their impact is almost entirely based on observational data from 
analytical epidemiology. 
Given the impact of obesity on breast cancer risk it is surprising that weight reduction 
in obese postmenopausal women and weight reduction in middle age is not explicitly 
examined in health promotion trials. Alternative means to increase exercise among 
young women may also merit further research. A randomised controlled trial will 
determine if dietary interventions with a vitamin A derivative will affect the rate of 
recurrence of breast cancer in women with previously diagnosed disease or the 
incidence of breast cancer in the contralateral breast89. 
A large randomised trial of dietary intervention is also underway in Canada and the 
USA90. This will test the impact of reduction of fat intake to 20% of calories from fat 
and to increase the intake of fruit and vegetables in postmenopausal women aged 50 - 
79. The trial discussed further in the section on diet below is sufficiently large to test 
the effects of vitamin D and calcium supplements on breast cancer incidence 
addressing the hypothesis that the variation in incidence between countries is in fact a 
north - south latitudinal trend associated with levels of solar radiation. 
Dietary fat and the risk of Breast Cancer 
The incidence of breast cancer varies about 6 fold throughout the world. International 
regression analysis of breast cancer incidence in relation to per capita fat intake 
suggests a potential for reducing the relative risk of breast cancer by around 24%9'. 
The quality of data on national per capita fat consumption has however been 
repeatedly criticised. At least part of the apparent correlation may be due to a higher 
prevalence of reproductive risk factors or other environmental determinants in 
countries with a high fat consumption. The results of case control and cohort studies 
on the association between dietary fat and breast cancer are considered below. 
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Cohort Studies 
A recent and assiduous review of cohort studies examining an association between 
dietary fat and breast cancer was undertaken by Willett92. Each study included at least 
50 incident cases of breast cancer and quantitative estimates of fat intake as a 
proportion of total calories in the diet were available in six of the studies; the 
remaining analysed intake of fat from dietary records. None of the ten prospective 
cohort studies examined showed a significant association between fat and breast 
cancer comparing the highest category of fat intake with the lowest. 
The average relative risk among studies which included a confidence interval (nine 
studies) was according to Willett 1.01 (95% CI 0.9-1.13). This covered a range from 
a relative risk of 0.62 in a 10 year follow up study with 99 incident cases identified 
out of a cohort of 5,485 to a relative risk estimate of 1.3 found in the Canadian breast 
screening cohort which identified 519 cases of breast cancer among a total cohort of 
56,837 women93. Moreover restricting the analysis of studies to those concerned only 
with post menopausal women - since results from information regression analysis 
suggest that an association between fat and breast cancer may be stronger in older 
women - also failed to show a significant association. Relative risk estimates in these 
studies varied from 0.79 (95% CI 0.5-1.09) to 1.17 (95% CI 0.79-1.72)94 
In reviewing the biases, which may affect the results of cohort studies, Willett 
concludes that none is sufficient to substantially alter his conclusion that there is no 
significant association between fat in the diet and the aetiology of breast cancer. It has 
been argued that non differential misclassification is responsible for effects that 
remain undetected in all epidemiological analysis95. This effect occurs where subjects 
are incorrectly assigned - in this case - either to high or low dietary fat categories. The 
effect is said to be non-differential where the magnitude of the error for one variable 
does not vary according to the actual value of other variables i. e. the fact of having 
breast cancer does not alter the direction of the bias. Non differential 
misclassification has the result of attenuating the rate difference towards its null value 
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thus reducing the likelihood of detecting a rate difference in incidence of breast cancer 
between subjects in high and low quintiles of fat intake. 
Discussing in particular the Nurses Health Study, the largest prospective study 
including 89,494 women followed for eight years, Willett dismisses the importance of 
non differential misclassification of the data. Repeated assessment of dietary intake in 
cohort studies can alleviate the impact of non- differential misclassification yet is 
rarely reported in studies of dietary fat and breast cancer. All of the studies reviewed 
by Willett classified subjects and controls using a single estimate of diet. The Nurses 
Health Study did however include a validation exercise with detailed assessment of 
the diet of a sub group of 173 participants. 
Willett suggested that correcting for measurement error using the increment of 
24g/day for total fat intake which corresponded to the difference between the 10th and 
90th percentile in relative risk assessment affected the relative risk only slightly from 
1.01 (95% CI, 0.92 to 1.10) to 1.00 after de-attenuation. While Willett has uniquely 
among epidemiological analyses of this kind sought to improve precision caused by 
incorrect dietary classification, such an approach does not adequately account for 
inappropriate ascertainment of subjects in fat categories. This is particularly so where 
a time lag between exposure and effect may be important or when cumulative effects 
of diet are important. Willett does not discount the possibility that fat intake earlier in 
life or at substantially lower levels could influence the rate of breast cancer. 
The Canadian Breast Screening Study, 96 although substantially smaller than the 
Nurses Health Study (total cohort size of 56,837 compared with 89,538) provides 
comparable quartile information for assessing the relationship between breast cancer 
incidence and dietary fat. The study by contrast to the Nurses Health Study concludes 
that there is a likely association between total fat intake and risk of breast cancer with 
a relative risk of 1.35 (95% CI 1-1.82) for 77g/day of fat. The association is shown to 
be independent of total caloric intake and not due to confounding by known breast 
cancer risk factors. This study was unable to distinguish unequivocally any difference 
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in effects from the major components of fat neither did it discern any increased effect 
for postmenopausal women. 
The third relatively large cohort study to have analysed quantitative information in 
reviewing the relationship between fat and breast cancer is the National Health and 
Nutrition Examination Survey93. This study is substantially smaller than the two 
largest cohort studies discussed above having a total size of 5,485 women with 99 
incident cases of breast cancer. The study showed no significant association between 
fat and breast cancer with the possibility of a negative association at low levels of fat 
intake. The study used a measurement method of 24-hour recall, which has been 
shown to be subject to considerable bias. The size of the survey is too small to 
distinguish effects for sub groups such as for different age of women or different 
components of fat in the diet. 
Cohort studies while in general being more likely to demonstrate an effect than case 
control or ecological studies are nevertheless subject to substantial measurement error. 
Difficulties in assessing the dietary habits of individuals is well documented and is 
likely to give rise to considerable distortion and attenuation of relative risk. It can be 
argued that none of the instruments used in assessing diet can be properly validated 
since the time period over which diet may be most relevant to cancer risk remains 
unknown. Moreover the characteristics of individual cohort studies may have 
different potential for bias making a coherent review of results problematic. 
In elucidating some of the effects of likely errors Howe94 pointed out that the recall 
bias, which may occur if people with breast cancer interviewed after diagnosis of 
cancer report their diet differently to control subjects may be enhanced among groups 
such as nurses who are more likely to be aware of the postulated association between 
diet and disease risk. He highlighted two studies, which provide empirical 
information to support this view. Relative risks derived from a comparison of 
incidence of breast cancer in the highest to lowest quintile of fat intake in the 
Canadian National Breast Screening. Study and the US Nurses Health Study were 
assessed from both retrospective and prospective dietary data. While there is no 
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evidence of recall bias in the Canadian study - the relative risks for total fat being 1.12 
(0.76-1.66) and 1.05 (0.72-1.54) for retrospective and prospective data respectively 
there does appear to be an association between fat and breast cancer with a relative 
risk of 1.43 (0.9-2.27) based on retrospective data from the nurses study. This result 
is not confirmed by the prospective data which has a relative risk of 0.87. 
Case Control Studies 
A recent analysis of case control studies by Howe et a197 show a significant 
association of increasing risk of breast cancer with increased fat intake in post - 
menopausal women which is unaffected after controlling for protein or carbohydrate 
intake or for non dietary variables. Relative risk was estimated per 45g/day of fat 
intake relating to consumption in a typical North American diet. Studies selected for 
inclusion in the analysis had all been completed by the end of 1986 and had used 
quantitative estimates of fat intake. From the 12 studies included - only 2 published 
during the relevant time period were excluded - there were 4,427 cases and 6,095 
controls. Dietary information was assessed by food frequency data from the studies, 
estimates of standard portion sizes and nationally validated composition tables. 
The strongest effect leading to an increased relative risk of 1.46 (95% 
CI=1.23,1.72; p<0.0001) for breast cancer was in postmenopausal women with an 
increased intake of saturated fat. The relative risk for monounsaturated fat was 
similar at 1.41 (1.19,1.67; p<0.0001). The relative risk for polyunsaturated fat was 
lower at 1.25 (0.9,1.71; p=0.16). In order to exclude the possibility that these findings 
were confounded by differences in the methodology or conduct of the studies, Howe 
et al undertook a restricted analysis of studies showing lack of heterogeneity. Intake 
of both total fat and saturated fat in postmenopausal women was associated with an 
increased risk of breast cancer with increased consumption and there was a 
statistically significant dose response relationship. These findings are unlikely to be 
due to chance. Howe et al argue that by removing inconsistencies between studies 
that may arise from differences in coding and techniques for analysis and by use of 
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original dietary records inconsistencies found in comparisons or reviews of case 
control studies have been removed. 
Selection bias remains a substantial problem in case control studies. Non 
participation by controls or differential participation by controls following particular 
dietary practices cannot be excluded. Most of the cases in the Howe study were 
however population based and the refusal rate was low. Where the analysis was 
restricted to population controls excluding hospital controls there were little difference 
in the results. 
An association between dietary fat and breast cancer ? 
Epidemiological studies are inconsistent in their ability to detect a relationship 
between fat and risk of breast cancer. A number of authors have reviewed the 
strengths and limitations of studies including cohort, case, control and regression 
analysis but have continued to place different emphasis on the conflicting results. 
In a "critical appraisal" of the evidence Goodwin and Boyd9S set out a number of 
criteria for assessing the quality of the evidence based on the work of Bradford Hill99. 
They conclude that further investigation including the possibility of an intervention 
trial is needed to resolve the association. While a number of small studies show 
positive results the results from stronger designs are equivocal. Time trends and 
ecological studies are on the whole consistent with a positive relationship between fat 
consumption and breast cancer. These studies can however be criticised for lacking 
precision in measurements of true fat intake or make sufficient adjustment for the 
confounding effect of total energy intake. 
In ecological studies the impact of dietary fat intake and risk of breast cancer are 
limited by the extent of variability of fat intake in the population (s) under review and 
the sensitivity of the measurement instrument for detecting true differences in dietary 
intake. If the heterogeneity of fat intake within populations is lower than that between 
countries, then the potential for detecting an association between fat and breast cancer 
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from national populations will be weaker than that found in international regression 
analysis and may be impossible to detect. 
None of the studies undertaken by the main protagonists in the debate about a 
plausible link between fat in the diet and breast cancer can be insulated from these 
sources of error. Lack of heterogeneity e. g. may well affect the power of the nurses 
health study to show an effect. In seeking to resolve these conflicting results, 
Goodwin & Boyd estimated the difference in cancer incidence that might be found in 
association with fat intake within a country if the international data are indicative of a 
causal relationship. 
Projecting onto a regression of breast cancer incidence and per capita fat consumption, 
the range in fat intake reported in the cohort study of Willet - from 44-32% of total 
calories - they concluded that this would be associated with only a small reduction in 
relative risk of cancer incidence of about 1.4. This estimate would be even smaller 
were it associated with other sources of measurement error. Using the validation 
study of Willet, Goodwin and Boyd10° estimate the effect of misclassification on 
cancer risk associated with the highest and lowest quintiles of fat intake. 
Comparing the numbers of women assigned to each quintile of fat intake according to 
their reported fat consumption from a semi quantitative dietary questionnaire or from 
diet records - an assumed gold standard more detailed record - and projecting relative 
risk from international regression analysis they estimated that misclassification could 
have reduced the apparent difference in risk in the nurses health study between the 
highest and lowest quintile from an expected 1.4 to only 1.16. This estimate is 
plausible in comparison with the relative risk found by Willet and is consistent with 
the more recent cohort study published by Howe. 
By contrast for studies tending to show a positive association insufficient adjustment 
made for the impact of changes in overall energy intake when measuring fat in the 
diet and errors from selection bias and recall bias may reduce reported rate differences 
substantially. 
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Moreover, the relative risk of 1.46 in the review of case control studies was reported 
for a difference of 45g of saturated fat/day. The validity of such a reduction is 
questionable since many women may not be consuming such a large amount of fat to 
begin with92. Despite considerable variation in records of fat intake from international 
studies the average intake of fat in the Nurses Health Study was 25g/day. Willet 
points out that even women who consume in excess of 45g of fat/day cannot 
realistically reduce their intake by this amount because they cannot appreciably 
change their total energy intake. He argues that even a lOg reduction in saturated fat 
intake would be substantial. Using this incremental reduction instead of the 45g 
suggested in the Howe review would produce a relative risk reduction from 1.46 to 
around 1.1; recall bias may reduce this estimate still further. 
Prentice and Sheppard9' have sought to understand the discrepancy between 
observational epidemiological studies in order to shed some light on the change in 
breast cancer incidence which might be expected from a practical reduction in fat 
consumption. They argue that projected relative risk estimates from international 
regression analysis correspond well with observational studies given the limited 
variation in fat intake categories in even the best of most recent studies and 
acknowledging random errors in dietary assessment. While this is certainly 
reasonable in interpreting those case control studies which showed a significant 
positive association between daily grams of fat and breast cancer risk for 
postmenopausal women, the relative risks estimated from the North American nurses 
study are lower and of borderline significance only when sampling variation and 
measurement error are considered. 
The results for premenopausal women are far less consistent. Indeed the trend for the 
nurses study appears to disagree with the international regression analysis. The cohort 
study published subsequently by Howe did however show a more consistent 
relationship between total energy adjusted fat consumption and breast cancer despite 
the first quintile being at increased relative risk to the second quartile. The results for 
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all women - both pre and post menopausal were 1.37,1.00,134 and 1.78 again broadly 
in line with error adjusted projections from international regression analysis. 
Observational epidemiological studies have an effect of adding to, rather than 
clarifying the controversy surrounding an effect with such potential public health 
importance as a causal relationship between dietary fat and risk of breast cancer. 
There are 3 factors which, when combined, are likely to give rise to severe attenuation 
of any possible effect. These are the lack of heterogeneity in the studies, the potential 
for non-differential misclassification of data and other measurement errors associated 
with estimating diet. 
This review of epidemiological evidence for the relationship between diet and breast 
cancer suggests that the better designed studies are able to control for family history 
or reproductive risk factors, but none of the studies has sufficient heterogeneity in fat 
intake to detect adequately the effect seen in international regression analysis. 
An understanding of the biological plausibility of causal link between dietary fat and 
breast cancer cannot exclude the possible importance of diet at key development 
stages. In particular, the relationship with onset of menarche and early adolescence 
where the impact of diet on breast carcinogenesis may be profound. A number of 
studies have demonstrated a relationship between plasma oestradiol and other 
reproductive hormones with changes in fat intake10.. '°2. This effect may be of major 
importance in determining age at onset of menarche and the pattern of ovulatory 
cycles setting the risk of breast carcinogenesis well before any potential mediation of 
effect with diet in adult life. The problems of a possible time lag between dietary 
intake and risk of breast cancer will also contribute to non-differential 
misclassification of subjects into fat categories, since early diet and adult diet may not 
coincide. 
The error estimates made by Prentice & Sheppard, based on the validation study in the 
nurses cohort, arising from possible non differential misclassification of subjects was 
based on measurement of adult diet. Revising this still further to account for early 
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diet would severely undermine the potential of the study to show an effect. Other 
measurement errors discussed above would further contribute to the attenuation of any 
effect towards the null. 
A number of authors have proposed a dietary fat intervention trial to tackle the 
controversy surrounding the possibility of a causal relationship between fat and breast 
cancer. The National Cancer Institute is now funding the Women's Health Initiative"' 
designed to determine the efficacy of low fat diet in reducing the incidence of breast 
cancer, colorectal cancer and coronary heart disease in middle aged women. The 
study requires the recruitment of 32,000 women aged 45-69 and is underway in 20 
centres in the USA. The trial is set to test the hypothesis with a statistical power of 
80% that a 50% reduction in % of calories from fat (from 40% - 20% of total calories) 
will result in a detectable reduction in breast cancer incidence. The dietary 
intervention was tested in a feasibility study9° and showed that dietary intervention 
can be achieved and sustained at relatively low cost. The women will need to be 
followed for 8.5 years to show an effect. While this approach will overcome many of 
the errors inherent in observational epidemiology it cannot fully address the question 
of aetiology of breast cancer because it only deals with adult diet. 
Another possible approach is to consider a combined observational study across 
different countries which have substantial heterogeneity in dietary practice and which 
could stratify subjects according to their fat intake at different ages while still 
controlling for increased risk due to family history and reproductive factors. Such an 
approach using a pooled cohort or case control study would need to be of considerable 
time and long duration to demonstrate an effect. The feasibility may be enhanced by 
the increasing reliability and availability of cancer registries. 
Deciding an appropriate public health strategy for primary prevention of breast cancer 
requires both an understanding of the aetiology of disease and the potential for 
modifying risk factors with specific interventions. A randomised controlled trial of 
suitable size and duration to assess the long term impact of dietary intervention, may 
elucidate the impact of reducing fat for women at different levels of risk. 
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A pooled epidemiological approach when corrected for both early diet and established 
risk factors would raise broader public health questions concerning the social 
determinants of diet during life phases where risk of breast carcinogenesis may be of 
greatest importance. 
The only means of obtaining aetiologic information particularly where a plausible 
hypothesis includes a long time lag between onset of carcinogenesis and development 
of symptoms is through assiduous observational epidemiology. An appropriate study 
of the impact of diet on breast cancer would require a detailed review of diet for 
subgroups of women at substantially different levels of baseline risk. Detailed dietary 
assessment would be needed, based on repeated measures to validate the measurement 
instrument used and to reduce the potential for misclassification. Appropriate ages for 
dietary assessment would cover the timing of main life events where hormonal 
changes and the potential carcinogenesis would be greatest: onset of menarche, early 
adolescence and establishment of ovulatory cycles. 
Conclusion 
Summarising the evidence of benefits arising from alternative means of reducing 
mortality from breast cancer shows high and comparable estimates for relative risk 
reduction. The early Breast Cancer Triallists collaboration have provided convincing 
evidence for a 45-50% reduction in relative risk of death for women with early breast 
cancer taking tamoxifen therapy. The screening trials have proposed a relative risk 
reduction in mortality of around 24% - for screened women. The results from 
international regression analysis for the effect of dietary fat reduction on population 
mortality from breast cancer also suggest a possible 24% reduction with a low fat 
dietary intervention. Projections from adjuvant studies suggested a 30% reduction in 
mortality for tamoxifen chemoprophylaxis and results from the NSABP P-1 
prevention trial increased this estimate to almost 50% based on reduction in incidence 
seen in the intervention group. 
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For an average district health authority population of 250,000 people with about 100 
deaths from breast cancer per year full implementation of effective adjuvant therapy 
may prevent around 30-40 deaths, the screening programme may prevent 10-15 
deaths. For preventive interventions the scope for dietary effects though far from 
proven may have the potential of saving 20-25 deaths; with tamoxifen 
chemoprophylaxis targeted only at say the 10% high risk women in the population 
would prevent only 5-10 deaths. These reductions in relative risk are of course 
tempered by the excess cost involved in each of the programmes, by the proportion of 
the population who may be affected and by the side effects involved. Screening for 
example has not yet been fully evaluated on a population basis but clearly has the 
limitation of being targeted only to a small proportion of the women at risk and 
potentially carrying a high cost per death prevented. The risks of both a high false 
positive and false negative rate further increase the costs involved. 
The range of cost effectiveness discussed above for alternative means of reducing 
mortality from breast cancer are wide covering $17-50,000 (£10,625-£62,500) for 
early treatment of established disease to $40,000-160,000 (£25-100,000) in the breast 
screening programme. New and innovative treatments for advanced disease are of 
considerable cost for small benefit in terms of survival and assessments of quality of 
life for women on high dose chemotherapy are limited. Against this background the 
scope for chemoprevention is wide though ought to be targeted towards a cost 
effectiveness of less than £25,000 per death prevented. 34 This is a low estimate for the 
screening programme and a midpoint for effective treatment of breast cancer for 
women in the age group likely to be eligible for chemoprevention. 
Chapter 2 sets out the rationale for chemoprevention of breast cancer with tamoxifen 
and addresses issues likely to impact on cost effectiveness. The issues are drawn from 
a literature review of the known adverse effects of tamoxifen as well as possible 
benefits associated with reduced risks of other conditions such as heart disease. Early 
discussion is included quantifying the risks and benefits for women who are taking 
long term tamoxifen despite being asymptomatic for breast cancer albeit at high risk 
for the disease. Information on the likely impact of long term use of tamoxifen on 
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morbidity is supported in subsequent chapters with empirical information measuring 
changes in the use of hospital services or use of prescribed medications by women 
taking tamoxifen or control within the International Breast Cancer Intervention Study. 
These are considered in Chapters 4 and 5 respectively. 
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Chapter Two 
Breast Cancer Prevention with Tamoxifen: Prospects for Morbidity and 
Mortality 
Introduction 
This section is concerned with the rationale for chemoprevention of breast cancer and 
in particular the use of the drug tamoxifen for prophylaxis. Issues relating to 
chemoprevention of disease and the special nature of prevention trials are considered 
in the context of the likely risks and benefits of long term tamoxifen use and the trials 
currently underway in the USA, Europe and Australia. The side effects of tamoxifen 
are discussed in order to inform decisions about the costs of changes in rates of 
morbidity and mortality for high risk though asymptomatic women wishing to take 
prophylactic tamoxifen to reduce the risk of death from breast cancer. A balance 
sheet of risks and benefits is proposed as a basic design for the cost effectiveness 
study of tamoxifen chemoprophylaxis developed in later chapters. Issues of concern 
to the economic analysis are also discussed. 
Chemoprevention can be defined broadly as the use of an anticancer substance - 
including pharmacological agents - to enhance intrinsic biological mechanisms that 
protect against the development of malignant cells. Such an intervention may be an 
appropriate action for individuals known to be at high risk for breast cancer or to have 
had precursor lesions identified through screening. 'oa, 105 The rationale for 
chemoprevention of breast cancer, now under investigation in a number of countries is 
based on the assumption that therapeutic agents known to be active in suppressing 
tumour growth for women with early and advanced breast cancer are likely to be 
similarly effective in prevention. The expectation is that an agent effective in reducing 
the rate of development of disease for women with established breast cancer may be 
successful in correcting or inhibiting neoplastic agents responsible for the onset of 
carcinogenesis. 
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A number of authors reviewing the impact of adjuvant therapies on the development 
of breast cancer have suggested that the mode of action of the drug tamoxifen in 
reducing the development of recurrent disease in women with early breast cancer 
might apply also to preventing the onset of tumour development in healthy 
women" "06,107,108 Tamoxifen, a non-steroidal antioestrogen is used as the front line 
treatment for breast cancer. It is widely used in both pre and postmenopausal women 
as an adjuvant treatment in early disease where it has been shown to delay recurrence 
and increase survival and a recent review has provided convincing evidence of similar 
value for premenopausal women as adjuvant treatment'. 
There is little doubt that oestrogen is implicated in breast cancer carcinogenesis and 
although the precise mode of action of tamoxifen on the aetiology of breast cancer is 
complex it is clear that it blocks the tumour promoting properties of oestrogen1°9. 
Laboratory studies suggest that it is the amount of available oestrogen that is a key 
factor in the aetiology of breast cancer1°. The amount of available oestrogen depends 
on levels of sex hormone binding globulin (SHBG) and other growth factors. Sakhai 
and other authors have reported that tamoxifen raised levels of SHBG"''"`''13. 
Tamoxifen appears to have a range of effects acting as both an oestrogen agonist and 
an oestrogen antagonist. The effect appears to vary with menopausal status. It is more 
likely to behave as an antiestrogen in premenopausal women and as an oestrogen in 
postmenopausal women. Evidence suggests that tamoxifen is effective in oestrogen 
negative tumours though with a stronger effect in oestrogen dependant tumours14. 
Tamoxifen seems to be cytostatic rather than cytocidal in laboratory studies using 
animal analogues, supporting its use in prevention as well as in adjuvant therapy. 
The impetus for testing tamoxifen prophylaxis in preventing breast cancer has been 
strengthened by concerns about the lack of progress made in reducing the burden of 
the disease despite advances in treatment and the development of breast cancer 
screening programmes. Moreover because of the high incidence of breast cancer even 
a small reduction in relative risk from a preventive intervention could considerably 
reduce morbidity and mortality and the high costs of surgical and medical therapies. 
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Estimates of the potential for tamoxifen prophylaxis of breast cancer on the burden of 
disease in the population have come from long term follow up in a number of 
adjuvant trials testing the effectiveness of tamoxifen in reducing the development of a 
second primary in the contralateral breast1'. It is argued that this may be an effect 
equivalent to reducing the incidence of breast cancer in high risk women. 
In the recent overview of trials of the use of adjuvant tamoxifen versus no adjuvant 
tamoxifen, the Early Breast Cancer Triallists Collaborative Group (EBCTCG) 
reported on 55 trials that began before 1990 and included almost 37,000 women. The 
overview divided trials into three categories of duration: one year, two years and more 
than two years; the latter being most usually five years or more. For these trials the 
proportional reductions in the incidence rate of contralateral breast cancer among 
women allocated tamoxifen were respectively 13% (SD 13), 26% (SD 9), and 47% 
(SD 9). The effect for one year was not significant but there was a significant trend 
(chi2 =7.3, p, < 0.004) for trials of tamoxifen of two years or more with longer duration 
leading to greater reductions in the incidence of contralateral breast cancers. Overall 
the review shows that approximately five years of tamoxifen reduces the annual 
incidence rate of contralateral breast cancer by 50%7. 
It can be argued that this effect is equivalent to the prevention of breast cancer in 
healthy individuals since it is essentially suppressing the development of a second 
primary tumour1'. It is possible however that the effect is to suppress the synchronous 
growth of tumours and that tamoxifen has no relevance in healthy women1'. 
Moreover, these trials were concerned only with the development of breast cancer in 
postmenopausal women. Prevention is likely to be focused towards large numbers of 
healthy premenopausal women where the conditions for the development of tumours 
in women with risk factors for disease may be quite different. 
The results from the EBCTCG overview of therapeutic interventions in breast cancer 
provides evidence that at least two years duration of tamoxifen can prevent recurrence 
and reduce mortality for women with early breast cancer by around 50%'-10. Were 
similar effects to be available for prevention particularly to women at high risk for 
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breast cancer the results could be of considerable public health significance since the 
incidence of breast cancer is high and the relatively long mean percentage survival 
relative to other cancers results in a prevalence : incidence ratio of about 10: 1. 
Reducing the burden of disease in the population by around half could have 
considerable benefits for overall population mortality and result in substantial savings 
on the cost of health care. 
Developing the concept of tamoxifen chemoprophylaxis within the broader context of 
a population based prevention trial. does however raise a number of issues1'. These 
include the likely costs and benefits of such an approach, the impact of the 
intervention on the burden of disease irrespective of the change in carcinogenesis 
found in individuals and the precise impact of deleterious side effects. Ethical support 
for a trial to test the hypothesis of chemoprevention in breast cancer would rely on the 
importance of identifying a group of women at relatively high risk for the disease in 
order to maximise benefit from a preventive intervention relative to possible harms 
involved1'. 
Net benefits of chemoprevention would be gained at a cost both to the woman 
involved and in the resource use needed to set up a service for prevention. This 
includes the means of identifying high risk women, securing the compliance needed to 
make such a programme economically worthwhile, and providing adequate support 
and follow up. The prospect of routine screening for adverse events may also need to 
be considered. The net effect of chemoprevention can be summarised in the balance 
sheet below: 
Cost of active chemoprevention 
0 the direct cost of the preventive intervention and associated treatment costs 
(drugs, staff, clinic facilities) 
" the differences in costs of health services (including primary care and 
community health services) between those receiving the preventive 
intervention and control women (those at high risk receiving no intervention) 
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" activity: number of women eligible and taking up the preventive intervention 
(may include costs of identifying women at relatively high risk) 
" the cost of "labelling" women at high risk creating anxiety 
Benefits of chemoprevention will depend on 
" the effectiveness of the intervention in reducing and delaying the development 
of the disease 
" reducing or delaying the need for surgical or medical therapies 
" improvements in quality of life 
" the uptake of the preventive intervention 
" beneficial effects on other organs 
" impact on the health experience of women 
How the allocation of aspects of chemoprevention set out in the box above is made 
could make a difference to the calculation of the ratio of costs to benefits and to the 
empirical results from the study developed in the analysis set out in Chapter 7. 
Consistency ofinethods in cost effectiveness analysis is clearly important also in the 
ability to make comparisons across health care programmes yet there appears to be 
little convention to guide the alicoationo f some of the a ttributes or indeed what 
attaributes shold be included. Some of the attributes listed as costs may arguably be 
considered benefits and vice versa. This is of particular concern for attributes such as 
changes in the quality of life or health experience of the women involved which are 
not always included in studies of cost effectiveness. 
In general the use of resources on health care has been included in the numerator and 
the improvements in health in the denominator. The direct costs of the intervention - 
costs of service delivery including treatment costs are identified as costs as have the 
differences in use of health services between women receiving the intervention and 
those who are not. The uptake of the intervention - time spent by women seeking the 
intervention or indeed receiving it and the cost of targeting women are also ascribed 
as costs. These activities use resources and have no intrinsic health benefit to the 
women involved. The possible costs of labelling women at high risk and effects on 
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health experience such as those associated with changing levels of anxiety are also 
included as costs though perhaps should more properly be considered in the 
denominator since they are effects on health outcome. For this reason the possibility 
of benefits associated with potential improvements in quality of life arising directly 
from use of the intervention and the beneficial effects on other organs arising from the 
intervention are included in the denominator. 
Less straightforward is measuring the costs or benefits associated with the 
effectiveness of the intervention and the impact on reducing or delaying the need for 
surgical or medical therapies. At this stage in our understanding of the potential for 
chemoprophylaxis of breast cancer it is difficult to know whether delayed onset of 
disease should be measured as changed resource use for health and personal costs of 
care - or as a health benefit. The problem arises because of possible changes in the 
morbidity experience of women with a raised risk profile for breast cancer. Neither 
do we know how the intervention may affect future risks or experience of life 
threatening illness and eventual cause of death. The attributes have been defined here 
as benefits based on the current evidence of changed health outcome from prevention 
trials particularly the NSABP Pl with 6 years of follow up. 
The issue will be kept under review as new information emerges to further understand 
the impact of changes in intervention related morbidity in years that would have been 
lived anyway, costs that would have occurred in those years and health care costs - 
both related and unrelated to the intervention - that ensue in years that may be added 
- or lost as a result of the intervention. Future non-health related costs such as costs 
of living expenditure during possible additional years gained are not included. 
Studies from continued follow up of the women involved in IBIS will address the 
uncertainty in the allocation of costs and benefits and define more clearly how they 
might affect the calculation of costs effectiveness of tamoxifen chemoprophylaxis of 
breast cancer. 
Chemoprevention - issues for both research and practice 
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The special nature of trials seeking to assess the efficacy of possible cancer prevention 
agents has been discussed by a number of authors108""8. Unlike treatment trials, 
prevention trials set out to recruit healthy individuals and usually need to be of long 
duration in order to monitor both the relatively rare event of the incidence of new 
cancers as well as assessing the progress of disease and the impact on mortality. In 
IBIS, for example, it is estimated that, for a power of 95% to show a significant 
difference of 40% between the two arms of the trial over ten years, 8,000 women are 
needed based on an average risk of breast cancer of 6 per 1,000 in the women 
recruited to the trial 
Identifying a target group for breast cancer prevention trials has most usually rested 
on those at high risk for the condition under review. Trials for chemoprevention in 
breast cancer have sought to recruit women at high risk since the presence of risk 
factors was thought more likely to secure compliance and to reduce the expected trial 
duration and size because of the high expected incidence of new tumours2S"19. In 
resolving the ethical questions concerning experimentation on healthy women it could 
be argued that recruiting women at high risk for a disease is more in line with 
treatment trials where the risk of mortality arising from the certain existence of a life 
limiting illness is balanced against the uncertain risks and benefits of the intervention 
under review. 
Women age 50 at five or ten fold risk for breast cancer because of family history or 
reproductive factors have between a 30-50% remaining absolute lifetime risk of death 
from the disease. Women with elevated risk for breast cancer may find it acceptable 
to balance, in favour of trial entry, their higher than average lifetime risk of breast 
cancer with the possible reduction in risk or prolongation of disease free life years the 
agent under review and any likelihood of adverse events. Providing that the agent 
used in chemoprevention itself does not confer significant toxicity, trial entry for 
women with increased risk of breast cancer may be considered analogous to eligibility 
of women with established disease in treatment trials"'. 
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There are few medical alternatives available for women at high risk of breast cancer 
who seek active intervention in order to reduce their risk of early mortality from 
breast cancer. There is some evidence to suggest that either frequent mammography or 
prophylactic mastectomy may reduce the risk of mortality from breast cancer though 
precise information on these options is limited. Evidence of benefit from primary 
prevention as discussed earlier is scanty though studies are underway which may 
improve knowledge in this area12'. 
There are, however, reasons why results obtained from studying women in high risk 
groups may not be generalisable to the general population. Evidence from studies of 
hereditary factors in the case of breast cancer suggests that women carrying the 
familial breast cancer gene, BRCAI are more likely to have hormone independent 
tumours than women without this gene9. Tamoxifen used as an as adjuvant therapy for 
women with breast cancer is least effective with oestrogen negative tumours and may 
have little preventive impact on women likely to develop this kind of tumour"'. 
Moreover the results from chemoprevention trials may be biased where power 
calculations for estimating trial numbers needed to show an effect are based on 
incidence of disease and not mortality9. Close monitoring of the population may result 
in detection of earlier stage disease and so reduce the perceived effect. 
Side effects from long term use of tamoxifen 
Large numbers of healthy asymptomatic women would need to take the preventive 
intervention in order to produce a significant impact on population mortality. Side 
effects found in adjuvant treated patients may be of greater concern in the context of 
prevention because of the importance of justifying the risk of possible harm from the 
intervention in relation to the benefits. Even rare side effects could lead to a large 
number of individual disease effects with considerable medical resource and social 
implications and any deleterious effects on common serious conditions such as 
coronary heart disease could outweigh the beneficial effects on breast cancer. It seems 
however that the balance of evidence suggests that a beneficial effect on lipid profiles 
which may reduce the risk of coronary heart disease in women taking tamoxifen is 
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more likely12'. There may also be beneficial effects for the risk of osteoporosis 
although studies are few and equivocal"', "'. Concerns remain about the long term 
metabolic impact of tamoxifen use particularly with regard to risks associated with 
endometrial cancer, thromboembolism and visual disturbance. 
There is little evidence other than from the development of hyperplastic nodules and 
tumours in laboratory animals of an increased risk of liver cancer in women treated 
with tamoxifen though ascertainment of a primary tamoxifen induced liver cancer 
may be difficult in adjuvant studies"'. Liver cancer is a rare condition and it is now 
generally agreed that any diagnosis of liver cancer in women taking tamoxifen is most 
likely to be due to metastatic spread of the disease. Cuzick reports that the available 
evidence from trials has failed to show an effect on liver cancer and a large scale 
epidemiological cancer registry based study in the United States found no sign of any 
increase in liver cancer after the introduction of tamoxifen in 1977126. In the EBCTCG 
there were slightly fewer deaths attributable to liver disease in the tamoxifen treated 
group than in the control group and there was no excess of liver cancers in the 
tamoxifen group even among Japanese women where the incidence of liver cancer is 
relatively high (no liver cancers in the tamoxifen group versus three in the control 
group). 
Ocular toxicity from long term tamoxifen treatment is uncommon though case reports 
and case series report clinical changes such as retinal deposits, macular oedema and 
corneal thickening. A review of tamoxifen related eye disease documented 
considerable variability in the presentation of these conditions which may be due to 
alternative explanations such as age related eye disease or ocular changes caused by 
other diagnosis such as diabetes. There does however seem to be an increase in 
severity of ocular findings and more serious visual impairment in patients with 
advanced breast cancer on high dose adjuvant therapy including tamoxifen. 
Prospective data from a review of randomised controlled clinical trials suggests that 
ocular complaints may be more frequent among patients taking chemotherapy but that 
there is little difference in symptoms for women on tamoxifen alone compared with 
control. Since there is, at present, no clear evidence that long term tamoxifen use 
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predisposes to ocular degeneration there is little justification for routine eye tests prior 
to treatment. Nevertheless some authors have suggested that close monitoring might 
be advised127"128129. 
Evidence from published studies concerned with the side effects from tamoxifen that 
are most likely to influence the beneficial effects of tamoxifen in chemoprevention of 
breast cancer is reviewed below. This includes general symptoms, endometrial cancer, 
thrombolic events such as deep vein thrombosis (DVT) and pulmonary embolism 
(PE) and effects on lipid profiles and cardiac health. Where possible the information 
has been summarised to identify a rate which could inform assumptions about the 
`cost' of side effects and the impact they may have on uptake of a preventive 
intervention and long term compliance with the treatment regimen. 
General symptoms 
Reporting of rates of symptomatic side effects is inconsistent though numerous case 
reports and observational studies document a change in endometrial epithelia with the 
appearance of polyps in tamoxifen treated women and frequent increase in 
gynaecological symptoms such as irregular menstruation, hot flushes and vaginal 
discharge8'130. Some of the reported side effects such as hot flushes are clearly 
associated with anti-oestrogenic properties of tamoxifen whereas vaginal discharge or 
bleeding may be associated with its oestrogenic properties13'. 
Many authors concerned with the survival value of adjuvant tamoxifen refer to the 
relatively infrequent reporting of symptomatic side effects by women taking 
tarnoxifen in comparison with control patients132. A six year follow up of women 
treated with tamoxifen as a single agent following surgery, for example, found that 
only 4% of patients treated with tamoxifen for two years had side effects requiring 
withdrawal from the trial133. Yet, many long-term studies do report an increase in side 
effects for women on tamoxifen. A large scale NSABBP134 study of over 3,000 
women with oestrogen receptor positive cancers randomised to receive either 
tamoxifen (n=1422) or placebo (n=1439) found that the frequency of occurrence of 
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many symptoms such as fluid retention and nausea was similar in the two groups. 
Symptoms such as hot flushes and vaginal discharge were however higher in the 
tamoxifen treated group and did cause women to withdraw from the study though the 
rate of withdrawal was not documented. 
Love specifically reported on symptoms associated with tamoxifen in a group of 140 
volunteer post menopausal women in the context of a blinded randomised trial1z'. 
They were assessed over 24 months. All of the women had axillary node negative 
breast cancer in remission. He found a significant level of side effects for those on 
tamoxifen compared with women on placebo. The study participants were 
comparable for mean age, years since menopause, body mass and prior hysterectomy 
and had comparable levels of the symptoms under review at the beginning of the 
study. None had active radiological, laboratory or clinically verifiable breast cancer at 
the time of the study. 
After the first 12 months of the study 61.7% (31/64) of women taking tamoxifen 
reported hot flushes compared with 48.4% (37/60) on placebo. The significant 
difference in rates appeared at the six month visit and was sustained over the study 
period. Fewer women overall reported severe hot flushes in the first six months 
though there was a significant increase for women taking tamoxifen. 13.3% (8/60) of 
women taking tamoxifen reported severe hot flushes compared with 3.1% (2/64) in 
the placebo group. Reporting of hot flushes of any kind were equivalent at baseline. 
Rates of moderate to severe face flushes also increased significantly for the tamoxifen 
group after the first three months. Powles found a similar result of a two fold increase 
in the occurrence of hot flushes in tamoxifen treated women though this effect was 
mostly confined to premenopausal women. 
A significant increase in general gynaecologic symptoms was also reported in this 
study. By 12 months of follow up, 26.7% of women in the tamoxifen arm reported 
gynaecological symptoms compared with 14.1% at baseline. Gynaecological 
symptoms also increased in the placebo arm though to a much lesser extent not 
reaching significance over baseline values. The women in the tamoxifen arm had a 
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higher proportion of gynaecological symptoms at baseline than the women in the 
placebo group though this difference was not significant. In the Powles pilot women 
also reported a significant increase in vaginal discharge and in menstrual 
irregularities. The Love study found no differences in a number of symptom areas 
such as in joint pain, fatigue and nausea though there was an apparent reduction in the 
rate of reports of headache in the tamoxifen group. The Powles study showed a 
reduction in reporting of nausea and vomiting in tamoxifen treated women though no 
difference in headaches between the two groups. 
In the Love study, the apparent delay in the appearance of side effects for some 
women and the fluctuation in reporting over time led the investigators to identify a 
category of persistent side effects. Women taking tamoxifen showed a higher level of 
overall toxicity with persistent side effects reported by 48.5% (16/60) at 12 months 
compared with 21.2% (14/66) in the placebo group. Undertaking an assessment of 
well being using a seven item quality of life measure the authors also found that 
women who experience symptoms are more likely to report anxiety about 
involvement in the trial. They conclude that a protocol should be devised for proper 
evaluation and management of the side effects and that the decrement in quality of life 
to women on tamoxifen be more fully documented 
Endometrial Cancer 
An excess of endometrial carcinoma has been identified from a number of studies of 
long-term follow up of women on adjuvant tamoxifen and more recently from the 
results of the NSABP P-12. These studies suggest that the effect may be related to the 
dose of tamoxifen used and the duration of use. The NSABP B14 trial of tamoxifen 
adjuvant therapy in women with breast cancer has now accumulated 18 cases of 
endometrial cancer out of 2,638 patients with no cases reported in the control group 134. 
This includes seven patients allocated to the tamoxifen group after the initial phase of 
randomisation and two patients who relapsed in the placebo group and were 
subsequently assigned to tamoxifen. The median time to development of endometrial 
cancer in the 11 randomised cases was 41 months (range 4-93 months) 
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In the Stockholm Adjuvant Tamoxifen Trial 13 out of 931 women (1.4%) taking 
tamoxifen developed uterine cancers compared with two out of 915 women (0.2%)in 
the control group. The stage of these tumours was not uniform 11. Both early and late 
stage grades were found challenging previous assumptions that tamoxifen induced 
cancers may be of lower grade and have a more favourable prognosis than those found 
in patients not taking tamoxifen16 
Dose is clearly an important factor in this trial since the women were taking tamoxifen 
at 40 mg/day which is twice that offered in most adjuvant studies or in prevention 
trials. It has been estimated that the median cumulative dose of tamoxifen needed 
before increased risk of endometrial cancer is around 29g. This level would be 
reached after four years of treatment with a daily intake of 20mg. Duration of 
treatment was also important in this study with the number of cases of endometrial 
cancer increasing in those treated for longer than two years137 
The Scottish Adjuvant Study 13S by contrast, found no association between endometrial 
cancer and tamoxifen therapy at a dose of 20mg/day in 4-10 years of follow up of 
1,070 randomly allocated postmenopausal women. The Danish Adjuvant study 139 also 
failed to show a statistically significant increase in endometrial cancer in women 
taking tamoxifen alone at a dose of 30mg/day or with radiotherapy although there was 
a non significant trend towards an elevated risk in the tamoxifen treated group. A 
similar result of a non significant increase of uterine cancer for women on tamoxifen 
was shown in the South Sweden study with 719 breast cancer patients randomised to 
either radiotherapy with tamoxifen, radiotherapy alone or tamoxifen alone, after nine 
years of follow up140. The NATO study'33 of 20mg daily of tamoxifen given to 
postmenopausal women with early breast cancer also found no endometrial cancer 
after two years of follow up. 
A recent report pooling the results of randomised studies on the impact of tamoxifen 
on endometrial cancer suggests that there is a statistically significant increase in 
relative risk of about 4.8 in the rate of development of endometrial cancer in women 
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with breast cancer treated with tamoxifen compared with women in the control group. 
For women receiving adjuvant tamoxifen at a dose of 20mg per day the relative risk 
appears to be about 4.08. 
The results from NSABP P- l2 show an increased relative risk of endometrial cancer of 
2.53 based on the appearance of 33 cancers in the tamoxifen treated group (out of 
6,681) compared with 14 (out of 6,707)in the control group. The increased risk was 
predominantly in women aged 50 or older with an increased relative risk of 4.01 (95% 
CI=1.7-10.9) compared with a relative risk of 1.21 in women aged 49 or younger 
(95%CI= 0.41-3.60). The appearance of endometrial cancer occurred early in the 
follow up period and had an average annual incidence of 2.3 per 1000 in the 
tamoxifen group compared with 0.91 in the control group. The cumulative incidence 
was 13 per 1000 women in the tamoxifen group at 66 months of follow up compared 
with 5.4 per 1000 in the control group. The estimate is lower than might be expected 
from adjuvant studies though a large proportion of the women in the trial had 
undergone hysterectomy. The increased relative risk found in adjuvant studies is 
similar to that seen in the Royal Marsden Chemoprevention pilot. In this study there 
were four endometrial cancers reported after 70 months of follow up out of 1238 
women on tamoxifen compared with one woman with endometrial cancer out of 1233 
analysed on placebo. 
Thromboembolic effects 
There is evidence of an increased risk of thromboembolic events in women taking 
tamoxifen though this mostly comes from case reports and large adjuvant studies of 
women with established breast cancer where the causes of changes in haemostasis 
may be complex and multifactorial. There is considerable evidence of both an 
association between cancer in general and risk of thromboembolism and of risks 
caused by cancer chemotherapy. It is difficult to isolate the likely increased rate of 
thromboembolism which can be attributed to tamoxifen from these studies because 
they compare a variety of different chemotherapeutic regimen vs. Tamoxifen. Few 
studies are available to isolate the impact of tamoxifen in comparison with placebo. 
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The regimen are inconsistent both in the dose and duration of tamoxifen and in the 
age, menopausal and cancer status of the women involved. Most of these studies arise 
as a secondary analysis in a design primarily seeking to assess the effect of tamoxifen 
on recurrence rate and survival rather than to identify the precise rates of likely 
thromboembolic complications. They may not have sufficient power or length of 
follow up to address questions of toxicity. The studies vary in the extent to which 
they record thromboembolic complications in particular at what level of severity 
symptoms are included. Not all studies for example include thrombophlebitis. Table 
1 summarises the rate of thromboembolic complications for women taking tamoxifen. 
Table 1: Summary of risks of Thromboembolic disease in randomised adjuvant 
studies (20mg tamoxifen daily) 
Study type n follow up event rate note 
Fisher -women<70 adjuvant tamoxifen , 
double 2644 analysed 4years Event rate 0.9% in designed to study the 
primary breast cancer, node blind placebo controlled 1326 on placebo; 1318 on follow up tanwxifen group, 0.2% in recurrence and survival 
negative estrogen + temoxifen(but 141 loss to placebo group. 
benefit of tamoxifee 
f/u) 
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Saphner A review of 7 adjuvant 2673 patients in total 3-S years follow up frequency of venous seeking estimates of the 
studies (USA) chemotherapy vs. complications in frequency of venous and 
chemotherapy w tamoxifen comparisons including arterial thrombo -embolism 
tamoxifen vary from 23- and the contribution of 
observation, chemo or 9.1% compared with 0.4% chemotherapy with 
ehern w tam for observation and tamoxifen by reviewing 
between 3.5 and 3 8%, for studies of combination 
tamoxifen vs. placebo chemotherapy in therapies and including 
postmenopausal women. patients on observation 
chemotherapy vs For premenopausal women alone 
observation range is 14-4.2% compared 
with less than I4%for 
chemotherapy w tamoxifen chemotherapy alone and no 
followed by radiation vs. findings for women under 
observation observation alone 
chemotherapy w tamoxifen 
followed by observation or 
chemotherapy with 
tamoxifen followed by 
tarnoxifen 
chemotherapy w tamoxifen 
vs. chemotherapy w tam 
Fornander Data on intercurent 1846 patients; 931 2 years with further 3 years The frequency of adjuvant study 
Stockholm Adjuvant morbidity (hospital tamoxifen. 915 control with re randomisation admissions for thrombotic 
Tarroxifen Trial admission) and mortality further randomisation by events was 2% in both the 
from an ret of adjuvant risk status to radiation and tamoxifen and control 
tamoxifen vs. no endocrine chemotherapy group 
therapy 
Pritchard & Paterson, 141 its of tarnoxifen for 2 years 352 women receiving tam 2 years combination therapy led to 
vs. tamoxifen and chemo (6 alone. 353 receiving tam 13.6 % thromboembolic 
months) plus chemo events ( with significantly 
more serious grades 
including 3 deaths) 
compared with 2.6% in 
women randomised to tam 
alone 
Breast Cancer Prevention ret of tamoxifen vs. placebo 13,388 women randomised median follow up is 3.5 women taking tamoxifen the absolute risk difference 
Trial for women at high risk of to either tamoxifen (6681) years 1.5% thromboembolic between the tamoxifen and 
breast cancer or placebo (6707) disease: pe (. 25%), placebo arte is less than 5 
dvt(. 45%, cva (. 5%) per 1000 women for all 
events (less than 2 events 
per 1000 women for pc 
alone) 
Only randomised studies of adjuvant therapy which are able to measure the incidence 
of thromboembolic events prospectively and account for possible confounding factors 
such as the age and menopausal status of the women involved are included. 
The study by Fisher et al compares the incidence of thromboembolic events in a 
double blind placebo controlled trial. The rates of thromboembolic events reported in 
this study are small compared with other studies though it was the clinically most 
important side effect occurring in 0.9% of patients receiving tamoxifen compared with 
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0.2% in the placebo group; a relative risk for women taking tamoxifen of 4.5. The 
excess was however mostly accounted for by thrombophlebitis and few details are 
given about the specific conditions involved or the grade and severity of the 
complications experienced. 
Thromboembolic complications were significantly more frequent among patients 
receiving adjuvant therapy than those `observed only' following surgery in a review 
paper summarising results from seven consecutive adjuvant studies by Saphner et al 
for the Eastern Co-operative Oncology Group14'. The paper seeks to subdivide and 
group the studies in order to make conclusions about the impact of both hormonal and 
chemotherapeutic treatment alone or in combination on the development of arterial or 
venous complications in both pre and post menopausal women. 
Arterial thrombosis occurred in the same frequency in both pre and postmenopausal 
women. Premenopausal patients receiving chemotherapy and tamoxifen developed 
significantly more venous thrombi than patients who received chemotherapy without 
tamoxifen. Premenopausal patients only developed arterial thrombosis when on this 
combined regime. Likewise among post menopausal patients the combination of 
tamoxifen and chemotherapy was associated with a significantly higher frequency of 
venous thrombosis than tamoxifen alone. Postmenopausal patients receiving regimen 
with tamoxifen alone or in combination with chemotherapy did not experience 
different levels of arterial thrombosis in comparison with patients on observation only. 
The study lacked patients in sufficient numbers with consistent regimen to fully assess 
the impact of tamoxifen alone although the tamoxifen placebo controlled trial 
included in the review suggests a rate for post menopausal women of 1.2% for arterial 
events and 2.3% for venous events. Post menopausal women taking placebo in this 
study did however experience a very high rate of arterial events (4.8%) by 
comparison. Tamoxifen appears in this review to be associated with only a marginally 
increased risk of thrombosis. The rate of arterial events did not exceed 2.9% in any of 
the studies which included tamoxifen. Venous events ranged from 1.4% to 10.4% 
though these were all in combination with chemotherapy. 
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No significant toxic effects were evident in a study reported by Fornander et al of 
hospital admissions of women involved in the Stockholm Adjuvant Tamoxifen Trial 
though the median follow up was only 4.5 years and the data are limited in detecting 
complications that do not result in a hospital visit. Thromboembolic events were 
reported in 2% of cases in both the tamoxifen and the placebo arm. 
The study by Pritchard and Paterson supports the finding emerging from the review 
study described above that the major risk of thromboembolism for women with breast 
cancer occurs primarily with combination therapy. In a randomised trial of tamoxifen 
vs. combination therapy the authors report a strikingly high incidence of 
thromboembolic events of 13.6% among women randomised to receive chemotherapy 
with tamoxifen while only 2.6% of women in the tamoxifen arm experienced 
thromboembolism of any sort. Most of the complications including a number of 
severe effects and 3 fatalities occurred during chemotherapy. The authors conclude 
that the relatively common and serious impact of thromboembolism in this trial may 
preclude the routine use of combination therapy for women with breast cancer. 
Thromboembolism resulted in 26 hospitalisations in the combination arm and only 
three in the tamoxifen arm. A broad definition of thrombotic events was however used 
in this study and superficial phlebitis was included. The trial used 30mg/day of 
tamoxifen which is a high dose compared with that used in most other adjuvant 
studies and in prevention trials. 
The Early Breast Cancer Triallists Collaboration have recently presented an updated 
overview of randomised trials of adjuvant tamoxifen which increases substantially the 
amount of information available on long term use'. The review reported one extra 
death due to thromboembolism per 5,000 woman years of tamoxifen use though this 
excess was not statistically significant. No thrombolic events were reported for 
women under 50, women over 70 or for those taking tamoxifen for five years of 
treatment or more. No information was collected on non fatal thromboembolic 
effects. 
69 
In NSABP P-1 there was a significantly increased risk of pulmonary embolism for 
women taking prophylactic tamoxifen. Women randomised to the tamoxifen group 
experienced a greater number of both pulmonary embolism (18 in the tamoxifen 
group compared with six in the placebo group) and deep vein thrombosis (35 versus 
22 cases) compared with women in the placebo arm. This included two episodes of 
fatal pulmonary embolism in women randomised to taking tamoxifen. This excess 
risk occurred primarily in women aged 50 and over. The increased relative risk of 
pulmonary embolism was almost three fold for women on tamoxifen though the 
absolute risk difference for all thromboembolic disease reported in the study between 
the control and intervention ann is less than 5 per 1000 women. This includes both 
stroke (34 cases for women on tamoxifen and 24 in the control arm) and transient 
ischaemic attack (TIA) (18 for women on tamoxifen and 21 for women in the control 
arm) with 99 events in total for women on tamoxifen compared with 70 in the placebo 
group. 
The overall relative risk of thromboembolic disease was less than two for women on 
tamoxifen compared with women on control. The result is similar taking deep vein 
thrombosis and pulmonary embolism together excluding cerebrovascular disease and 
when the incidence of stroke and TIA is included. A similar result was found in 
findings from the Royal Marsden study 144 with a relatively low incidence of 
thromboembolic events but an increased relative risk of 1.7 for deep vein thrombosis 
and pulmonary embolism in the tamoxifen arm compared with women on placebo. 
A number of studies have sought to assess the biochemical effects of tamoxifen on the 
haemostatic system. Decreases in antithrombin III - which inhibits thrombin and 
other activated clotting factors have been reported in patients treated with tamoxifen 
for advanced disease 145 or as an adjuvant therapy in node positive breast cancer 
although these have not been recorded to the levels which might be expected to 
increase the frequency of blood clotting. Manucci et al in the Italian prevention study 
146 published results of heamostasis and lipid measurements on the first 68 consecutive 
women enrolled in the study at one, two, three and six months after entry. Tamoxifen 
induced a modest non significant decrease in anticoagulant proteins though there were 
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no signs of activation of fibrinolysis or protein markers of coagulation. Other studies 
have also demonstrated a decrease in levels of antithrombin III though few have found 
changes which would appear to have clinical significance 
Jones and Powles147 found no increase in fibrinogen levels which would be associated 
with an increased risk of thromboembolism in healthy women participating in the 
randomised double blind prevention trial underway at the Royal Marsden up to 36 
months after recruitment though any history of venous thrombosis or pulmonary 
embolism are significant exclusion criteria for the trial. In fact for both pre and post 
menopausal women there was a sustained, significant reduction in fibrinogen levels 
over the first year of follow up. There was no reduction in antithrombin III for 
premenopausal women and only a small reduction (less than 10%) in postmenopausal 
women. In the absence of positive results with fibrinogen and antithrombin III the 
authors measured other molecular derivatives involved in blood coagulation, 
principally Protein C and Protein S. Inherited deficiency in these proteins is 
associated with an increased incidence of deep vein thrombosis. 
The study found a marginal reduction in Protein S at six months though not at 
clinically significant levels and no change in Protein C. The authors speculate that the 
increased risk of thrombotic events associated with tamoxifen use may be due to an 
14s inherited tendency in patients at risk of breast cancer or with diagnosed disease, ýas 
The increased risk for women taking tamoxifen as adjuvant therapy may be 
considered acceptable because it is outweighed by the beneficial effect of tamoxifen 
on disease free survival. Further research is needed to establish whether prior 
screening for congenital clotting disorders is likely to be feasible and effective for 
women seeking tamoxifen prophylaxis, especially given the low incidence. In any 
event eligibility criteria should continue to exclude women with previous history of 
thromboembolic disease. 
By contrast there is convincing evidence for a beneficial effect of tamoxifen on risk 
factors associated with cardiac health. In general, studies conclude that the favourable 
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impact of tamoxifen on lipid profiles is likely to translate into reduced risk of both 
death from coronary heart disease and cardiac morbidity requiring hospitalisation or 
long term drug treatment 149,150 This relationship has however been more thoroughly 
investigated in men than in women. Clinical reports and case studies suggest that the 
change in lipid profiles for women taking tamoxifen may be mediated by the drug's 
oestrogenic effect producing a reduction in total serum cholesterol principally due to a 
lowering of low density lipoprotein. Follow up of patients mostly in studies of 
adjuvant tamoxifen for women with breast cancer suggest that the reduction in mean 
total serum cholesterol might be around 12% with a lowering of LDL cholesterol of 
20%'5' Such an effect if sustained could lead to an anticipated reduction in risk of 
coronary heart disease which might be as much as 20%'S2. 
Lipids 
In a double blind randomised trial of 140 postmenopausal women who were disease 
free after primary treatment for node negative breast cancer, Love"' reported a 
significant decrease of 12% in total cholesterol, largely due to a 16% reduction in 
LDL cholesterol at three, six and 12 months of follow up. There was a also a small 
but significant reduction in HDL cholesterol which might be expected with a 
reduction in total cholesterol. Powles et a! "9 in early reports from the UK 
chemoprevention pilot found significant reductions of around 15% in total cholesterol 
and reductions in LDL cholesterol in both pre and post menopausal women after two 
years of follow up. These findings were confirmed in further follow up" with a total 
of 400 women with the addition of a significant reduction in apolipoprotein B in 
postmenopausal women. There was no effect on HDL cholesterol. A subgroup 
analysis from this study152 found a 13% reduction in total cholesterol in a small group 
of women who were also taking hormone replacement therapy. 
Studies of the impact of lipid lowering on coronary heart disease suggest that the 
effect is related to both the extent of lipid lowering and the duration of the effect. The 
effect appears to increase with duration of taking tamoxifen although published 
reports from such sub group analysis is limited"" 54 
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Few studies are available however to quantify the impact of tamoxifen on death from 
coronary heart disease or on cardiac morbidity. In the first report from the Early 
Breast Cancer Triallists Collaboration overview of adjuvant trials tamoxifen was 
associated with reductions of 25% (SD13.2p=0.06) in deaths from vascular causes24. 
Results from the more recent longer term follow up of these randomised trials' were 
consistent with these findings though the difference for vascular causes was not 
significant. There was no significant difference in deaths from myocardial infarction 
between the two arms of the trial. Likewise tamoxifen administration did not alter the 
average annual rate of ischaemic heart disease in the NSABP P-12. The number of 
women who had a myocardial infarction was 28 in the placebo group and 31 in the 
tamoxifen group. There was no significant difference in fatality between the placebo 
and tamoxifen group with 7 and 8 deaths respectively. There was also no significant 
difference in reporting of cardiac morbidity between the two groups including angina 
and acute ischaemic syndrome. 
A significant reduction (p<0.005) in the incidence of fatal myocardial infarction was 
also demonstrated in the Scottish Adjuvant Tamoxifen Trial although there was no 
significant difference in the incidence of other fatal vascular events in the two arms of 
the trial'55. Of 200 deaths in the tamoxifen arm (n=539) ten were due to myocardial 
infarction compared with 25 out of 251 deaths in the control arm (n=531) of the trial. 
This 38% reduction in relative risk of death from myocardial infarction was measured 
after a mean duration of 29 months (9-93) with tamoxifen taken at a dose of 20 mg 
daily. The results may underestimate the effect since the non intervention arm of the 
study included some women who crossed over to taking tamoxifen on relapse. 
Further follow up of this trial population using record linkage with the inpatient 
record scheme at the Scottish Home and Health Department found statistically 
significant differences between the rate of admission to hospital for women taking 
tamoxifen and those in the control arm of the trial with a hazard ratio 2.03 (1.05 - 
3.92, p=0.033) for myocardial infarction. The effect was greatest in current users of 
tamoxifen suggesting that the protective effect may diminish once treatment stops'56 
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These results are consistent with studies showing that the reduction in serum 
cholesterol and LDL cholesterol is greatest in current users than in former and non 
users of tamoxifen'sa Some non significant reduction in the incidence of other cardiac 
ischaemic episodes was also seen in this study. 
A significant reduction in overall cardiac morbidity in women taking a daily 40mg 
dose of tamoxifen as adjuvant therapy was shown by the Stockholm Breast Cancer 
Study Group15'. The confidence intervals are too wide to offer a convincing effect for 
specific cardiac causes; there is a significant reduction in relative hazard of 
admissions for MI (0.68 0.48-0.97) and a trend towards reduction for angina pectoris 
as well as other forms of ischaemic heart disease such as congestive heart failure and 
myocardial ischaemia. This study did however show a statistically significant benefit 
in terms of cardiac morbidity for longer duration of treatment with patients treated for 
five rather than two years. There was a significant decrease of admissions due to any 
cardiac disease in the five year group (relative hazard, 0.37,0.15-0.92 p=0.03). The 
authors conclude that longer follow up is needed to determine whether this benefit 
will be translated into a significant reduction in cardiac mortality. 
In the context of chemoprevention of breast cancer for women at high risk the impact 
of tamoxifen on mortality from coronary heart disease may be at least as important as 
the reduction in risk from breast cancer' 12 5' Among women at high risk for breast 
cancer the probability of death from breast cancer relative to death from other causes 
decreases with time; mortality from coronary heart disease particularly ischaemic 
heart disease becomes of far greater significance. 
Bones 
Because of its oestrogenic properties it is assumed that tamoxifen may have a 
beneficial effect on the rate of bone loss in post menopausal women. Studies in 
postmenopausal women taking tamoxifen have found positive changes in bone 
activity markers and in general a significant increase in bone mineral density (BMD). 
The clinical significance of these changes in terms of reduced fracture risk or 
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mortality is less clear though, it is unlikely from present evidence that the effect will 
be deleterious. The NSABP P-1 recorded fracture rate and reported a significant 
reduction in hip fractures for women taking prophylactic tamoxifen. The effects of 
tamoxifen on premenopausal women is more difficult to discern because the numbers 
of younger women included in studies is small. Some authors have expressed concern 
that tamoxifen may antagonise oestrogen in premenopausal women leading to bone 
loss15'. 
A number of adjuvant studies have included an assessment of the impact of tamoxifen 
treatment on bone mineral density. In general, even where studies have been unable 
to demonstrate a reduction in the rate of bone loss in postmenopausal women the 
effect has been one of no difference in comparison with women in control groups 
rather than of an acceleration in bone loss160"161162. A study of the interaction between 
HRT use and tamoxifen use also concluded that there were no adverse effects in 
postmenopausal women. 152 
Larger and better controlled studies have on the whole shown an increase in bone 
mineral density in postmenopausal women taking tamoxifen of the order of 1.5% per 
year compared with - as expected -a loss of bone mineral density in control groups. 
In a randomised study of 140 postmenopausal women with breast cancer taking either 
20mg daily of tamoxifen or placebo, Love et al found strong evidence for a significant 
reduction in the rate of bone loss in the lumbar spine in tamoxifen treated women"'. 
There was no similar effect in comparison with the placebo group on radial bone; 
bone mineral density in both the tamoxifen and placebo group declined over the two 
years of measurement. Assessments of bone mineral density in the femur were not 
made and there was no assessment of the impact on long term fracture rate. The 
authors conclude that tamoxifen is an anti - resorptive agent affecting those bone sites 
normally affected by oestrogen. The 3% increase - in bone mineral density, over the 
two year follow up, found in this study - even after correcting for menopausal status 
at the time of diagnosis of breast cancer in the lumbar spine, is within the range seen 
with agents commonly prescribed for oestrogen replacement therapy. 
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Results from a 40 month follow up of women enrolled in the Marsden tamoxifen 
prophylaxis pilot found no effect on bone mineral density in the forearm for women in 
the tamoxifen arm of the study even where postmenopausal women only were 
considered14°. Results of BMD in the lumbar spine and hip did however show an 
effect of tamoxifen and are discussed below. The same effect from forearm 
measurement was found in 75 women enrolled in the Swedish tamoxifen trial after 
either two or five year follow up"'. Forearm measurement of bone mineral density 
showed no significant differences for women randomised to tamoxifen in the 
treatment arm compared with control even at the high dose of 40mg daily. 
Evidence on the longer term impact of tamoxifen is available from a five year 
assessment of 62 of the original subjects by Love et al165. This study confirmed the 
increase in bone mineral density in post menopausal women taking tamoxifen though 
with no significant further increase from the two year level. Further assessment of 
longer term effects are reported by Cuzick and Baum142 reviewing a wide range of 
biological markers including measures of bone mineral density in the spine and 
trochanter of both current and ex - users of tamoxifen. 73 ex - users were compared 
with 60 controls; the median follow up was seven years. Bone mineral density was 
about 11% higher among current users compared with both ex - users and controls and 
the effect was greater in postmenopausal women. None of the differences achieved 
significance though the consistent difference between current users compared with 
both ex - users and control suggests that the effect of tamoxifen may 
be lost with 
cessation of use. Measurements were not made on 21 of the women in this study and 
the number of premenopausal women included was too small for subgroup analysis. 
Significant results were found in an analysis of bone mineral density made in the 
lumbar spine and femur over three years for women enrolled in the Royal Marsden 
Prevention pilot as discussed earlier144. In premenopausal women, BMD in the lumbar 
spine decreased progressively and was significantly lower than pre-treatment values at 
year one (n=49), year two (n=32) and year three (n=19). Overall, there was a loss of 
BMD in the lumbar spine of 1.44% per year for women in the tamoxifen group 
compared with a small gain of 0.24% per year for premenopausal women on placebo. 
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At the hip there was a significant loss of BMD in premenopausal women in the 
tamoxifen group compared with baseline values by the third year and compared with 
the placebo group by the second and third years. For postmenopausal women taking 
tamoxifen compared with placebo there was a significant increase in BMD at both the 
hip (average annual increase of 1.71 %) and the lumbar spine (average annual increase 
of 1.17%) mostly occurring in the first year of treatment. Larger studies are needed to 
confirm the results for premenopausal women. For postmenopausal women taking 
tamoxifen there appears to be a consistent effect increasing bone mineral density by 
an annual average of 1.5% though the long term duration of this effect and its clinical 
significance are not properly understood. 
Quantifying risks and benefits of chemoprophylaxis 
Few authors have been able to quantify the health benefits and costs of 
chemoprevention for breast cancer in terms of life expectancy or in terms of costs in 
relation to life years gained because of the lack of information on efficacy or costing 
from randomised controlled trials or observational studies. Broad theoretical 
estimates derived from the rationale for the NSABP P-1 trial have been attempted by 
Nease and Ross'2. Based on a 50 year old woman with a breast cancer risk twice that 
of the average woman her age they argue that prophylaxis with tamoxifen offers an 
increase in life expectancy of about nine days. This estimate is based on decision 
analysis which accounts for increased relative risks of non fatal endometrial cancer 
and of death from thromboembolism of 2.4 and 3.5 respectively - and beneficial 
effects on risk of death from myocardial infarction and hip fracture of 0.2 and 0.25. 
Risk of mortality from breast cancer is estimated to reduce by 35%. These results are 
in line with findings from Cuzick126 who estimated a slightly higher result of 40% 
reduction in breast cancer incidence, the same level as for ischaemic heart disease risk 
with slightly greater benefits on bone (reduction of spinal fractures by 33%) with a 
lower adverse effect on thromboembolic disease (approximately two fold increase). 
Such a modest net improvement in health is clearly dependant on the estimates used 
for comparative relative risks between detrimental and beneficial effects and widely 
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differing conclusions arise from relatively small changes in the assumptions. No 
account is taken in this model of changes in quality of life or other non life threatening 
conditions or of the weight to be attached to changes in risk of death from different 
causes. The changes discussed in this study include changes in mortality from 
myocardial infarction, thromboembolic causes, hip fracture and breast cancer and 
nonfatal changes in risk of endometrial cancer. Estimates of reduction in risk of 
mortality from ischaemic heart disease are inferred from a number of authors who 
report beneficial effects of tamoxifen on lipid profiles. The findings from the 
Scottish Adjuvant Trial discussed above suggest a reduction in risk of myocardial 
infarction of 20%. 
They use weaker evidence to derive estimates of changes in hip fracture mortality. 
Assumptions are based on studies of changes in the bone mineral density of women 
on tamoxifen though no studies have found any conclusive evidence of a direct impact 
of tamoxifen on fracture risk let alone mortality. Nease and Ross also assume that 
tamoxifen will be at least as half as effective as oestrogen in relation to hip fracture 
risk in postmenopausal women though present little evidence for this view. Since the 
relationship between oestrogen use, hip fracture risk and mortality from hip fracture is 
extremely unclear the assumption of a reduction in fracture risk of 25% for all women 
on tamoxifen is unsupported. 
The significance of the change in risk of death from endometrial cancer may be 
regarded as of less importance in relation to beneficial effects on breast cancer risk 
since the absolute risk of death from endometrial cancer is low. Increased risk of 
thromboembolic disease are well documented in women taking tamoxifen and Nease 
and Ross take their estimate from published studies showing an increase in the range 
of 3-4 fold relative risk. Estimates of reduction in risk of breast cancer mortality of 
35% are taken from the early work of the Early Breast Cancer Triallists Collaboration 
and from the projections set out in the rationale for the NSABP P-1 Breast Cancer 
Prevention Trial. This is in line with some of the early findings from breast cancer 
chemoprevention studies. 
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The analysis from Nease and Ross highlights the importance of baseline risk of breast 
cancer, the effects of tamoxifen on breast cancer mortality and the effects of 
tamoxifen on cardiovascular mortality in determining cost effectiveness of 
chemoprevention. The importance of the effect on cardiovascular mortality can be 
further illustrated by reference to an English health district population. Prevention 
trials in general target women at increased relative risk of breast cancer. For a 
hypothetical population of 400,000 women say between the ages of 35 and 69 around 
10% might be expected to be at 3 or 4 fold relative risk of breast cancer with an 
absolute lifetime risk of between 20 and 30%. This would give rise to between 800 
and 1200 cases of breast cancer. If the impact of tamoxifen prophylaxis were to 
reduce the risk of breast cancer by 30 to 50% a range of 266 to 600 cases might be 
prevented. Any adverse impact of tamoxifen on serum lipids however would have to 
be only relatively small to offset this benefit. The average 50 year old women has a 
lifetime risk of coronary heart disease of about 45% . 
Increasing the absolute lifetime 
risk by 1% for the high risk group would result in an additional 400 cases of coronary 
heart disease. An increase of 2% would considerably outweigh the numbers of breast 
cancer cases prevented. It has been argued that the latitude over cardiovascular 
disease effects is small and that even a change in relative risk from 1 to 1.03 would be 
sufficient to abolish any beneficial effects of tamoxifen149. 
Nevertheless, it seems clear that tamoxifen reduces the hazard of cardiovascular 
events. A number of authors have shown that effects on lipid profiles occur within 2 
weeks of first taking tamoxifen and although the levels appear to return to normal 
after stopping the benefits may persist15'. Cuzick et al'45 point out that as 
cardiovascular benefit is cumulative any period of lowered cholesterol may translate 
into long term benefits on risks of cardiovascular events. The feasibility of 
chemoprevention for breast cancer relies on a neutral or beneficial impact on 
cardiovascular risk for any potential pharmacological agent. Subgroup analysis is also 
clearly important in this regard since women taking HRT and women at different 
menopausal status may experience different effects of an oestrogen agonist on lipid 
profiles. 
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Economics of tamoxifen chemoprophylaxis 
In an economic analysis of chemoprevention in Australia, Butler" uses the estimates 
from the Nease and Ross model described above to derive possible values for the cost 
per life year gained for tamoxifen prophylaxis. Leaving discounting aside and basing 
his calculations only on costs for tamoxifen over five years, costs of treating an 
increased incidence of endometrial cancer and savings from both a reduced incidence 
of breast cancer and myocardial infarction and from discontinuation of HRT -a 
requirement of the USA trial - Butler concludes that the net cost of treatment over five 
years is around $2,500 of which the cost of tamoxifen has the greatest impact on 
overall cost. The most significant savings in the Butler analysis come from 
discontinuation of HRT by women taking tamoxifen. The estimates for expected 
change in the resource intensive outcomes reviewed come from the NSABP P-1. 
Taking an 18 day gain in life expectancy from the study set out by Nease and Ross but 
not including the prospect of being randomised to a non tamoxifen arm, Butler goes 
on to conclude that the cost per life year saved is over $50,000 (£31,250). If the 
higher USA costs of tamoxifen are included then the overall cost per year of life 
gained rises to over $100,000 (£62,500). Increasing the relative risk of women 
exposed to the preventive intervention reduces the cost per year of life saved. For a 50 
year old women at 5x average risk, for example, the estimate falls to around $43,000 
(£26,875) per year of life gained. 
Different assumptions underpin IBIS. Firstly the costs of tamoxifen in the UK and the 
rest of Europe is considerably lower than in the USA since patent restrictions on 
pricing no longer apply. Secondly discontinuation of HRT is not a requirement in the 
UK study and so the substantial savings estimated for the NSABP P-1 are not 
relevant. Finally estimates for both the incidence of endometrial cancer and the cost 
of treatment are high in relation to the change in event rate of breast cancer and the 
associated costs. 
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Broad costs of chemoprevention for breast cancer looking solely at the cost of 
tamoxifen in the UK study are around £ 120 over 5 years or £24 per women per year 
taken at a dose of 20mg/day. If the 2% absolute risk reduction in incidence of breast 
cancer found in the NSABP P-1 applies to the women recruited to IBIS then the cost 
per tumour prevented is around £6,000. The costs in this simple calculation are based 
solely on the costs of tamoxifen. They illustrate that the cost of chemoprevention will 
be affected by the costs of delivering the preventive agent to the number of women 
who need to be treated in order to prevent one breast cancer (NNT) and the cost of 
treating side effects in relation to the unit of effect for those who do benefit. 
More precise estimates at the cost of morbidity due to long term tamoxifen use are 
developed in Chapters 4 and 5. Morbidity of women enrolled in IBIS is measured in 
terms of changes in use of hospital services or prescribed medications respectively for 
women in the 2 arms of the trial (taking tamoxifen or control). 
The following chapter makes conclusions about the likely range of costs involved in 
delivering a service for tamoxifen chemoprophylaxis. These are based on estimates of 
the costs of running clinics for women enrolled in IBIS. Directly related research costs 
are not included. 
Summary and Conclusions 
The rationale for tamoxifen chemoprophylaxis comes from the mode of action of 
tamoxifen both as an antioestrogen in suppressing carcinogenesis but also a possible 
effect on preventing the development of neoplastic agents. Clinical adjuvant studies 
have shown a reduction in the incidence of new contralateral breast cancers with 
apparently low overall toxicity from the drug. 
Tamoxifen has been seen as the front line treatment for breast cancer since the early 
1970s and a number of important studies are available to assess long term outcome 
including time to recurrence and 5 year survival. Many of these studies have reported 
on serious side effects of the drug such as deep vein thrombosis & pulmonary 
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embolism and endometrial cancer. As a result long term breast cancer adjuvant 
studies are useful in providing information on the safety of trials for tamoxifen 
prophylaxis but more detailed studies are needed to assess the effect of long term 
exposure to tamoxifen for chemoprevention of breast cancer in healthy asymptomatic 
women. 
Evidence for the impact of tamoxifen on levels of morbidity which may have 
consequences for use of health services is scanty both in adjuvant studies and 
prevention trials. Yet, the impact of tamoxifen on general health and well being may 
be the key factor in deciding its use for prophylaxis once efficacy has been 
established. Moreover detailed information on the resource implication for the health 
service is needed prior to the introduction of an intervention which may have 
widespread use. 
Acute toxicity of tamoxifen is low and prolonged exposure in adjuvant studies does 
not appear to result in adverse effects on coronary heart disease or bone mineral 
density despite its anti - oestrogenic properties. In fact, where serum levels of lipids 
and lipoproteins have been monitored tamoxifen appears to have an oestrogenic effect 
improving the lipid profile. Various oestrogen - like effects of tamoxifen do however 
appear to produce premature or recurrent menopausal symptoms. 
Evidence from adjuvant studies suggests that the increase in persistent general 
gynaecological effects from long term tamoxifen use may be around a 25% increase in 
symptoms sufficient to have an impact on psychological well being. Symptoms may 
well be underreported in adjuvant studies or more likely to be tolerated by patients 
than might be expected in a healthy population. 
There are concerns about an increase in the relative risk of endometrial cancer for 
women taking adjuvant tamoxifen. This effect appears to be dose and duration 
dependant. For women receiving adjuvant tamoxifen at a dose of 20mg per day the 
relative risk appears to be between two and three fold. Estimates from 
chemoprevention studies are now as high as a five fold increase though the former 
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may be explained by the high number of hysterectomies at baseline for women 
enrolled in the NSABP P-1. The median cumulative dose of tamoxifen needed before 
diagnosis of endometrial cancer estimated from the Stockholm Trial was 29g. This 
level would be reached after four years of treatment with a daily intake of 20mg. 
There is both clinical and biochemical evidence of an increased risk of 
thromboembolic events in women taking tamoxifen. The effect is clearly complex 
and multifactorial influenced also in adjuvant studies by the presence of disease and 
the impact of chemotherapy. The relative risk for women taking tamoxifen alone 
either as an adjuvant therapy or for prophylaxis may be between three and five fold 
although was less than two for all thromboembolic disease in the NSABP P-1. The 
relative risk appears to increase when tamoxifen is taken in combination with 
chemotherapy with implications for treatment options; the effect is greater in 
postmenopausal women. 
In terms of benefits of tamoxifen chemoprophylaxis, the impact of long term exposure 
to tamoxifen on cardiac health may be at least as important as the end point of primary 
breast cancer reduction. Consistent findings of an effect on lipid lowering may give 
rise to a relative protective effect of tamoxifen on mortality from myocardial 
infarction of around 2.0 though the recent updated overview of randomised trials of 
adjuvant therapy among women with early breast cancer showed no significant 
difference in the aggregate of all cardiac or vascular deaths after about five years of 
tamoxifen. The long term impact on cardiac morbidity in general is unclear and will 
require further research to establish fully. The precise duration of the effect after 
cessation of tamoxifen treatment is also uncertain. 
The impact of tamoxifen on bone mineral density in postmenopausal women seems to 
be an increase primarily in the lumbar spine and hip by an annual increment of around 
1.5% though this increase appears to occur only during the early years of tamoxifen 
use. Some evidence also suggests that the protective effect on BMD may be lost after 
cessation of use and similar effects on radial bones appear doubtful. Larger studies 
are needed to confirm the reduction in bone mineral density in premenopausal women 
83 
suggested in results from the Royal Marsden prevention pilot and to assess both the 
duration of this effect and the clinical significance. 
Estimates of the likely reduction in risk of death from breast cancer with 
chemoprevention have been predicted from adjuvant studies where a review of long 
term follow up has shown a consistent improvement of around 50% in ten year 
survival with use of tamoxifen after surgical resection of disease. Consistent with this 
finding, NSABP P-1 found a 49% reduction in risk of invasive breast cancer in 
healthy women taking tamoxifen. This has not been confirmed by the publication of 
two further preliminary reports from chemoprevention studies. Differences in the 
study populations may may be responsible for these contrary findings. 
84 
Chapter Three 
Cost of delivering tamoxifen chemoprophylaxis (using the pattern of work and 
models of service delivery in IBIS centres). 
Introduction 
This section sets out a range of likely costs for delivering a service for 
chemoprevention of breast cancer with tamoxifen. The costs are based on the process 
for care established within the International Breast Cancer Intervention Study. (IBIS)' 
A distinction is made between those costs, which should be primarily attributed to 
service delivery within the NHS and those which derive primarily from the research 
protocol. These issues are discussed with conclusions drawn about possible 
alternative models for service delivery should tamoxifen prophylaxis prove to be 
effective in reducing incidence and mortality from breast cancer. 
Method 
A number of models of care have emerged in establishing IBIS within existing routine 
breast care services. These probably represent the range of options for any future 
development of preventive care for women at high risk for breast cancer though the 
structure and function of the IBIS centres has arisen largely from expedience in each 
of the host services - fitting a research trial alongside busy breast care services - 
rather than with the economic aim of aim of maximising the efficiency of service 
provision. Information about costs are derived both from a survey sent to each of the 
centres and followed up through telephone discussion as well as direct observation on 
10 occasions in 4 centres. Additional information was obtained from the IBIS co- 
ordinator. 
Costing information is derived from national pay scales and standard costs for drugs 
and tests. Comparisons are made between the different possible models of care for 
delivering tamoxifen chemoprophylaxis based on approaches used in IBIS centres. 
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Centres and settings for IBIS 
At 1 April 1997, there were in the UK 16 centres involved in the IBIS trial with a total 
accrual of 1,917 women. The rate of women attending the centres who are not 
subsequently randomised into the trial is low although considerable time can be spent 
by discussing the trial with women who choose not to be randomised. 
Table 1 shows the number of sessions per week run in each of the centres and the 
setting in which women recruited to the trial are seen. 
Table 1 Sessions /week and settings of IBIS Centres 
Centres Sessions per week setting 
Aberdeen I ibis* 
Belfast 0.25 th** 
B'mingham I fig 
Bristol 3 g. brst***/th 
Cardiff 3 g. brst/fh 
Chelmsford I ibis 
Edinburg' I ibis 
Glasgow I ibis 
Guys 3 ibis 
H'dersfield I ibis 
Leeds I g. brst 
Leicester I fh 
Manchester I th 
Newcastle I fh 
Nottingham I fh 
S'hampton I ibis 
Total 21.25 
Mean/week 1.33 
* refers to standalone clinic 
** refers to IBIS clinic integrated into the family history clinic 
***refers to IBIS clinic integrates with general breast outpatient clinic 
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In general centres run one IBIS session per week though there are three possible 
sessions in Bristol, Cardiff and at Guys with one each month in Belfast. In at least six 
out of the 16 IBIS centres women recruited to the trial are seen within family history 
clinics (fh); in Cardiff and Bristol two further sessions are held alongside general 
breast care clinics(g, brst). In the remaining six centres IBIS clinics have been 
established as standalone sessions though working closely with and receiving referrals 
from the main breast care clinics. In Aberdeen and Chelmsford the IBIS clinics are 
sited within the breast screening unit. 
A broad range of staff are involved in running IBIS clinics. Doctors involved are 
usually surgeons involved in examining women prior to their recruitment to the trial. 
Consultant radiologists and geneticists are also closely involved. A number of the 
centres have the close involvement of clinical assistants or associate specialists who 
may also be involved in supporting clinics in other parts of the breast care service 
particularly family history clinics. Nurses working in IBIS are for the most part F or 
G grade nurses usually with a breast care qualification. A number of the nurses 
involved are also qualified in research. IBIS sessions in general run with a 1: 1 doctor 
to nurse ratio with other specialist advice available where needed. 
The rate of recruitment was lower than anticipated in all of the centres with the 
possible exception of Bristol which has the highest total number of women enrolled 
into IBIS and the highest rate of accrual of new recruits. Table 2 shows the average 
number of new women recruited to each of the centres and the average number of 
women attending for follow up visits per week. 
Table 2: Numbers of new and follow up attendance's/week in IBIS Centres 
Centres 
Aberdeen 2.2 8 
Belfast 1.5 1.5 
Birmingham 3 6.5 
Bristol 2.5 8.5 
Cardiff 2 6 
Chelmsford 1 1.5 
Edinburgh 1.5 5 
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Glasgow 3 3 
Guys 2.5 12 
Huddersfield 0.5 3.5 
Leeds I 1 
Leicester 0.25 
Manchester 1.5 13.5 
Newcastle 0.25 3.5 
Nottingham 1 3 
Southampton 2.5 6.5 
Total 26.2 84 
Mean/week 1.64 5.25 
An average of around 1.6 new women are seen per week with a range of 0.25-2.5 
depending on the size of the clinic. Although the time involved in seeing women for 
follow up visits is considerably less than that for new recruits the follow up visits 
represent a considerable workload for the centres because of the numbers and total 
amount of time involved. The average number of follow up visits per week is 5.25 
with a range of 1-13.5 depending on how long the centre has been running. 
Women are seen 2x per year according to the schedule set out in the IBIS protocol. 
The time spent with new recruits varies between the centres though is on average 
about 3x higher for new visits than for follow up visits. Table 3 shows the estimated 
mean time spent with women on the first and subsequent visits across all centres. 
Table 3: Time (mins) spent with patients (mean (std dev)) 
New Visits Follow up visits 
Dr 23(16) 5(4) 
Nurse 36(28) 14(9) 
Total 59(44) 19(13) 
At the initial visit the trial is discussed with the woman and any questions answered in 
detail either by the nurse or the doctor depending on the usual practice in the centre. 
In most centres initial enquiries about the trial are made outwith the clinic session and 
the time involved is not included here since it does not relate directly to service 
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delivery. Once the women have consented to participate in the trial a randomisation 
number is obtained from the IBIS office at the Imperial Cancer Research Fund (ICRF) 
and the recruitment process takes place. A complete clinical history is taken along 
with measurements of height, weight and blood pressure according to the IBIS 
protocol. Women have a mammogram at the initial visit unless they have had one 
within the last 12 months. 
A blood test is also taken at this visit which the nurse spins and sends to St Mary's 
NHS Trust for analysis for cholesterol levels; no other test is made though the bloods 
are stored for subsequent review of compliance or further tests should they be needed. 
The women are provided with supplies of tablets (tamoxifen or placebo) according to 
randomisation and future appointments are made. Written information is given to all 
patients with a telephone number for queries or concerns. Supplies of tamoxifen or 
placebo are counted, prepared and stored either by the IBIS nurse or co-ordinator 
though in some centres the pharmacy department take responsibility themselves for 
storing and dispensing. 
Most of the activities undertaken for the initial visit within IBIS would be the same 
within routine service delivery. Activities such as randomisation and discussion of 
the aims and objectives of the trial would not of course take place in an NHS clinic. 
The former is however a small part of the overall time taken at the initial visit and the 
latter would be equivalent if adopted in routine practice to time spent describing the 
evidence on which the prophylaxis was being offered. 
Staff Costs 
Table 4 shows the estimated staff costs per new patient visit per centre. The costs are 
based on the number of new patient visits and incremental costs of staffing the 
sessions assuming £300 per consultant sessions, £100 per clinical assistant session 
and £50 per nurse session. The length of each session is taken as 3 hours. The 
secretarial/administrative costs are not included at this stage since they vary 
considerably between the centres. Moreover many of the tasks involved in advertising 
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the trial and recruiting women are not included here since they relate to the running of 
IBIS and are not relevant to routine service delivery. 
Table 4: New Recruits - Staff Costs 
IBIS Doctor 
Centre Specialty mean tim 
(m) 
e number new Dr cost Nurse time spent nurse Total staff" cost 
per woman women/week * grade by nurse(m) cost# er new recruit 
1 rad/altsurg/onc 45.00 2.20 162.36 d 5.00 1.21 74.35 
2 surg 10.00 2.00 32.80 h 20.00 12.30 22.55 
3 scmo 25.00 3.00 41.25 h 10.00 12.30 17.85 
4 scmo/surg 2.00 2.50 8.20 g 15.00 11.63 7.93 
5 surg 30.00 2.00 98.40 f 120.00 50.40 74.40 
6 surg 5.00 1.00 8.20 f 15.00 3.15 11.35 
7 genetics 35.00 1.50 86.10 f 45.00 20.93 71.35 
8 surg 10.00 3.00 49.20 h 40.00 37.20 28.80 
9 surg 40.00 2.50 164.00 g 45.00 34.88 79.55 
10 surg 0.50 0.50 0.41 g 30.00 4.65 10.12 
11 surg 20.00 1.00 32.80 f 60.00 18.60 51.40 
I2 ass spec 10.00 0.25 1.38 f 20.00 1.05 9.70 
13 oncol/gen 15.00 1.50 36.90 f 20.00 6.30 28.80 
14 gp/surg 30.00 0.25 4.13 f 45.00 2.36 25.95 
15 sr/clin asst/surg 50.00 1.00 27.50 g 50.00 15.50 43.00 
16 clin asst 40.00 2.50 55.00 2xg 40.00 62.00 46.80 
Total 367.50 26.70 808.62 294.45 41.31 
mean 22.97 1.67 50.54 0.00 18.40 41.31 
td dev 16.10 0.93 52.32 27.60 18.45 76.28 
*at £300/consultant session 
#at £50/Nurse session 
**Dr and nurse only 
The mean costs per new patient are just under £42 , the range is 
from £8 in centre 4 to 
almost £80 in centre 9. The variation in costs per new patient are explained by the 
difference in doctor time spent with new patients . 
Costs are directly proportional to 
the amount of time spent by doctors irrespective of the differences in costs of doctor 
time between grades. Lower costs are found in centres where nurse involvement 
'Advance letter April 1995 NHS(E) 
Nursing and Midwives NM 1/1995 
Doctors and Dentists MD 1/1995 
90 
occupies the greatest proportion of time spent by clinical staff. In centres such as 
Guys, Aberdeen, Cardiff and Edinburgh where doctors spend relatively more time 
explaining the trial and the process of care for women involved costs are higher. 
The process of care in IBIS is well illustrated by the centre with the highest rate of 
recruitment to the trial. This centre also has the lowest cost per patient. Until recently 
this centre was based only in the family history clinic. The nurse discusses the trial 
with women referred from either the family history clinic or from general 
practitioners. She also completes. the history for entry to the trial, takes blood and 
secures referral for mammography. The doctor examines the patient between routine 
consultations within the general clinic. On occasions staff in training grades are 
available to support this process and may be able to examine women recruited for 
IBIS. In general the surgeon's time is not much reduced by this process since queries 
can take a good deal of time and trainees are likely to see far fewer women than the 
consultant. More recently a clinical assistant has been recruited to support the general 
clinic and is available to see IBIS women. Again, in general the clinical assistant sees 
fewer women than the consultant and takes longer. Queries are discussed with the 
consultant. Routine ultrasound is offered to women in this clinic yet the costs in 
terms of doctor time are not affected. Follow up costs in terms of clinical staff time 
are shown in table 5 below: 
Table 5. Follow up staff costs per woman 
IBIS number Cost Total cost 
Centre Vu per week nurse t(m) Cost Nu t(£) Dr t (m) Dr time Dr&Nu (£) 
1 8.00 17.50 15.40 2.00 26 42 
2 1.50 20.00 12.30 2.00 5 17 
3 6.50 1.00 2.67 5.00 18 21 
4 8.50 15.00 39.53 5.00 70 109 
5 6.00 25.00 31.50 2.00 20 51 
6 1.50 10.00 3.15 2.00 5 8 
7 5.00 15.00 15.75 15.00 123 139 
8 3.00 20.00 24.60 2.00 10 34 
9 12.00 10.00 37.20 10.00 197 234 
10 3.50 10.00 10.85 0.50 3 14 
11 1.00 15.00 3.15 10.00 16 20 
12 1.00 0.00 0.00 10.00 6 6 
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13 13.50 25.00 70.88 1.00 22 93 
14 3.50 12.50 9.19 5.00 29 38 
15 3.00 30.00 27.90 3.50 17 45 
16 6.50 15.00 60.45 2.00 21 82 
Total 84 365 77 587 952 
Mean 5 23 5 37 59 
Std dev 4 21 4 52 61 
Overall the follow up visits during the week increase the total cost per new recruit per 
week by a factor of about 1.5. The numbers of follow up visits quickly accrue 
particularly in centres with a high rate of recruitment. The time spent with women 
during follow up visits by both the doctor and nurse is however considerably less than 
with women new to the study. The amount of time spent with the doctor is still the 
main factor explaining the cost differences between the centres. The centres with the 
highest follow up costs are those where medical staff spend a large proportion of the 
total time of the visit with the patient. Where doctor time is also relatively higher in 
centres such as 11 and 12 with lower overall costs this is because of the lower grade 
of the doctor involved. Clinical assistants and associate specialists are responsible for 
IBIS patients in five of the centres. 
This analysis has focussed on costs most likely to influence the cost effectiveness 
rates for tamoxifen chemoprophylaxis. Where breast cancer chemoprevention was to 
be introduced into routine services fixed costs would need to be considered. This 
study demonstrates however only a small increase in the proportion of women seen 
compared with the overall numbers attending breast services. Moreover where service 
delivery was offering in general practice changes in fixed costs to women attending 
for chemoprevention would be negligible. 
There are a number of hidden costs involving staff time which could be attributed to 
IBIS because they may bear on the overall costs of the trial; they are less likely 
however to play a significant role in service delivery. These include the time spent 
discussing the trial with potential new recruits in settings other than those designated 
for the study. In some hospitals the trial is discussed extensively with eligible women 
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attending genetics clinics, particularly those under 50; one centre estimates that only 
1 in 8 women decide to become involved in the study though about 3-5 eligible 
women are seen per week and a substantial amount of time is spent with them. 
Another centre based in a screening unit asks women if they have a family history of 
breast cancer in order to assess eligibility for IBIS. Where eligible women are 
identified they are referred to the IBIS clinic but only via a referral to the genetic 
clinic. Direct costs which can be attributed to IBIS from general practice emerge in 
one centre where women are routinely referred back to their GPs for breast 
examination. 
In most centres the hospital pharmacy has been helpful in storing, counting and 
dispensing tablets though there have been concerns about funds available to support 
this work. Where pharmacy has been unwilling or unable to store and process 
supplies the centre co-ordinator or nurse has taken on this task. 
A considerable amount of time is spent in writing to or phoning women who have 
expressed an interest in the study, or those who have missed an appointment or have a 
particular problem. Most centres also contact women prior to appointments or to 
follow up an initial discussion since this is thought to be an efficient means of 
screening out those women who are unlikely to pursue the study and to reduce the rate 
of missed appointments. Centre co-ordinators also spend time working through the 
press or within local networks seeking to publicise the study and to encourage new 
recruits. A range of estimates are reported from centres on the time spent on these 
activities although all report the need to increase the time available for recruitment. In 
general it might be expected that an additional three-hour session of clerical time may 
be needed. This would increase the cost by around £13/new patient visit. This cost is 
excluded from the analysis since it is a research cost rather than directly attributable 
to service delivery. 
Costs of tests and drug supplies 
Additional costs (see table 6) include an annual mammogram at around £56, blood 
tests taken at the beginning and end of the study costed at £10 in total and drug 
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costs16'. Other consumables including equipment used during in examination and set 
up costs for the clinic are omitted since they are unlikely to add substantially to the 
cost of clinic visits. Tamoxifen is a relatively inexpensive drug and at around £30 per 
year will represent a small proportion of the total overall costs. The cost for each new 
patient visit is around £81. The average cost for follow up visits is around £33.8. 
Table 6: Costs of Tests and Drug Supplies (£) 
For women in IBIS 
Visit Mammography Blood Drugs Total (new) 
1 56 10 15 
Total new 56 10 15 81 
Follow up month 
6 0 0 15 
12 0 10 15 
18 56 0 15 
24 0 0 15 
30 0 0 15 
36 56 
42 0 
48 0 
54 56 
P 
60 0 
total f/u 168 338 
£/per fu 
visit 
16.8 15 33.8 
Costs per woman per five year recruitment 
The staff time costs set out above together with the costs of drugs investigations and 
mammography outlined above are used to derive an estimate of the overall cost for 
delivering tamoxifen chemoprophylaxis per woman. This is set out in the table 6. 
Estimated cost per woman recruited to IBIS 
Item £/episode over 5 years % 
Mean staff cost (new recruit) 42.00 42.00 4% 
Mean staff cost( follow up visit) 59.00 590.00 53% 
Tests, investigations (new recruits) 66.00 66.00 6% 
Tamoxifen prescriptions(new recruits) 15.00 15.00 1% 
Test, investigation (follow up) 18.80 188.00 17% 
Tamoxifen(follow up) 15.00 150.00 13% 
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Administration cost/woman/year 13 65.00 6% 
1 Total 1116.00 100% 
The overall cost per woman over the 5-year period of taking tamoxifen is around 
£1000 per woman. The cost of recruitment (4%) is a relatively small proportion of the 
overall cost of offering tamoxifen chemoprophylaxis. Staff costs for time involved in 
follow up visits accounts for by far the greatest proportion of the overall cost (53%). 
The costs of prescription and investigations(mammography and blood tests) account 
for a similar proportion (around 15% and 17% respectively) 
Discussion 
The costs discussed here based on the amount of time spent by staff involved in 
delivering tamoxifen prophylaxis together with the costs of mammography and 
routine blood tests. Only costs, which are clearly associated with service delivery, are 
included. Costs attributable to the context of a research trial are excluded. These 
include the time spent outwith clinic sessions discussing the trial with potential 
recruits, time spent in talking with women's groups or press activity. The time spent 
in randomisation is likely to be small in terms of the overall time spent recruiting 
women. Discussion about the trial, which takes place within the clinic session, may 
be assigned as a research cost but would be equivalent to time spent discussing the 
rationale and evidence for prophylaxis with women in a service context. 
Fixed costs are not included since they would be likely to vary considerably between 
centres irrespective of the model of care for IBIS. The overall cost of service delivery 
at less than £200 per new women per year recruited is relatively low in comparison 
with many other areas of health care. This level of cost might be considered 
equivalent to outpatient costs for some medical specialties where there are few 
expensive investigations and the costs of medical therapies are low. The difference 
between the cost of routine service delivery and the research protocol is likely to be 
small since there are relatively few investigations for women recruited to IBIS other 
than annual mammography. Blood tests are taken only at the beginning and end of 
the recruitment period. Routine endometrial screening and other tests undertaken in 
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the NSABP P-1 study2, which would considerably increase the difference in costs 
between the research and the clinical setting, are not included in the IBIS protocol. 
It is possible however that in the context of a clinical trial more frequent follow up 
and investigation might be considered necessary than for routine service provision. 
Women involved in chemoprevention of breast cancer may potentially require 
minimal investigation. Even annual mammography for example required within the 
trial protocol may be inappropriate within the context of service delivery. The 
evidence for improved health outcomes with frequent mammography screening for 
women under 50 is poor and women over age 50 would have access to mammography 
as part of the NHS Breast Screening Programme (every 3 years until age 65). Such an 
approach would also reduce overall costs and the pressure on mammography services. 
The amount of time spent by specialist breast surgeons either in breast examination or 
in providing information to women about the risk and benefits of tamoxifen 
prophylaxis accounts for the greatest proportion of staff cost. If this task were 
appropriate to be performed by a nurse with specialist support staff costs could be 
much reduced. Such an approach is within the range of models of service delivery 
currently used within the IBIS trial protocol and might be adopted with minimal 
additional training for nursing staff within the umbrella of breast care services in the 
UK. Where the service is led by nurse practitioners minimal input from a consultant 
surgeon may be reduced to a single session to discuss the risks and benefits of 
tamoxifen prophylaxis in terms of individual level of risk of breast cancer. Such an 
approach with nurse only follow up visits and mammography reduced to 3 times over 
the course of the 5 year period of active prevention would reduce costs per woman to 
around £535 over the 5 year period. The burden of cost likely to fall on breast units 
adopting this approach would depend on the numbers of additional women eligible for 
prophylaxis and willing to comply with long term drug treatment - and the marginal 
increase in numbers of women within the breast service likely to increase the demand 
for additional members of clinical staff and clinic sessions. 
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The pattern of service delivery may well be more appropriate to general practice than 
to most hospital care possibly with referral for specialist support should problems or 
anxieties arise. In practice symptoms or signs emerging during the course of 
prophylaxis are likely to be dealt with in primary care or referred on by GPs to 
appropriate specialists. Evidence from other areas of health care suggests that there is 
little value in routine follow up visits to specialist centres. Where general practice 
were to be considered a more appropriate setting particularly for follow up visits costs 
may reduce to around £410 per woman over the 5 year period assuming as in the 
nurse led model a single visit to a specialist breast surgeon and 5 annual visits to a 
GP. Most GPs would expect to see only 2 or 3 women per year with the eligibility for 
tamoxifen prophylaxis and the motivation to undertake long term drug therapy. 
These issues are discussed further in Chapter 7 where a consolidated estimate for cost 
effectiveness is modelled from the costs set out in this and subsequent chapters. The 
baseline estimate for the cost of service delivery used in the model is of a hospital 
based service led by consultant breast specialists though with significant involvement 
of specialist nurses (£535/woman) as described above. Sensitivity analysis does 
however include other estimates including the possibility of a service delivered 
through general practice at £410/woman and with the lower estimates of £200/woman 
underpinning the budgets available to centres within IBIS 
Summary and Conclusions 
Costs for service delivery are based on a direct observation and a telephone survey of 
workload, staffing and the clinical protocol used in IBIS centres. Costings are 
based 
on bottom up assessment of the time spent by staff with IBIS recruits using national 
pay scales. Mammography is costed at £56, blood tests at £10 in total and the cost of 
20 mg tamoxifen daily is taken as £15 per year from the National Drug Tariff. 
The 
overall cost for delivering tamoxifen prophylaxis within the context of the trial 
is 
£1116 per woman per 5 years. The largest proportion of cost (57%) is in staff time. 
The cost of doctor time is the largest element; the amount of time spent by the doctor 
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explains the difference in cost between the centres. Tests and investigations account 
for a further 23% of the cost and provision of the drug tamoxifen for 14% of the cost. 
Costs of administration make up the remainder of the cost (6%) 
Hidden costs are discussed and include the time spent discussing the trial by other 
health professionals particularly geneticists running family history clinics and GP 
time. In one centre for example the physical examination is carried out by the GP. 
The review illustrates that there is little specialist input to the provision of tamoxifen 
prophylaxis and that the main time element is in discussing the concept to the women 
and the protocol for consent to enter the trial. While the time element in `consenting' 
woman may translate into time spent discussing the evidence base and side effects of 
tamoxifen prophylaxis if the approach was adopted in routine practice some savings 
could be made. 
Leaving aside the research costs included in the overall estimate and reducing the time 
spent by women in the clinic as well as some of the investigation two scenarios for 
service delivery are proposed. These are £535 for a nurse led hospital service or £410 
for a service run in general practice. The hospital service is used as the baseline 
approach for the model developed in chapter 7 and the GP run service is explored 
through the sensitivity analysis. Both approaches would rely on minimal input from a 
consultant surgeon or equivalent with only 1 visit included for the 5-year period. The 
frequency of mammography would reduce to a maximum of 3 times in the 5-year 
period. Both scenarios exclude the costs attributable to the research trial particularly 
the need for annual mammography, the taking and processing of blood and time spent 
recruiting women to the study. 
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Chapter Four 
Morbidity and Resource Use: 
Use of Hospital Services 
Introduction 
Following the review of literature about the risks and benefits for women taking the 
drug tamoxifen in Chapter 2, this and the following chapter derive more precise 
estimates of the likely impact of morbidity on the cost effectiveness of tamoxifen 
chemoprophylaxis. This chapter is concerned with the prospect of changes in the use 
of hospital visits for symptoms associated with long term tamoxifen use and Chapter 
5 measures changes in the rate of use of prescribed medications. The analysis is based 
on measurements of differences in the morbidity experience of women in the 
tamoxifen or control arm of the International Breast Cancer Intervention Study (IBIS). 
Small changes in the use of hospital services or prescribed medications for the age 
group targeted in prevention trials could have a significant impact on overall cost if 
large numbers of women were affected. Yet, there have been few studies published on 
the effect of tamoxifen on morbidity as measured through changes in hospitalisation 
rates or use of medications. As discussed earlier there have been great many studies of 
the effects of tamoxifen when used as adjuvant therapy. 
Most prevention studies have been primarily concerned with the effects of tamoxifen 
on adverse outcomes such as thromboembolism or endometrial cancer. Primary 
endpoints in NSABP P-12 and in the Powles8 and Veronesi' l studies all include 
incidence and mortality from histologically confirmed breast cancer. Other incident 
cancers including endometrial cancer are also recorded and all causes of death during 
the trial verified. Secondary endpoints include ischaemic heart disease events, other 
vascular events and fractures. `Other disease' and medical problems are sometimes 
recorded at each visit yet there has been no systematic reporting of morbidity from 
these studies. 
Fornander et al142 considered the impact of adjuvant tamoxifen on the intercurrent 
morbidity and mortality of women involved in the Stockholm Adjuvant Trial using 
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information on hospital admission records and death certification but no studies have 
reported the detailed pattern of hospital use by women involved in prevention studies 
or their use of prescribed medications for conditions relevant to known side effects of 
tamoxifen or for their health in general. 
Women may experience symptoms arising directly from the use of tamoxifen 
necessitating a hospital referral or the use of a drug or by contrast they may 
experience a reduction in the frequency of morbidity because of a protective effect of 
prophylaxis. Changes in the pattern of morbidity may also arise indirectly from 
different health behaviour elicited by involvement with a preventive intervention. 
Women taking long term preventive therapy may be more likely to seek medical 
advice as a result of heightened awareness of their risk of disease; greater personal 
awareness of health and illness may reduce their threshold for consultation about 
relatively minor symptoms. Alternatively they may feel more reassured by the fact of 
the preventive intervention and reduce their use of health services. Women recruited 
to IBIS for example may make use of routine consultations with health care 
professionals at IBIS clinics for discussion of broader health issues and as a 
consequence reduce their use of other health facilities. 
Quite apart from the relatively rare adverse outcomes from tamoxifen therapy there 
are common side effects which may have consequences for the pattern of morbidity in 
patients treated with tamoxifen over a long period of time. These side effects may 
affect both compliance with prophylaxis in healthy women who are otherwise 
asymptomatic for breast cancer or related diseases and if translated into use of health 
services or the rate of prescribing may influence the relative cost effectiveness of 
chemoprevention. Information from women recruited into IBIS is used in this section 
to identify and quantify this effect through measuring changes in the use of hospital 
services by women recruited to IBIS. 
Method 
The information presented below is collected from self-reports of hospital visits made 
by women recruited into IBIS. Women are asked at recruitment, at the first follow up 
visit at 6 months and at each of the subsequent visits at 6 monthly intervals over the 5- 
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year duration of the trial about any hospital visit. A brief outline is requested on the 
data collection form and the study co-ordinators in each centre are asked to forward 
details on an illness report form together with any confirmatory information including 
pathology reports or copies of correspondence between GPs and hospital consultants. 
Information on the use of hospital services since the previous visit is also occasionally 
recorded on the section of the follow up form requiring details of side effects. This 
covers a range of usual symptoms and includes a request for details of `other' 
symptoms where information about hospital use is sometimes entered. All 
information on hospital visits from the follow up forms is entered into an oracle 
database by data entry clerks. 
The information selected to assess the hospital resource use included all women 
recruited to IBIS who had a hospital visit by the end of December 1997. 
Completeness and accuracy of the follow up entries for the women was checked 
through hand searching of the patient records. A great many incomplete records were 
found necessitating validation and completion of the information by reference to the 
woman's original notes or through discussions with the study centre co-ordinators. 
The data were downloaded to an Excel spreadsheet for each of the women reporting 
hospital use and then summarised to produce where possible a diagnosis using 3 digit 
codes from the International Classification of Diseases 9th series (ICD9) and main 
ICD9 chapter headings for the diagnosis given on the form. 
Since the main aim of the study was to assess any change in use of health services by 
women taking tamoxifen for breast cancer prophylaxis it was important to quantify 
the use of health care resources arising from hospital visits. This was done by 
assigning each of the procedures recorded in the notes to a health care resource group 
(HRG) 15' The HRGs are readily costed with standard prices from the District 
General Hospital Accounting System used within the National Health Service 
(NHS) 166 HRGs were developed by the National Case Mix Office funded by the 
NHS. They aim to provide a straightforward means of assigning hospital admissions 
including both day case and inpatient episodes into clinically meaningful groups 
representing similar levels of health care resource consumption. The main value of 
HRGs is that they include case mix information and so can provide appropriate 
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comparison for assessing the efficiency of resource use between different hospitals. 
Case mix adjustments include the age of the patient and the presence of comorbidities 
or secondary diagnosis in relation to the main condition under review. The use of 
HRGs in this study is to derive a likely cost for each hospital visit that is based on 
more detailed information than diagnosis or procedure code alone. Costs can vary 
considerably depending on the severity of the condition, the age and general health of 
the patient. A number of studies have use of HRGs in predicting cost differences 
between hospitals and they have been adopted as the main means for costing health 
care contracts in the NHS. 167,168,169,170 
Hospital visits involving any clinical procedure in the 6 months prior to each IBIS 
follow up visit had an HRG assigned to them where possible using the primary 
diagnosis from the information given on the women's record, the procedure and the 
age of the woman. Each assignment was checked by a general practitioner advisor to 
the National Case Mix Office and a reference set of HRGs established for the most 
frequent symptoms and information found within the records. In the main the final 
set of HRGs included in the analysis presented here include only those which would 
normally be classified in the routine information from the NHS as `inpatients' or `day 
cases'. Out patient visits do however increasingly result in the use of procedures such 
as endoscopy or breast biopsy and where possible an HRG has been assigned to them. 
The information included under the heading of outpatient activity therefore includes 
only those cases where no specific procedure was reported for example where the 
woman may have been offered advice, given a test result (recorded at a previous visit) 
or referred back to her general practitioner. These `outpatient episodes' have been 
costed using GP Fundholders price tariffs from the specialty reported on the record or 
that most usually associated with the diagnosis or procedure166. 
In order to preserve the blinded nature of the IBIS trial the data have been separated 
into 2 groups: A and B for women taking either tamoxifen or placebo; the 2 groups 
are anonymised and do not label the same arm of the trial throughout this analysis. It 
was not possible to assign an ICD 9 Chapter to 68 of the visits reported, 33 in group A 
and 35 in group B. For 9 women -5 in group A and 4 in group B it was unclear 
whether a procedure had taken place as a result or their visit to hospital. For these 
women hospital expenditure of £100 was assumed since it was clear from the record 
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that they must have incurred at least an outpatient visit. For 2 women, pregnancy was 
the reason for the hospital visit. Since pregnancy is unlikely to have been affected by 
tamoxifen chemoprophylaxis but immediately excludes the woman from further 
participation in the study they have been excluded from the final analysis. 
Statistical analysis 
For all women recruited to the trial descriptive information on the use of hospital 
services is grouped and ranked according to the number and proportion of visits by 
main reason for visit within main ICD9 chapter heading, for specific diagnosis 
associated with 3 digit codes) and by main procedure undertaken (HRG). The number 
of visits per woman is also calculated overall and per follow up visit. A frequency 
distribution of the cost of hospital visits is used as the most suitable means to 
demonstrate the shape of the cost distribution. 
Differences in the rates of use of hospital both by diagnosis category and for 
procedures undertaken are calculated as odds ratios with confidence intervals 
calculated by the standard method of Cornfield. Comparisons of the mean cost per 
visit overall in each of the 2 series is calculated with Fishers exact test using a normal 
approximation. The size of the sample and the shape of the distribution may affect 
the significance of the finding between the 2 series. Once a larger sample is available 
consideration may be given to a Wilcoxon Sum test to account for the non normal 
shape of the distribution of costs to women although as the sample size increases the 
conditions for assuming a normal distribution increase. Applying the test at this stage 
would have discerned no further information. A student's t test was used to compare 
the distribution of costs per women within each of the disease categories. A non 
parametric test on ranked data may have been more appropriate although the 
distribution of costs per women within disease categories more greatly approximates a 
normal distribution than seen in the overall costs. 
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Results 
Women recruited to IBIS: broad patterns of hospital use 
Out of the 2531 women recruited to the study with a total of 6696 IBIS follow up 
visits at the time of analysis a total of 825 (32.32%) women reported 1321 hospital 
visits since their previous assessment at an IBIS clinic; a rate of 1.6 visits per woman. 
There were 814 outpatient visits where no procedure was undertaken and 507 visits 
made by 429 women (16.9%) included procedures which could be assigned to an 
HRG. By comparison, the rate of admission either for a day case or an ordinary in- 
patient admission to an NHS hospital in 1994/5 was around 17.8% of women aged 
45-64 (see fig 1) 167. 
Fig 1. The rate of admissions to NHS hospitals (ordinary and day cases) for all 
women in England. The rate of all admissions is shown (rate) and the rate for 
genitourinary (genito) conditions only. 
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Age 
Women in the 45-64 age group most likely to be targeted for breast cancer 
prophylaxis are relatively high users of hospital and other health services for 
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conditions associated with breast care and genitourinary problems though they have a 
lower overall rate of admission than both older and younger adult women. The higher 
rate of admission to hospital for all conditions in younger women (aged 15-44) is due 
to pregnancy and childbirth. Older women in the age groups 65-74 and 75+ have the 
highest rates of admission for all causes, these are principally due to cardiovascular 
conditions, cancer and other chronic diseases such as respiratory problems and 
diabetes. 
The mean age of women recruited to the study overall is 49.5 years compared with a 
mean of 49.8 years in series A and 49.1 years in series B. The median time of follow 
up was 18 months. Table 1 shows the main reasons for attending hospital by all 
women reporting a hospital visit. In the table all diagnosis are grouped for all women 
under the main ICD9 chapter headings since it is expected that tamoxifen may have 
similar effects in similar body systems. Also, there are small numbers in some of the 
specific disease categories and review of broader groupings may allow more 
meaningful statistical analysis. Some analysis of specific diagnosis at the level of 
ICD9 3-digit code has been possible for the more common diagnosis and is discussed 
below. 
Table 1. Numbers and % of Visits in each ICD9 Main Disease Chapter 
Disease Chapter Number of Visits % of total Cumulative % 
Genitourinary(X) 429 32.48% 3248% 
Musculoskeletal(XIII) 195 14.76% 47.24% 
Digestive(IX) 137 10.37% 57.61% 
Vascular(VII) 92 6.96% 64.57% 
Nervous and sense organs(VI) 77 5.83% 70.40% 
Endocrine and Metabolic((III) 74 5.60% 76.00% 
Neoplasms(II) 61 4.62% 80.62% 
Injury and Poisoning((XVII) 61 4.62% 85.24% 
Respiratory System((VIII) 57 4.31% 89.55% 
Skin(XII) 31 2.35% 91.90% 
Infectious(I) 17 1.29% 93.19% 
Mental disorders(V) 14 1.06% 94.25% 
Blood(IV) 5 0.38% 94.63% 
Unassigned 71 5.37% 100.00% 
Total 1321 100.00% 
Number of women 825 
Mean age of women 49. Syears 
Median follow up 18 months 
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Overall, the main reason for hospital visits accounting for over a third of the total 
(32.4%) fall into Disease Chapter 10 - diseases of the genitourinary system covering 
disorders of the female genital tract, urinary tract and breast diseases. Musculoskeletal 
disorders including fractures form the second major category of reasons for visits 
(14.7%). Diseases of the digestive system account for 10.3% of the total visits and 
diseases of the circulatory system covering cardiological and vascular disease account 
for 6.9% of visits. Diseases of the endocrine and metabolic system, the nervous 
system including sense organs, injury and poisoning including fractures and the 
respiratory system each account for less than 6% of the reasons for visits and 5% were 
unclassified; 4.6% of the women had visits due to neoplasms. 
The distribution of hospital visits by main ICD9 Disease Chapters for women 
recruited to IBIS overall is similar to that found in the NHS routine admissions data 
(ordinary and day cases) although the NHS routine data do not include outpatient 
visits (Table 2). 
Table 2: Number and % of Admissions (Ordinary and Day Cases) to NHS 
Hospitals in England (1994/5) by main ICD9 Disease chapter for Women aged 
45-64. 
Admissions 
Disease Chapter ordinary and day cases 
Numbers % 
Neoplasms 160534 15.58% 
Genitourinary 156835 15.22% 
Musculoskeletal and injury 142393 13.82% 
Digestive 125722 12.20% 
Vascular 96426 9.36% 
Nervous and sense organs 56512 5.48% 
Respiratory 41248 4.00% 
Mental disorders 28145 2.73% 
Skin 25144 2.44% 
Endocrine and metabolic 18412 1.79% 
Blood 11584 1.12% 
Infectious 6968 0.68% 
Other 160775 15.60% 
TOTAL 1030698 100.00% 
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The largest category in the NHS admissions data is women admitted for neoplasm - 
these women would be ineligible for recruitment to IBIS. Apart from this category the 
ranking of reasons for hospital attendance is broadly the same by main ICD9 chapters 
for both women reporting hospital visits in IBIS and women in routine NHS data. 
The proportions in the 2 series are not directly comparable. NHS data are based on 
hospital episodes rather than individual visits. The routine NHS data do not include 
information on outpatients although they do cover a rather broader range of reasons 
for admission than is seen for women in IBIS. Nevertheless it is interesting to note 
that women enrolled in IBIS appear to report the use of hospital services for 
genitourinary conditions at a higher rate than seen for women in the NHS data set. 
238 women out of the 2,531 women recruited to IBIS (9.4%) reported a visit to 
hospital including a procedure categorised within an HRG in the disease chapter 
concerned with genitourinary conditions compared with a consultation rate seen in the 
NHS for these conditions (see fig 1) of 2.71%. By contrast the reported rate of 
consultation for musculoskeletal conditions, the second highest reason for hospital use 
by women in IBIS was similar to that seen in the NHS data set. There were 62 
women out of the 2,531 reporting a visit involving a procedure in this group, a rate of 
2.4%. This compares with around 2% in the NHS data set (113,612 admissions 
including ordinary and day cases out of a population of 562,4364 in the relevant age 
group). The comparison is imprecise since the 2 data sets are not directly comparable 
though the indication of an increased rate of consultation by women recruited to IBIS 
merits further investigation. 
Comparison between the use of hospital services by women in IBIS and the pattern of 
admissions for women in England does offer face validity to the IBIS data set. The 
range and ranking of hospital visits seen for women enrolled into IBIS are as might be 
expected from routine sources. 
Main diagnosis within disease chapters 
The tables below show the specific diagnosis based on the 3 digit ICD9 code which 
contribute the greatest overall proportion of hospital visits for each of the main 
chapter headings. 
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Diseases of the Genitourinary System 
For diseases of the genitourinary system, the most frequent cause of any hospital visit, 
almost a third of hospital visits are due to disorders of menstruation and other 
abnormal bleeding from the genital tract. Slightly more than half is for diagnostic 
procedures such as hysteroscopy - or for hysterectomy. A further 20% of visits are 
due to disorders of the breast including fibroadenoma, cysts and benign lumps as well 
as inflammatory disease of the uterus (615) such as fibroids or secretory changes in 
the endometrium and inflammatory disease in the cervix, vagina or vulva. The 
remaining causes include problems of pelvic floor, abnormalities resulting from 
prolapse (618) and other symptoms such as pain and urethritis. 
Table 3: Hospital visits made by women recruited to IBIS: Diseases of the 
Genitourinary System by main cause. 
Main primary diagnosis for diseases of the genitourinary 
system 
Numbers % Cumulative % 
Disorders of menstruation (626) 129 30.07% 30.07% 
Disorders of the breast(611) 87 20.28% 50.35% 
Inflammatory diseases of the uterus(615) 47 10.96% 61.31% 
Inflammatory diseases of the cervix, vagina, vulva(616) 34 7.93% 69.23% 
Genital prolapse(618) 24 5.59% 74.83% 
other 108 25.17% 100.00% 
Total 429 100% 
Diseases of the Musculoskeletal system 
The main diagnosis for women with musculoskeletal conditions is shown in Table 4. 
Back problems account for the highest proportion of visits. Other arthropathies 
account for a further 10%. Osteoarthritis and other joint disorders make up around 
8% each. 
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Table 4: Hospital visits made by women recruited to IBIS: Diseases of the 
Musculoskeletal System 
3 digit code Diagnosis Numbers % 
724 Disorders of the back 41 21.03% 
716 Arthropathies 20 10.26% 
715 Osteoarthritis and allied disorders 17 8.72% 
717 Internal derangement of knee 17 8.72% 
727 Disorders of tendon and synovium 16 8.21% 
714 Rheumatoid arthritis 15 7.69% 
722 Intervertebral disc disorders 14 7.18% 
Other 1 -1 55 J 28.21% 
Total --T 1 195 
Diseases of the Digestive System 
Table 5 shows the main reasons for attending hospital with digestive disorders. 
Cholelithiasis is the main specific diagnosis accounting for around 20% of the reasons 
for visits in this group. Other less specific diagnosis have been classified under 537 
for disorders of the stomach and duodenum including hiatus hernia and celiac disease 
or under 564 covering pain and other symptoms in the lower abdomen. Together 
these 2 diagnoses make up about 35% of the total. Other conditions reported include, 
for example, 7 women with diverticulitis, 4 women having 6 visits due to 
gastrointestinal haemorrhage and 4 women admitted with acute appendicitis. 
Table 5: Hospital visits made by women recruited to IBIS: Diseases of the 
Digestive System 
3 digit code Diagnosis Numbers of visits % 
564 Digestive disorders 33 24.09% 
574 Cholelithiasis 28 20.44% 
537 Disorders of stomach and duodenum 15 10.95% 
530 Disorders of oesophagus 7 5.11% 
562 Diverticula of intestine 7 5.11% 
520 wisdom tooth problems 6 4.38% 
578 Gastrointestinal haemorrhage 6 4.38% 
577 Disease of the pancreas 5 3.65% 
Other 29 21.17% 
outpatient 1 0.73% 
Total 137 100.00% 
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Diseases of the Vascular System 
The largest proportion of visits for vascular conditions are for varicose veins(25%) 
(see Table 6). There were also 13 visits for angina and 11 for hypertension. Other 
forms of heart disease and heart failure account for a further 15% of the visits. A total 
of 6 visits were recorded for venous embolism and venous thrombosis with a further 2 
visits for thrombophlebitis and 2 for peripheral vascular disease. There was 1 
subarachnoid haemorrhage and 3 women with transient cerebral ischaemia; there were 
2 visits for acute myocardial infarction. 
Table 6: Hospital visits made by women recruited to IBIS: Diseases of the 
Vascular System 
3 digit code Diagnosis Number of visits % 
454 Varicose veins 22 23.91% 
413 Angina 13 14.13% 
401 Hypertension 11 11.96% 
427 Cardiac dysrhythmias 7 7.61% 
429 Complications of heart disease 6 6.52% 
453 Venous embolism/thrombosis 6 6.52% 
428 Heart failure 3 3.26% 
435 Transient Cerebral ischaemia 3 3.26% 
410 Acute myocardial infarction 2 2.17% 
443 Peripheral vascular disease 2 2.17% 
448 Disease of capillaries 2 2.17% 
451 Phlebitis 2 2.17% 
396 Disease of aortic / mitral valve 1 1.09% 
402 hypertensive heart disease 1 1.09% 
414 Chronic ischaemic heart disease 1 1.09% 
426 Conduction disorders 1 1.09% 
430 Subarachnoid haemorrhage 1 1.09% 
444 Arterial embolism 1 1.09% 
447 Other disorders of arteries 1 1.09% 
344 Other 1 1.09% 
Outpatient 5 5.43% 
Total 92 100.00% 
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Diseases of the Nervous System and Sense organs 
The majority of conditions listed under diseases of the nervous system and sense 
organs in Table 7 below, are concerned with either visual disturbances (25%) or 
disorders of the eye (7.7%). 19 women experienced visual disturbance requiring a 
visit to an ophthalmologist. Other conditions included here are 5 visits by 4 women 
for epilepsy (345) and 8 women with 9 visits for vertigo (386). 
Table 7: Hospital visits made by women recruited to IBIS: Diseases of the 
Nervous System and Sense Organs. 
3 digit code Diagnosis Number of visits % 
368 Visual disturbances 19 24.68% 
386 Vertigo 8 10.39% 
375 Lacrimal disorders 6 7.79% 
345 Epilepsy 5 6.49% 
361 Retinal detachment 4 5.19% 
365 Glaucoma 4 5.19% 
369 Low vision 3 3.90% 
389 deafness 3 3.90% 
Other diagnosis 23 29.87% 
Undefined 2 2.60% 
Total 77 100.00% 
Diseases of the Endocrine and Metabolic System 
Endocrine, nutritional metabolic diseases and immunity disorders are shown in Table 
8. Diabetes accounts for a large proportion of the visits in this group (9 women with 
12 visits) with thyroid disorders in general being the most frequent. 11 women in this 
group made 13 visits for mineral disorders. There were 4 visits for disorders of the 
immune system, 7 for ovarian dysfunction and 3 for thyrotoxicosis. 
Table 8: Diseases of the Endocrine, Metabolic and Immune System 
3 digit code Diagnosis Numbers of visits % 
246 Thyroid disorders 18 24.32% 
250 Diabetes mellitus 12 16.22% 
275 Mineral disorders 13 17.57% 
256 Ovarian dysfunction 7 9.46% 
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279 Immune disorders 4 5.41% 
242 Thyrotoxicosis 3 4.05% 
244 Hypothyroidism 3 4.05% 
272 Disorders of lipid metabolism 3 4.05% 
240 Simple goitre 2 2.70% 
252 Parathyroid disorders 2 2.70% 
253 Disorders of pituitary 2 2.70% 
251 Pancreatic disorders 1 1.35% 
266 Vitamin B deficiency 1 1.35% 
271 Carbohydrate transport disorder 1 1.35% 
274 Gout 1 1.35% 
276 Fluid imbalance 1 1.35% 
Total 74 100.00% 
Procedures undertaken during visits to hospital by women recruited to IBIS 
There were 507 hospital visits where an HRG was reported out of 1321 total visits 
reported (see Table 9). The proportion of HRGs reported at each of the IBIS follow 
up visits is around 8% on each of the visits apart from at 6 months where it is only 
slightly lower at 6.7%. Overall there is no indication of an increase in the rate of 
hospital use requiring a procedure by women in IBIS with increasing time on the trial. 
Table 9: Number and proportion of hospital visits including a procedure 
assigned to an HRG and % of all follow up visits including a procedure. 
(Ordinary outpatient visits defined as those without procedures undertaken. ) 
Month MONTH06 MONTHI2 MONTHI8 MONTH24 MONTH30 MONTH36 MONTH42 MONTH48 Grand Total 
HRG 132 123 96 65 39 24 18 10 507 
Outpatient 221 166 148 103 90 50 21 11 810 
not known 2 1 1 0 0 0 0 0 4 
Total 355 290 245 168 129 74 39 21 1321 
All IBIS visits 1966 1545 1160 851 480 262 110 21 6395 
% HRG 6.7% 7.96% 8.27% 7.63% 8.12% 9.16% na na 7.92% 
The numbers and causes of hospital procedures, which are assigned an HRG reported 
by women in the study, are shown in Table 10. The HRGs are given for all major or 
minor causes of hospital admission and day cases; breast biopsy and other diagnostic 
procedures such as those for investigation of the digestive system are included. 
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Table 10: Women recruited to IBIS undergoing Procedures (assigned to Health 
Care Resource Groups - HRGs) during hospital visits. 
Hospital visits made by women In IBIS by procedure and 
Health care Resource Groups (HRGs). 
HRG Procedures Number 
Ophthalmic procedures 
b04 operation on eyelid 
b05 corneal graft 
b06 cataract 2 
b07 detached retina, vitreous detachment and tear duct operation 3 
Cancer 
BRCA breast cancer 18 
CABLA bladder cancer I 
CACOL colon cancer 
OVCA ovarian cancer 2 
d02 lobectomy (lung cancer) 
Ear, nose and throat procedures 
c04 wisdom tooth extraction 
5 
c22&c32 surgery to nasal passages & sinus operations 4 
c24 mouth or throat procedures including throat biopsy and treatment for 
vocal cords 
5 
c34 operation on salivary gland 
Respiratory 
p04 pneumonia 9 
d07 bronchoscopy 
d14 atypical viral pneumonia 
d22 asthma 3 
Vascular 
e12 acute myocardial infarction 
2 
e21 deep vein thrombosis 
7 
a06 subarachnoid haemorrhage 
ql 1 varicose veins 19 
Digestive system 
fl6&f35 endoscopyor sigmoidoscopy 34 
f12 surgery to stomach or duodenum(very major) 
f32 surgery to large intestine (very major) 1 
f47 other general abdominal disorders 3 
f65 gastrointestinal bleed 
f71 abdominal hernia(w cc) 
f82 appendectomy 5 
f95 haemorrhoidectomy 4 
Liver or biliary 
g05 l iver biopsy 
1 
g08 polycystic disease 
g12 c holecystectomy 
11 
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g15 residual gallstones 1 
Musculoskeletal 
h02 primary hip replacement 2 
h04 primary knee replacement 4 
h07 shoulder, ankle or elbow replacement 2 
h09 ant cruciate ligament reconstruction 1 
h l0 arthroscopy 7 
hl M12 12 foot operations, amputation of toe I1 
h13&h l4 operations for carpal tunnel syndrome and other hand procedures 7 
h l7 soft tissue or other bone procedures 
h22 musculoskeletal (minor) procedures 1 
h26 Inflammatory spine joint or connective tissue 1 
h37 fractures of ankle heel or other lower limb 5 
h40 shoulder, elbow, wrist and other upper limb fractures 13 
h44 Major cranial visceral or blood vessel injury 
h52 removal of fixation device 
101 minor spinal procedures 
r02 surgery for degenerative spinal disorders 4 
r04 vertebral column injury w decompression or fluid I 
Breast and skin care 
j02&j03 major breast surgery inc. plastics 9 
j05&j07 minor and intermediate breast surgery including breast biopsy, fna, 
cyst aspiration and removal of lump breast surgery 
71 
j37 minor skin procedures 9 
j39 major dermatological 
j42 major skin infections I 
j43 major skin tumours II 
j44 benign tumours or dermatological conditions 3 
Thyroidectomy 
kOl partial thyroidectomy I 
k02 thyroidectomy 
k08 fluid or electrolyte disorders 
Kidney or urinary tract infection 
110 kidney infection 1 
119 bladders tones and bladder polypectomy 3 
123 bladder or urinary mechanical problems 3 
126 bladder neck procedure 
130 endoscopy(bladder) 1 
153 r enal stones and renal colic 4 
154 i ntravenous pyelogram 
T 
Genital tract 
mOl&mo2&mo3 c olposcopy, plus vault smear, D&C 
30 
m05 h ysteroscopy 
70 
m06 s terilisation 7 
m07 h ysterectomy 
4 9 
Other 
n12 p regnancy 
2 
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q07 surgery for Raynauds syndrome 1 
q 10 procedures on the lymphatic system I 
a25 transverse myelitis 1 
a30 epilepsy 
s04 coagulation disorders I 
s13 pyrexia of unknown origin 1 
s14 other viral illness 2 
s16 poisoning or overdose 2 
s25 other admissions I 
t07 depression w/o section I 
Total (HRGs) 507 
O outpatient 814 
Grand Total 1321 
The 2 most frequent reasons for admission to hospital among women experiencing a 
hospital visit were either minor or intermediate gynaecological procedures, principally 
m05 - hysteroscopy or j07 - breast interventions such as breast biopsy, fine needle 
aspiration of suspicious breast lump , removal of benign lump or cyst aspiration. The 
gynaecological procedures shown in the table as m05 (hysteroscopy or other minor 
procedures in the upper genital tract), m07 (hysterectomy and other more major 
procedures in the upper genital tract) and m03 (procedures such as D&C or 
colposcopy in the lower genital tract together account for over a quarter of all 
procedures. Including mOl and m02 (minor and intermediate procedures in the lower 
genital tract ), gynaecological procedures are a third of all procedures experienced by 
this group of women. 
Of breast care excluding breast cancer, which is discussed separately below, 
procedures included under j07 together with j05 (minor and intermediate breast 
surgery account for some 13% of all procedures. Major breast procedures - 
principally prophylactic mastectomy - account for only an additional 2% of the cases. 
None of the women undergoing procedures in these categories had a diagnosis of 
breast cancer, most were classified under Disease Chapter 10 for disorders of the 
genital tract including `other disorders of the breast'. The reason for prophylactic 
mastectomy was in most cases given as due to concern about family history from 
breast or ovarian cancer though in one case cancer phobia was the stated reason. 
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There were 18 breast cancer cases identified in this group of women. None have been 
assigned to an HRG since women leave the study once a breast cancer diagnosis has 
been made; no treatment details are available. An average cost for the treatment of 
breast cancer of £6000 has been assigned to these cases. Other cases of cancer 
identified in this group of women are one case each of gastric cancer, cancer of the 
colon, lung, bladder and 2 cases of cancer of the ovary. HRGs were assigned to 2 of 
these cases since the women remained in the study. These were d02 for lobectomy of 
the lung and f12, for major gastric surgery. 
Eleven women have a procedure code for skin tumours (j43). This includes 2 women 
with malignant melanoma and 9 with other skin neoplasms such as rodent ulcer or 
basal cell carcinoma; a further 2 women had benign tumours removed (j44). 
Admissions to hospital for disorders of the digestive system are also common in this 
group. Most (f16 and f35) are for endoscopy or colonoscopy (including 
sigmoidoscopy). A small proportion of women had haemorrhoidectomy and 2 cases 
of major surgery either of the stomach or large intestine (including the case of gastric 
cancer described above. 
Any impact of tamoxifen on osteoporosis or musculoskeletal system in general is 
likely to be slow to progress. There were only 18 fractures requiring a hospital 
procedure recorded among this group of women, these were mainly in the wrist or 
other upper limb region (shoulder and elbow) with only 5 fractures in the ankle or 
lower limb. A small number of 11 women experienced orthopaedic operations due to 
arthritis mainly foot operations with 4 for carpal tunnel syndrome. There were 7 
arthroscopies. 
Other than the cancer cases described above, very few procedures of concern to 
women taking tamoxifen have been recorded in those reporting hospital visits. 
There have been 7 reports of thrombosis (pulmonary embolism or deep vein 
thrombosis) and no reports of endometrial cancer in this group. 7 women reported 
hospital procedures involving ophthalmic problems: problems of detached retina and 
vitreous humour, cataract, corneal graft and an operation on an eyelid. Visual 
disturbances, in general, are more likely to be seen as outpatients. 
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Distribution of cost 
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Frequency 
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A frequency distribution of the total costs including all ordinary outpatient visits and 
those assigned an HRG is shown below. 
Fig 2. Frequency distribution of the cost of hospital visits per woman recruited to 
IBIS. 
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Of women reporting a hospital visit the mean cost per hospital visit is £945.80. The 
median cost of hospital visits for all women reporting a visit is less at £507 suggesting 
that most of the resource use is in the early part of the distribution. Although only the 
reported visits are shown in the histogram, the total distribution of costs of hospital 
visits for all women recruited to IBIS is in fact non normal having a long left hand tail 
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since most women (over 60%) have not had a visit to hospital. The range of costs for 
those reporting a hospital visit is £74 - £7793 for 823 women. 
Figure 3. shows how the total resource use on hospital visits by women in IBIS is 
distributed among the major ICD9 Disease Chapters. 
Fig 3: Costs of visits to hospital by women in IBIS by main ICD9 disease chapter. 
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In line with the distribution of numbers of visits the greatest costs are seen in the 
disease chapter concerned with gynaecological and breast symptoms. The second 
major category of costs is however in the group containing malignancies. Visits 
concerned with musculoskeletal disease account for the next largest category of cost 
followed by diseases of the digestive system including biliary disease and diseases of 
the vascular system. 
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Differences in the pattern of hospital visits for women taking tamoxifen or 
placebo 
Method of Analysis 
The data were separated into tables comprising women taking tamoxifen or placebo. 
The two groups are labelled A and B though may not represent the same arm of the 
trial throughout the analysis. Adverse disease end points and such as serious 
malignancies or pulmonary embolism are not reported separately in the 2 groups. The 
costs associated with these endpoints are aggregated under main disease headings or 
within the HRGs. The main aim here is to assess the likely level of morbidity 
associated with women in each of 2 arms of the trial as measured through visits to 
hospital. 
Results 
The number of women reporting a hospital visit in each of the 2 groups A and B is 
remarkably similar. By December 1997 - the cut off taken for this analysis - there 
were 1988 women enrolled in IBIS, 1000 in group A and 988 in group B. Of these 
women, 407 in group A (40.7%) and 418 in group B (42.3%) had reported a hospital 
visit. The total number of follow up IBIS visits made by all of the women recruited to 
the study was 6471 a mean of 3 IBIS follow up visits for each women recruited 
consistent with a median of 18 months follow up. There were 664 visits to hospital by 
women in group A, a total of 1.63 visits per woman compared with 657 visits made 
by women allocated to group B, a total of 1.57 visits per woman. 
Reasons for hospital visits by main disease chapter 
The rate of reporting of hospital visits is the same in each of the two groups A and B 
as for all women. In Table 11, the ranking of the disease chapters in terms of the 
number and proportion of total visits in each series is similar in both series to that 
seen in the total of hospital visits presented earlier. 
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Table 11: Number and % of Hospital visits made by women in either A or B by 
main ICD 9 Disease Chapter. 
Disease Chapter 
In order of% 
Series A % of Total 
In Series A 
Disease Chapter 
In order of Series A 
Series a % of Total 
in 
in Series B 
Genitourinary 226 32.90% Genitourinary 203 32.02% 
Musculoskeletal 114 16.59% Musculoskeletal 81 12.78% 
Digestive 62 9.02% Digestive 75 11.83% 
Vascular 47 6.84% Vascular 45 7.10% 
Endocrine and metabolic 38 5.53% Endocrine 36 5.68% 
Respiratory system 33 4.80% Respiratory 24 3.79% 
Nervous/sense organs 32 4.66% Nervous system 45 7.10% 
Neoplasm 32 4.66% Neoplasms 29 4.57% 
Injury and poisoning 29 4.22% Injury 32 
0 5.05% 
Skin 13 1.89% Skin 18 2.84% 
Infectious disease 12 1.75% Infectious 5 0.79% 
Mental disorders 9 1.31% Mental 5 0.79% 
Pregnancy 3 0.44% Pregnancy 0 0.00% 
Blood 2 0.29% Blood 3 0.47% 
Unassigned 35 5.09% Unassigned 33 5.21 % 
Total 687 100.00°h Total 634 100.00°/. 
Most women attended hospital for reasons associated with principally Disease 
Chapters 10,13,9 and 7: diseases of the genitourinary system ( both breast diseases 
and reasons associated with the genital organs such as menstrual disorders), 
musculoskeletal disorders, digestive and cardiovascular problems respectively. 
There are no obvious differences in the rate of hospital use between the 2 series of 
women (Table 12). For the most part the width of the 95% confidence intervals for 
the odds ratio between the 2 series reflects the small sample size for most of the 
disease categories. There may be a statistical association in the rate of visits for 
vascular causes between series A and B with an odds ratio of 1.06 (CI: 1.04-1.07). 
For neoplasms the odds ratio is1.12 (CI: 1.06-1.1). In the largest category - that of 
genitourinary diseases - the odds ratio is 1.13 but the confidence 
interval includes 1.0 
suggesting that the result is not significant for p=0.05. Likewise for musculoskeletal 
conditions the odds ratio suggests an effect though the confidence interval is wide and 
includes the null value suggesting that there is no statistical significance at this level. 
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Overall the odds ratio of 1.1 between series A and B for all hospital visits also has a 
confidence interval that includes 1.0 (CI: 1.00-1.21). 
Table 12: Hospital Visits for Series A and B in each main Disease Chapter 
Disease chapter Total (A&B) Total (A) Total (B) Odds ratio Confidence 
interval 
(95%) 
Genitourinary 429 226 203 1.13 1.0-1.29 
Musculoskeletal 195 114 81 1.43 0.59 - 3.44* 
Digestive 137 62 75 0.84 0.69-1.01 
Vascular 92 47 45 1.06 1.04-1.07 
Endocrine and metabolic 74 38 36 1.07 1.05- 1.09 
Respiratory system 57 33 24 1.39 0,89-2.19 
Nervous system and sense organs 77 32 45 0.72 
0.44-1.19 
Neoplasm 61 32 29 1.12 1.06-1.18 
Injury and poisoning 61 29 32 0.92 
0.89-95 
Skin 31 13 18 0.73 0.54-0.98 
Infectious disease 17 12 5 2.43 0.44-13.54 
Mental disorders 14 9 5 1.83 0.87-3.82 
Other 8 5 3 
Unassigned 68 35 33 1.08 1.05-1.10 
Grand Total 1321 687 634 1.1 1.00-1.21 
"signlflcant(p<0.05) 
Procedures undertaken by women taking tamoxifen or placebo during hospital 
visits. 
Table 13 shows the differences between the 2 series in use of all of the procedures 
categorised as HRGs. The list contains only those procedures where visits occur 
in 
sufficient numbers to allow meaningful analysis and for conditions or disease areas, 
which might be affected by tamoxifen. Conditions such as multiple sclerosis, asthma 
and eczema are not included in this part of the analysis since they occur in this series 
in extremely small numbers and there is no evidence that they are affected 
by 
tamoxifen. 
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The following analysis includes HRGs in main ICD9 Disease Chapter : 
" 10: including 2 main categories of procedures for either breast disease or the 
female genital tract. These are j02 & j03 covering major breast surgery including 
plastics, j05 & j07 covering minor and intermediate breast surgery including 
breast biopsy, fine needle aspiration, cyst aspiration and surgery for removal of 
lump and mOl, m02, m03 covering colposcopy, vault smear and D&C or m05 for 
hysteroscopy, m06 for sterilisation or m07 for hysterectomy 
" 13: principally separating the fractures which are all included in this disease 
chapter (both of lower limb(h37) and upper limb(h40)) from other procedures 
mostly associated with arthritis including h02 (primary hip replacement), h04 
(primary knee replacement), h07 (shoulder, ankle or elbow replacement), 
arthroscopy (h 10), operations for carpal tunnel syndrome and other hand 
procedures (h13 and h14) and h52 (removal of fixation device) following hip 
replacement 
" 9: there are 2 main categories covering either the digestive tract or biliary 
conditions. The former include the diagnostic procedures of endoscopy & 
sigmoidoscopy (fl6&f35), surgery to stomach or duodenum (fl2) surgery to large 
intestine (f32), other general abdominal disorders (f47), gastrointestinal bleed 
(f65), abdominal hernia (f71) appendectomy (f82), haemorrhoidectomy (05). 
Biliary conditions in this chapter include g05 (liver biopsy), g08 (polycystic 
disease), g12 (cholecystectomy) and g15 (gallstones) 
" 7; vascular conditions have been grouped. These include: acute myocardial 
infarction (e12), deep vein thrombosis (e21), subarachnoid haemorrhage (a06) and 
varicose veins (q 11) 
" 6; ocular conditions have also been grouped. These include bo7 (detached retina 
(vitreous detachment and tear duct operation), b04 (operation on eyelid) b05 
(corneal graft), b06(cataract). 
The major disease chapter responsible for the largest numbers of procedures in both 
groups of women is for genitourinary disorders (See Table 13). This disease chapter 
includes procedures for genitourinary conditions concerned with breast disease and 
with the genital tract as listed in the bullet points above. 
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Table 13: Numbers of Procedures (HRGs) in the most frequent disease areas for 
women taking tamoxifen or placebo (Groups) 
Groups 
A B OR CI (95%) 
Musculoskeletal 
Fractures 10 12 0.85 0.79-0.91 
Other 19 20 0.96 0.96-0.97 
Total 29 32 0.92 0.89-0.95 
Genitourinary 
Breast 49 31 1.6 0.56-4.59 
Genital 85 63 1.37 0.74-2.53 
Total 134 94 1.45 0.53-3.93 
Circulatory 
Vascular 15 14 1.09 1.06-1.11 
Digestive 
Biliary 9 5 1.83 0.87-3.82 
Renal 2 9 0.23 0.01-7.37 
Other 25 23 1.1 1.06-1.14 
Total 36 37 0.93 0.91-0.95 
Ocular 5 3 2.54 0.76-8.46 
The odds ratio between groups A and B is indicative of a difference between the two 
groups for diseases of the breast and genitourinary system though the result is not 
significant. The confidence intervals are wide and include 1.0. This result does merit 
follow up in a larger series of women. Renal procedures do also show apparent excess 
in 1 group over the other although the numbers are small and the difference is not 
significant (p<0.05). For other main procedures there are no significant differences in 
the observed numbers of procedures for women in each of the two series. 
Cost 
There is no significant difference (p=0.241) between the overall cost in series A and B 
(see Table 14). 
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Table 14: Mean, median and range of costs for all hospital visits in series A and 
B. 
Mean Median and range of overall cost for women in series A and B 
f series A series B 
mean 990 890 
median 553 451 
range 74-6374 1-7793 
n 418 407 
sum 413,892 362,612 
The mean total cost of visits in series A is £990 (standard error, £61.41) and median is 
£553 
. 
The mean in series B is slightly lower at £890 (standard error, £61.41) and the 
median is £451. The histograms in fig 4 and fig 5 present the distribution of cost for 
all hospital visits in each of the 2 series A and B. 
Distribution of resource use 
Looking at the cumulative distribution of cost for each of the 2 series A and B it 
seems that a large proportion of the total cost of hospital visits is accounted for by a 
small number of women. 
Figure 4: Cumulative distribution of resource use by women in series A 
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1 27 53 79 105 131 157 183 209 235 261 287 313 339 365 391 
Figure 5. Cumulative resource use distribution for all hospital visits by women in 
series B. 
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Number of women 
The lower part of the distribution in series A shows that 203 women (50%) account 
for only 15% of the total cost (£53,369). By contrast, at the other end of the 
distribution, 11 women (3%) account for 15% of the cost. 
Differences between women taking tamoxifen or placebo for the cost per hospital 
visit in each main disease chapter 
Table 15 shows the total cost by chapter and the cost per visit within each chapter for 
the 2 groups A and B. The mean cost per visit for each of the main disease chapters is 
very similar between the 2 groups at £540.82 for group A and £540.94 in group B. 
There are however interesting differences between the rank order for cost across 
disease chapters compared with simply ranking the numbers of visits in each chapter. 
Moreover the differences in cost between chapters indicates that small changes in the 
disease profile for a group of women may affect health services costs quite 
considerably. 
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Table 15: Cost per hospital visit within each disease chapter for women taking 
tamoxifen or placebo (groups) 
DISEASE CHAPTER Group A Group B 
Total Cost Visits Mean cost pe 
visit 
r Total Cost Visits Mean cost per 
visit 
NEOPLASMS 93,964.00 32 2,936.38 59950 29 2,067.24 
GENITOURINARY 127,107.00 226 562.42 128223 203 631.64 
INJURY 15,854.00 29 546.69 17688 32 552.75 
MUSCULOSKELETAL 58,617.00 114 514.18 46476 81 573.78 
VASCULAR 23,924.00 47 509.02 29270 45 650.44 
RESPIRATORY 16,612.00 33 503.39 15141 24 630.88 
MENTAL 3,988.00 9 443.11 3452 5 690.4 
DIGESTIVE 25,240.00 62 407.1 40929 75 545.72 
INFECTIOUS 4,633.00 12 386.08 2096 5 419.2 
ENDOCRINE 12,742.00 38 335.32 11560 36 321.11 
NERVOUS 6,744.00 32 210.75 10853 45 241.18 
BLOOD 400 2 200 1215 3 405 
SKIN 2,336.00 13 179.69 3802 18 211.22 
PREGNANCY 204 3 68 0 0 
UNASSIGNED 7,756.00 25 310.24 5728 33 173.58 
MEAN 540.82 540.94 
MEDIAN 407.1 545.72 
The table shows clearly how the costs of neoplasms is considerable; this chapter has 
by far the highest cost per visit despite a relatively low number of cases. Most of the 
women presenting with a malignant neoplasm left the study and so the costs in this 
category cover the total cost of care whereas costs in other categories of disease are 
restricted to specific procedures recorded during the visit. 
The high costs of other categories of disease such as injury and poisoning and mental 
disorders are also apparent in the order of costs. The mean cost per patient for injury 
makes this the third highest cost category after the cost per patient for genitourinary 
disorders - the most frequent reason for attending hospital. In group B the cost per 
patient for mental disorders is also relatively high at £630.88 compared with an 
average of £540.9 overall. The difference is not significant (p<0.05). The cost per 
patient for vascular conditions is high in group B (£650.44 per visit) suggesting that 
the case mix is more complex compared with group A (£509.02 per visit) despite 
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there being a similar number of patients in the 2 groups: 47 in group A and 45 in 
group B. 
The costs per patient are lowest in those specialities where patients are most likely to 
be seen in the outpatient setting. These include endocrine, metabolic or immunity 
disorders in ICD9 Chapter 3 with a mean cost per patient of £335.32 in group A and 
£321.11 in group B. This chapter includes diabetes. Diseases of the blood in chapter 
4 with a mean cost of £200 per patient in group A and £405 in group B includes 
common conditions such as atrial fibrillation which is treated through anticoagulation 
clinics usually in outpatient settings. For diseases of the sense organs in chapter 6 the 
mean cost per patient is £210.75 in group A and £241.18 in group B. This includes 
routine visits for eye conditions and diseases of the central nervous system such as 
epilepsy also treated in outpatient settings. 
The cost per patient for genitourinary conditions is higher in group B than in group A 
with a higher overall cost despite a smaller number of patients in this group. The 
series clearly includes patients having a greater severity of disease requiring more 
costly intervention. 
Cost of main procedure (assigned to an HRG) undertaken during hospital visits 
for women taking tamoxifen or placebo. 
Table 16 sets out the costs per HRG for the most frequent procedures undertaken 
during hospital visits. Costs are similar for women in the two arms of the trial. 
However in reviewing specific procedures it seems that the costs involved per 
procedure can vary within disease areas. Fractures, for example, are clearly a smaller 
part of the overall cost of musculoskeletal disorders than other conditions grouped 
under this heading. This difference is more apparent in group B. 
Case mix differences between the series are also clear. Procedures concerned with the 
breast and genital organs for example, though more frequent in A have a higher cost 
per case than found in those in B. 
127 
Table 16: Cost per HRG for women taking tamoxifen or placebo (groups) 
Group A 
Main HRGs Nos. of HRGs Cost of HRGs % of total cost 
in group A 
Mean cost per 
procedure 
Genital organs 85 82305 53.00% 968.29 
Breast 49 31867 55.00% 650.35 
Musculoskeletal 19 24030 41.00% 1264.74 
Digestive 25 17321 66.00% 692.84 
Biliary 9 12253 68.00% 1361.44 
Vascular 15 11910 44.00% 794 
Fractures 10 10990 56.00% 1099 
Ocular 5 4863 76.00% 972.6 
Renal 2 400 11.00% 200 
Total 219 195939 
Mean Cost Per HRG 889.25 
Group B 
Main HRGs Nos. of HRGs Cost of HRGs %of total cost in 
series B 
Mean cost per 
procedure 
Genital organs 63 73979 47.00% 1174.27 
Musculoskeletal 20 34570 59.00% 1728.5 
Breast 31 25642 45.00% 827.16 
Vascular 14 15173 56.00% 1083.79 
Digestive 23 8865 34.00% 385.43 
Fractures 12 8508 44.00% 709 
Biliary 5 5702 32.00% 1140.4 
Renal 9 3051 89.00% 339 
Ocular 2 1550 24.00% 775 
Total 179 177040 
Mean Cost per HRG 906.95 
Discussion 
Comparison of the rate of hospital use by the women in IBIS with routine information 
from the NHS admissions data supports the validity of the information collected here 
since the rate of hospital use is broadly that which might be expected for women 
in 
the age group. Moreover the reasons for hospital visits are similarly distributed 
amongst disease groups within the IBIS women and the NHS admissions data. 
Comparing the rate of admission to hospital (for both ordinary admissions and day 
cases) for women in the general population in England (aged 45-64) 
161 with the use of 
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hospital services by women recruited into IBIS for specific causes, does however 
seem to suggest a higher consultation rate for genitourinary conditions among women 
recruited to IBIS. Further investigation of this estimate would require more detailed 
information from NHS routine sources than is generally available and it is important 
to note that the IBIS data set is not strictly comparable with routine data collected 
from the NHS returns. This is because the NHS data set counts consultant episodes 
rather than individual women and because of the eligibility criteria for IBIS that 
excludes women who are likely to have a high rate of illness 168. In particular women 
with a history of neoplasm or some vascular conditions such as deep vein thrombosis 
are ineligible for recruitment to the trial. This finding does however merit further 
review once recruitment is completed and analysis of hospital visits can be completed 
on a larger sample over a longer time period. 
The pattern of reported morbidity in terms of the kinds of conditions presented is 
consistent with that seen in the NHS hospital admissions data with the exception of 
the rate of admissions for neoplasms - the commonest reason for admission in the 
NHS for women in this age group. Women recruited to IBIS are most likely to use 
hospital services for conditions associated with the breast or due to genital disorders 
such as fibroids or abnormal bleeding. Other frequent causes of hospital use are, for 
musculoskeletal disorders, digestive disease and vascular disease. These causes of 
admission are seen in the same rank order for women in IBIS and in the NHS data set 
for the general population. 
There are few differences in overall reported hospital morbidity for women in the 2 
arms of the trial in terms of the numbers of visits for all causes. There do however 
appear to be some differences emerging for women in the two groups for disease 
associated with the breast and for genital conditions. This finding does indicate the 
need for further study in this area. In particular it will be important to discern - once 
the trial is completed - whether the difference between the 2 groups is an increase in 
the frequency of symptoms in these 2 disease areas for women taking tamoxifen or 
whether it is a protective effect. 
Looking at the analysis of procedures undertaken during hospital visits (assigned to an 
HRG) it is apparent that small differences in cost may have a large impact overall 
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considering the potentially large numbers of women who might wish to be involved in 
taking tamoxifen prophylaxis. For breast symptoms, for example the difference in the 
cost per visit per HRG for women taking tamoxifen or placebo is £177 per woman 
with an odds ratio of 1.6 for women undergoing a procedure for breast symptoms 
between the two groups. Should this represent a saving on the cost of benign breast 
disease to the health service for women taking tamoxifen prophylaxis the impact may 
be substantial. 
By contrast, an increase in the numbers of procedures needed to treat a possible 
increase in gynaecological symptoms in the intervention group by say one third of 
women - the difference seen between group A and B here - with the cost difference 
between the 2 groups of around £200 as found between A and B may give rise to a net 
cost of health care due to women taking tamoxifen prophylaxis. The direction of the 
effect found in breast and gynaecological procedures is unknown at this stage but the 
possible impact on the cost effectiveness of chemoprophylaxis will be tested in the 
sensitivity analysis presented in the subsequent chapter. 
The distribution of cost for women in each of the 2 arms of the trial show that a high 
proportion of overall cost of hospital visits is due to a small number of women. This 
suggests that it is the outcome in terms of high cost adverse events particularly 
neoplasms which will determine the balance of cost effectiveness for tamoxifen 
prophylaxis of breast cancer. 
The methodology used in this analysis of categorising the diagnosis into major ICD9 
disease chapters is broad enough to allow comparison across major disease areas 
between women in the 2 arms of the trial. Costing the procedures undertaken by the 
women during hospital visits using HRGs takes account of possible differences in 
case mix between the women which may affect the costs of health care. This method 
of costing has been well validated within the NHS. It would not have been possible 
because of the small numbers involved to compare specific diagnosis between the 2 
series of women or to assess in more detail the individual costs of care. 
The analysis is limited at this stage because of the need for longer term follow up and 
the importance of retaining the blinded nature of the study. It is also important to note 
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that a number of biases are possible at this stage which may underestimate aspects of 
morbidity particularly those likely to have a lag time or latency period before 
symptoms develop. These will arise firstly because the period of time over which the 
sample was taken will underestimate longer term effects. Secondly, it is possible that 
women most likely to develop adverse symptomatology in relation to recruitment to 
the trial may have a greater tendency to withdraw than those for whom any effects of 
long term tamoxifen use are benign or beneficial. The nature of the randomised trial 
design with complete randomisation of subjects should be sufficient to address biases 
concerned with the latter effect though further follow up is needed to fully understand 
the potential for changes in morbidity of women taking long term tamoxifen on 
resource use associated with health services. 
More detailed assessment of the hospital visits made by the women will be possible 
once the trial is complete and a full unrestricted analysis can take place. At this stage 
it appears that in general no substantial deficits or improvements in morbidity seem to 
occur for women recruited to IBIS or between the 2 arms of the trial. There are no 
differences in the pattern of morbidity in comparison with that of the general 
population. 
Summary 
The costs of changes in morbidity which might be attributable to long term use of 
tamoxifen is assessed through review of the use of hospital services by all women 
recruited to IBIS at the end of December 1997 (1988 women). Small changes in the 
use of hospital services or prescribed medications for the age group targeted in 
prevention trials could have a significant impact on overall cost if morbidity worsened 
or indeed improved for large numbers of the women involved. Yet, there have been 
few studies published on the effect of tamoxifen on morbidity as measured through 
changes in hospitalisation rates or use of medications. Prevention trials have 
published endpoints other than the incidence and mortality from breast cancer though 
have mostly been concerned with ischaemic heart disease and vascular events or with 
thromboembolism. There has been a great deal of concern about endometrial cancer. 
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The morbidity reported here is derived from information given by women recruited to 
IBIS during the first and all subsequent follow up visits. The diagnosis are recorded 
and assigned to an ICD 9 diagnosis code and by Health Care Resource Groups 
(HRGs) in order to quantify and cost them. The main value of HRGs is to provide a 
validated method for producing case mix adjusted information with which to compare 
the morbidity patterns for both arms of IBIS. No previous studies have reported the 
use of HRGs to describe changes in morbidity patterns in this context. 
The information is aggregated to compare the numbers and reason for hospital visits 
looking at both diagnosis and treatment in the two arms of the trial. The approach has 
face validity from a comparison of the proportion of visits in each main lCD 9 
grouping with the routine data available for women of the same age in the NHS 
hospital episode system. Although not a directly comparable data set the proportion 
and magnitude of women in each category is similar. 
The highest proportion of visits for women recruited to IBIS were for disease of the 
genitourinary system (32.4%) including diseases of the female genital tract, urinary 
system and breast diseases followed by diseases of the musculoskeletal system 
(14.7%) including fractures, the digestive system (10.3%) and diseases of circulation 
including cardiological conditions and vascular causes (6.9%). 
Of the diagnosis for genitourinary problems over 50% were for abnormalities of 
menstruation and abnormal bleeding resulting in procedures such as hysteroscopy or 
hysterectomy. An additional 20% were for breast diseases including fibroadenoma or 
benign breast disease and treated with fine needle aspiration or cyst aspiration. There 
were a number of fractures in the musculoskeletal category (18) mostly of the wrist or 
upper limb though most reports in this group were of back problems (21%). 
Procedures reported included carpal tunnel syndrome and arthropathies. 
Cholelithiasis was the most commonly reported diagnosis in the digestive disease 
category (20%). Procedures most often reported were endoscopy or colonoscopy. 
Among diseases of the circulatory system a large proportion of the procedures were 
for varicose veins (25%) with a smaller number for angina and hypertension. 
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Major adverse events in this series were breast cancers, and a number of other cancers 
including colon, lung bladder and 2 cases of cancer of the ovary. There were a 
number of skin tumours reported. 
Separating the series into A and B according to the 2 arms of the trial, there were 
407(42.3%) women reporting a hospital visit in group A and 418(40.7%) in group B. 
The mean costs for hospital visits were £889.25 in series A and £906.95 in series B. 
There were no significant differences between the 2 arms of the trial. The odds ratio 
for disease of the breast and genital organs does indicate a difference between the 2 
groups though the confidence intervals are wide. This trend will need to be pursued 
further with greater accrual. Likewise some case mix differences do appear between 
the 2 arms of the study such that the procedures for breast disease and disorders of the 
female genital tract do seem to be more costly in group A than in group B. In terms 
of the distribution of cost a small number of women do account for a large proportion 
of the overall costs. This finding suggests that it will be the impact of tamoxifen 
chemoprophylaxis on increasing or reducing the incidence of high cost procedure that 
determines the cost impact from morbidity. The findings presented here suggest that 
there are no major differences in morbidity for women taking tamoxifen or control 
though the results may warrant further investigation particularly for disease of the 
genitourinary system. The method of quantifying the data with HRGs is a useful 
means of categorising and costing data of this kind. 
Consequently in the model of cost effectiveness of tamoxifen chemoprophylaxis 
developed in Chapter 7 the baseline case does not include the cost of morbidity for 
women taking tamoxifen although the likely increased risk of endometrial cancer is 
included. In constructing the sensitivity analysis for cost effectiveness in Chapter 7 
however, it did however seem reasonable to include a possible effect of long term 
tamoxifen use of hospital visits for benign breast disease. Further work pending 
continued recruitment to IBIS will clarify this issue. Including morbidity within the 
sensitivity analysis provides information on the impact of possible changes in 
morbidity within a range of estimates. 
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Chapter Five 
Morbidity and Resource Use: 
Use of Medication 
Introduction 
As discussed earlier, this chapter builds on information set out in Chapters 2 and 4 
seeking to define a cost estimate for the likely impact of changes in morbidity of 
women taking tamoxifen chemoprophylaxis. In this chapter measures of morbidity are 
made from changes in the use of prescribed medications for women recruited to either 
the tamoxifen or the control arm of the International Breast Cancer Intervention Study 
(IBIS). 
Analysis of the reported use of medications by women enrolled into IBIS provides an 
independent means of understanding possible morbidity of tamoxifen prophylaxis and 
the costs (or savings) associated with it. This section presents information on the 
medications taken by a series of women enrolled in IBIS during each of their routine 
six monthly visits over a maximum of 48 months. Only those drugs thought to 
interact with or be affected by tamoxifen, as discussed in Chapter 2, have been 
reviewed in detail. Most of the drugs included in the main analysis are available on 
prescription only with the exception of evening primrose oil which is purchased as an 
over the counter medication for the relief of breast pain and other menstrual or 
menopausal symptoms. 
Method 
The sequence of visits, for women enrolled into IBIS, to the study centres has been 
described earlier (Chapter 3). The information on use of medications is collected in 
the same way as for hospital visits. Women are asked at each six monthly visit about 
medications prescribed in the previous six-month period. The name of the drug and 
the dose are recorded on the follow up form. 
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This information was downloaded onto an Excel spreadsheet for all women enrolled 
up until the end of December 1997. The information was first reviewed to ensure 
completeness of data collection particularly to ensure correct labelling for drug names 
to avoid confusion when assigning to generic categories using the British National 
Formulary (BNF)16. Drugs unlikely to be associated with tamoxifen use were then 
removed from the data set. These included antibiotics, antimalarials, asthma drugs 
and inhalers, analgesics other than for breast pain or migraine, vitamins and food 
supplements such as iron, calcium and cod liver oil. 
It is of course possible that the numbers of drugs taken by women in the study is a 
measure of their overall health and well being and that this may be affected in some 
general way by tamoxifen prophylaxis. It was not however considered possible to 
make general conclusions about this issue by studying all categories of drugs 
irrespective of their likely interaction with tamoxifen. Changes in use of a wide 
variety of different drugs would not be comparable and the small number of drugs in 
each of the excluded categories as well as the wide spectrum of indications for their 
use would make subcategorisation difficult to interpret. Antibiotics for example, are 
widely prescribed for a range of conditions with well-known differences in the 
threshold of symptomatology preceding a decision to prescribe. Changes in the use of 
antibiotics by women recruited to IBIS could have a variety of interpretations with no 
clear relevance to tamoxifen prophylaxis. 
The remaining drugs, those used for the treatment of symptoms in three main systems: 
for cardiovascular disease, for abnormalities of the endocrine system, and for 
symptoms associated with the central nervous system - mostly psychiatric drugs for 
the treatment of depression are set out in Table 1. Drugs for migraine and the specific 
drug thyroxine are included separately. The numbers of women reporting taking each 
one of these drugs is included in the table. The two largest categories of drugs: those 
associated with cardiovascular or psychiatric treatment have been further subdivided. 
Medical advice was sought to support the assignment of drugs according to usual 
prescribing practice. Disaggregation only down to the level of major sub categories 
was favoured since local variations in prescribing practice would reduce the value of 
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further analysis. The drugs were then grouped by generic categories under the main 
headings described above. 
Comparisons between the rates of use of drugs for women in IBIS with those in the 
general population are made using data from a single General Practice and by 
reference to the National Morbidity Survey1'. Routine information on drug use by 
age is not collected nationally. The GP research database administered by the 
Department of Health contains information on GPs prescribing, but this is not 
routinely broken down into age categories relevant to women enrolled into IBIS. 
Moreover the reasons for prescribing a particular drug may overlap and indeed many 
different drugs are prescribed for the same condition. An example relevant to this 
study is the use of the beta-blocker, propranolol, which can be used either as a 
migraine prophylaxis or as an antihypertensive agent. 
The main aim of this study was to gain an understanding of the likely differences in 
morbidity and costs between the two arms of IBIS as measured by differences in 
prescribed medicines for women taking tamoxifen and those on placebo. Also, the 
results could highlight areas where further study of prescribing patterns for women 
taking tamoxifen prophylaxis may be productive. 
Once the drugs to be studied were separated from all other reported medications, 
tables were obtained for women in the two arms of IBIS. In the same way as for the 
hospital visit data, these remain anonymised pending completion of the trial. The 
results are set out below. A further analysis was undertaken to review differences for 
women who were prescribed new medications after they were recruited to IBIS. 
Results 
Main categories of drugs reported 
Over the time period reviewed, 1279 women out of 2531 women recruited to the 
study during the time period (50.5%) reported having taken 3054 drugs since their last 
IBIS visit as discussed above. Large proportions of these drugs (79.7%) are not 
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included in the final analysis because they are unlikely to have any relevance in 
relation to tamoxifen. Table 1 below shows the remaining 687 women (27.1% of 
those recruited) who reported taking prescribed medications in the categories thought 
most likely to indicate morbidity associated with tamoxifen chemoprophylaxis. The 
proportion of drugs in each of main categories and the rate of use of drugs in each 
category by women recruited to the trial is also given. 
Table 1. Self reported use of medications by women recruited to IBIS in main 
BNF categories. 
Main Categories of Drugs (BNF) 
Cardiovascular Psychiatric Endocrine Migraine Thyroxine Total 
(without propranotol) 
Number of women 302 174 84 48 79 687 
% in category 43.9 25.3 12.2 6.9 11.5 ! 00% 
rate of use 11.9 6.87 3.32 1.89 3.1 27.1 
The main categories include drugs associated with the cardiovascular system (43.9%), 
the endocrine system including thyroxine (11.5%) as well as drugs prescribed for 
breast pain and associated symptoms (12.2%), and finally the central nervous system 
including the psychiatric drugs (25.3%) - tricyclics and SSRIs for the treatment of 
depression, hypnotics - sleeping tablets - and anxiolytics, for the treatment of anxiety 
as well as analgesics for migraine (6.9%). 
Drugs associated with the cardiovascular system 
302 women report taking at least one of the drugs listed in Table 2 prescribed for 
cardiovascular symptoms. The numbers below each of the subheadings for 
cardiovascular drugs show how many drugs were reported in each category. 67 
women report taking more than one drug and a small number of women (7) report 
taking three prescribed medications. 
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Table 2. Cardiovascular drugs reported by women recruited to IBIS: numbers 
in each subcategory. Specific drugs are also listed. 
Beta Diuretics Lipid Calcium ACE Glycosides Alpha Arrhythmia Nitrates 
Blockers lowering Blockers Inhibitors Blockers 
Atenolol Bendrofluazide Bezafibrate Diltiazem Captopril Digoxin Doxazosi 
n 
Flecanide GTN 
Bisoprolol Frusemide Cholestyramin 
e 
Lacidipine Enalapril lsosorbide 
Metoprolol Indapamide Clofibrate Nicardipin 
e 
Lisinopril Nitrates 
Oxprenolol Spironolactone Pravastatin Nicorandil 
Propranolol Triamterene Simvasatin Nifedipine Perindopril 
Sotalol Atorvastatin Verapamil Ramipril 
Timolol Fluvastatin Trandolapril 
131 109 36 52 57 2 3 2 7 
Beta blockers and calcium blockers together account for the highest proportion of 
prescribed medications in this category (45.8% of the total drugs prescribed) and are 
used primarily for angina and hypertension. Diuretics, ace inhibitors and glycosides 
(42% of the total number of drugs), form the second largest group and are prescribed 
primarily for heart failure though there is increasing cross over in prescribing between 
these sub categories of drugs. 
Lipid lowering drugs accounting for just less than 10% of the total prescribed drugs 
are used for secondary prevention of myocardial infarction though are being 
increasingly used in primary prevention for people with a high cardiovascular risk 
profile. Women taking more than two drugs are most likely to be hypertensive 
prescribed a diuretic and either a beta blocker (11 women), or a calcium blocker (13 
women), or an ACE inhibitor (15 women). Other combinations (28) include beta 
blockers and lipid lowering drugs most likely to be given after myocardial infarction 
for secondary prevention or beta blockers and ace inhibitors for prevention of heart 
failure. 
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Drugs associated with the endocrine system 
There were 84 women reporting use of four drugs concerned with the endocrine 
system taken for the treatment of breast pain and associated symptoms (see Table 3). 
These drugs are collectively referred to as Epos. Evening primrose oil was most 
commonly reported (68%). This is the only medication in the data set, which is 
purchased rather than prescribed. A small number of women reported taking two 
drugs. 
Table 3. Endocrine system: Drugs reported by women recruited to IBIS for 
treatment of breast pain and menstrual symptoms 
Drug Number reported 
Efamast 14 
Epogam 14 
Evening Primrose Oil 61 
Efamol 1 
Total 90 
In addition, thyroxine was reported by 79 women. This drug is taken for an 
underactive thyroid gland causing symptoms of persistent tiredness, lethargy and 
weight gain. 
Drugs associated with psychiatric symptoms 
There were 174 women reporting taking drugs for psychiatric morbidity (see Table 4). 
Most are taking only one drug most likely to be an antidepressant - either Tricyclics or 
Selective Serotonin Re-uptake Inhibitors (SSRIs), together these account for 85% of 
the total. Hypnotics (sleeping tablets) and anxiolytics for anxiety are each less than 
10% of the total. A small number of women are taking two drugs usually an 
antidepressant in the SSRI category and a hypnotic to aid sleeping. 
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Table 4. Psychiatric drugs: numbers reported in each subcategory. Specific 
drugs are also listed 
Hypnotics Anxiolytics Tricyclics SSRIs Total 
Zoplicone Diazepam Amitryptyline Venflexane 
Temazepam Buspirone Dothiepin Sertraline 
Nitrazepem Nortyptyline Paroxetine 
Lofepramine Fluoxetine 
Imipramine Paroxetine 
Clomimpramine 
18 11 97 67 193 
Analgesics and prophylaxis for migraine are set out in Table 5. The drug Propranolol 
is included in this table since it can be used both for the treatment of migraine or as an 
antihypertensive agent 
Table 5. Drugs reported by women recruited to IBIS for Migraine. 
Specific drug Number 
Propranolol 25 
Pizotifen 3 
Paramax 2 
Migril 1 
Migraleve 4 
Migraine Tabs 2 
Imigran 21 
Ergotamine I 
Clonidine 16 
Inderal 14 
Total 89 
80 women reported taking 89 drugs in this category. Omitting propranolol there were 
48 women taking 51 drugs. 
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Differences in prescribed medication between those taking tamoxifen or 
placebo 
The tables below are the results of separating the data for women in each of the 2 arms 
of IBIS. The identity of each arm remains anonymised pending the completion of the 
trial. The first section is concerned with all women reporting use of drugs in the 
series. Table 8 deals with woman reporting drugs newly prescribed subsequent to 
their recruitment to IBIS. 
Cardiovascular drugs 
The odds ratios for each of the categories of cardiovascular drugs shown in Table 6 
suggest that there is no significant difference between the 2 arms of the trial for ace 
inhibitors or diuretics for p=0.05. For beta blockers, calcium blockers and lipid 
lowering drugs the confidence intervals are wide including 1.0 in each case suggesting 
that while there may be an effect between the two arms of the trial the sample size is 
too small at this stage for meaningful analysis. 
Table 6. Differences in the use of Cardiovascular drugs by women taking 
tamoxifen or placebo (groups) 
Cardiovascular drugs 
(number of women) 
Ace Beta Diuretics Lipid Calcium Others 
Groups Inhibitors Blockers Lowering Blockers 
A 27 81 57 23 22 7 
B 30 50 52 13 30 7 
Odds ratio 0.9 1.66 1.1 1.78 0.73 
Cl 0.86-0.94 0.40-6.87 1.05-1.16 0.67-4.73 0.51-1.04 
Psychiatric drugs 
Table 7 shows the drugs prescribed for anxiety and depression separated into two 
groups A and C corresponding to the two arms of IBIS. There may be an association 
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between chemoprophylaxis and use of antidepressants although the strength of the 
effect for SSRIs seems greater than for women on tricyclics and grouping these two 
categories reduces the effect. There are too few women taking hypnotics and 
anxiolytics to demonstrate an effect between the two arms of the trial. 
Table 7. Differences in the use of drugs by women taking tamoxifen or placebo 
(groups) 
Psychiatric drugs 
Tricyclics SSRIs Hypnotic Anxiolytics 
Groups 
C 50 29 7 7 
D 47 37 10 3 
Odds ratio 1.07 0.78 0.7 2.34 
95%CI 1.05-1.09 0.61-1.00 0.54-0.91 0.8-6.9 
Endocrine system 
Of the 84 women reporting taking drugs in this category, 38 were in one arm of the 
trial and 46 in the second. The odds ratio is 0.82 (95%CI =0.69-0.98) indicating that 
there might be a small effect for this category of drugs. 
Migraine 
For the migraine drugs including propranolol the women separated into the two arms 
of the trial with 43 in on group and 37 in the second group. The odds ratio is 1.17 
(95%CI=1.3-1.05) suggesting a small but potentially interesting difference between 
the two groups. 
Drugs initiated while on the study 
Table 8 below shows the numbers of women whose first report of a prescribed drug 
began on the first or subsequent follow up visits i. e. women whose report of 
142 
prescribed medications began after recruitment to the trial. These are separated into 
the main categories described above and to each of two groups corresponding to either 
the tamoxifen or placebo arm. 
Table 8. Differences in reports of drugs newly prescribed subsequent to 
recruitment to IBIS for women on tamoxifen or placebo (groups) 
Drugs initiated while on the study 
Group 
Drugs E F Odds ratio 95% Cl 
Migraine 10 14 0.71 0.54-0.94 
Migraine 
(inc. 
Propranolol) 
17 21 0.81 0.70-0.93 
Epos' 30 31 0.97 0.96-0.97 
Thyroxine 10 17 0.59 0.28-1.21 
Cardiovascular Drugs 
Beta 
blockers 
31 46 0.67 0.33-1.35 
Lipid 
lowering 
drugs 
9 18 0.5 0.15-1.68 
Calcium 
blockers 
20 23 0.87 0.81-0.93 
Ace 
inhibitors 
13 18 0.72 0.54-0.97 
Others 3 7 0.43 0.15-1.25 
Psychiatric drugs 
Hypnotics 4 5 0.8 0.74-0.86 
Anxiolytics 2 5 0.4 0.14-1.13 
Tricyclics 31 32 0.97 0.96-0.97 
SSRIs 21 30 0.7 0.44-1.10 
There does appear to be a difference between the two groups for migraine both where 
Propanolol is excluded (OR=0.71,95%CI=0.54-0.94) or included (OR=0.81, 
95%CI=0.7-0.93) in the sample although both include confidence intervals 
approaching 1.0 suggesting that the effect is unlikely to be significant. For 
cardiovascular disease the odds ratio for beta blockers and lipid lowering drugs are 
0.67 and 0.50 respectively though the confidence intervals are wide and in both cases 
include 1.0 suggesting that the effect is not significant for p=0.05. 
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For women taking antidepressants the main difference again appears to be a higher 
number of women taking SSRIs though again there are only small numbers involved 
and the difference is not significant. For medications in other categories more women 
initiated thyroxine in one arm compared with the other; the difference is not 
significant. 
Discussion 
Analysing the use of drugs by women in IBIS is limited by the quality of the data 
collection. A great deal of time was spent in validating the records entered into the 
system and establishing the identity of the drugs recorded, moreover it is difficult to 
assess the completeness of the data collection. In particular it was not possible to 
assess dose from the records since this was not recorded consistently. It is likely also 
that there may be some error in assignment of drugs to causes. Nevertheless it is 
clear that a large proportion of the drugs listed are unlikely to have any association 
with tamoxifen chemoprophylaxis. Only a small proportion of the drugs excluded 
from the analysis indicate any major illness or morbidity for women recruited to IBIS. 
Of those excluded the use of an anti-inflammatory drug is probably the most 
important category suggesting morbidity from musculoskeletal disorders primarily 
osteoarthritis. Other drug usage suggest relatively minor and probably self limiting 
illnesses such as chest infections, chronic disease such as asthma or diabetes or use of 
food supplements such as vitamins and minerals. 
Just under a third of all women recruited to IBIS during the time period reviewed in 
this sample are taking - mostly - prescribed medications for morbidity which is 
associated with tamoxifen chemoprophylaxis. The highest proportion of drug use 
(43.9%) reported by almost 12% of women recruited to IBIS is for cardiovascular 
disease. The second largest category - psychiatric drugs accounting for just over a 
quarter (25.3%) of the total reported are taken at a rate of nearly 7% per women 
recruited to IBIS. 
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Coronary heart disease and mental illness particularly depression are common reasons 
for attendance in General Practice. There are few routine sources of information with 
which to compare these results. PACT data are available for monitoring prescribing 
in general practice though are not based on individual patients and are not published 
routinely. Findings from the review of activity in general practice published as 
Morbidity Statistics from General Practice1' is relevant though rarely relates 
consultations in general practice to specific drugs. For this reason information was 
requested from a general practitioner14 covering a large practice population(10,000) 
on the rate of use of the specific categories of drugs reported by women in IBIS. On 
the whole this information suggested that prescription rates are comparable for 
coronary heart disease though may be high for antidepressants. Over an annual period, 
14.5% of women aged 45-64 in the General Practice were taking drugs for 
cardiovascular disease in the BNF categories described above (compared with 12% of 
women in IBIS) whereas only 4% were taking drugs for depression (compared with 
nearly 7% of women in IBIS) 18' It is possible to speculate that women who perceive 
themselves to be at increased risk of breast cancer are likely to have a higher rate of 
use of antidepressants than the general population. Alternatively, involvement in the 
IBIS trial may reduce depression. There are few reports to suggest that tamoxifen 
itself leads to low mood although the known side effect of symptoms such as hot 
flushes and headaches may give rise to mood swings. 
Comparing the results with the most recent findings from Morbidity Statistics from 
General Practice (fourth national study)"' supports these conclusions with 
consultations for coronary heart disease of the order of 15% for women aged 45-64 
and for depression around 7%. Since not all of these consultations would have 
resulted in the provision of a prescription the results are not directly comparable. 
They do however lend validity to the estimates given above for the overall morbidity 
of women in IBIS. 
For specific drugs 5.6% of the General Practice population in the age group 45-64 
were taking betablockers compared with 5.2% for women recruited to IBIS. Only 
3.3% of women in IBIS report taking the category of drugs labelled Epos (12.2% of 
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the total drugs reported) for the relief of breast pain and other gynaecological 
symptoms. It is not possible to compare this drug directly with reports from general 
practice since many women take Evening Primrose Oil for the relief of gynaecological 
symptoms, which can be purchased over the counter. About 3% of women in IBIS 
report the use of thyroxine, which is similar to the rate reported in the General 
Practice population (3.7%). Acquired hypothyroidism is the reason for prescription of 
thyroxine and this was reported at a rate of 0.87% for women aged 45-64 in the 
Morbidity survey. Migraine was reported at a rate of 1.89% of women in IBIS 
compared with I% in the General Practice population. 
Differences between the two arms of the trial in the frequency of use of drugs reported 
here cannot be fully evaluated because of the small numbers involved. Nevertheless, 
there does appear to be an indication from the data of a potentially interesting 
difference in the two groups in the use of beta blockers. The potentially beneficial 
effect of tamoxifen on cardiovascular health has been discussed earlier though it is 
equally likely that women taking tamoxifen are prescribed betablockers to counteract 
vascular symptoms such as hot flushes. Since the two arms of the trial are not 
unblinded at this stage it is not possible to assess whether the women more likely to 
be taking drugs for cardiovascular disease are those randomised to the control or to 
the tamoxifen arm. At this stage the significance of any differences in the use of 
drugs for vascular symptoms in terms of cost appears to be small. 
Broad cost implications might be estimated by taking the rate of use of beta blockers 
by women aged 45-64 in the general practice population discussed above (5.6%) and 
assuming that there may be a relative risk of 1.63 or 0.61 in the intervention group 
from IBIS data. For 1000 women assuming prescription of the drug Atenolol -a 
commonly used betablocker at a cost of £1/month (50mg/day) the cost for 560 women 
at 10 years would be £67,200. Using the assumption of an increased relative risk of 
1.63 the additional cost would be £42,240 (352 women) for 10 years - around £4 per 
woman per year. For a reduction in relative risk of 0.62 the savings would be £26,280 
(219 women) over 10 years - around £2 per woman per year. 
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Summary 
Analysis of the medications taken by women enrolled into IBIS is used to assess 
changes in the morbidity of women taking tamoxifen chemoprophylaxis for breast 
cancer. The information was collected from reports by the women themselves during 
routine (6 monthly) visits to IBIS centres. Information was validated and then 
categorised using groups from the British national formulary (BNF). Data on 1279 
women out of the 2531 recruited to the study in total (50.5%) reporting use of one or 
more drugs were included initially although the report is based on around on third of 
women (27%) of those recruited once inclusion criteria were applied. 
Medications were excluded where there was thought to be no association with 
tamoxifen or where a precise reason for prescription would be difficult to obtain. 
Criteria were based on the literature review reported in Chapter 2 and independent 
medical advice was taken. Drugs excluded were, for example, antibiotics for self 
limiting illness such as chest infections, antimalarials and medications for chronic 
diseases such as diabetes or asthma as well as food supplements and analgesics for 
inappropriate causes such as bee stings. 
The remaining medications were primarily concerned with cardiovascular symptoms 
(43.9%), for abnormalities of the endocrine system (12.2%) and for symptoms 
associated with the central nervous system (25.3%) - mostly for the treatment of 
depression. Drugs for migraine (6.9%) and the drug thyroxine (11.5%) were 
categorised separately. 
Betablockers and calcium blockers account for the highest proportion of drugs 
prescribed for cardiovascular symptoms; these are used primarily for angina and 
hypertension. Lipid lowering drugs accounting for around 10% are primarily used for 
secondary prevention of heart disease though there is increasing use for primary 
prevention Of the 4 drugs used for the relief of breast pain evening primrose oil - the 
only non prescribed medication included - was the most frequent comprising 68% of 
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reports in the endocrine category. Thyroxine use was reported by 79 women. This 
drug is taken for underactive thyroid and for the relief of symptoms such as tiredness 
and lethargy. 174 women reported use of an antidepressant accounting for 85% of 
drugs for psychiatric symptoms. Migraine drugs were used by 80 women (though 
excluding Propanolol which can also be used for hypertension the number was 48 
women). 
Comparison of the rates of use of medications for women recruited to IBIS with that 
found in a large general practice (8,000 registered patients) provides face validity for 
the data set since the rates of use are comparable across all categories and for a 
number of specific drugs such as betablockers. For example, around 14.5% of women 
aged 45-64 were prescribed drugs for cardiovascular symptoms in general practice 
compared with 12% of women in IBIS and around 4% of women are prescribed 
drugs for depression in the general practice compared with 7% of women in IBIS. 
The results are also comparable to those reported in the National Morbidity survey. 
There are no significant differences between the 2 arms of the trial for any of the 
major categories of drugs or for any sub category although this may be due to the 
small numbers involved. Further recruitment is needed to fully elucidate any 
differences, which may exist. In particular there is a trend towards a difference in the 
use of betablockers between the 2 arms of the study; a sub group of drugs used for the 
relief of vascular symptoms such as hot flushes. The additional cost (or saving) in the 
use of betablockers is estimated at around £4 per woman per year. 
This estimate is included in the sensitivity analysis for the model of cost effectiveness 
developed in Chapter 7. No morbidity estimate is included in the baseline case for the 
model because of the lack of sufficient evidence of either a difference in the use of 
prescribed medications or in the use of hospital visits (discussed in the previous 
Chapter) between women in the 2 arms of IBIS. Including an estimate for morbidity 
in the sensitivity analysis does however identify the range within which any impact on 
morbidity would bear on the cost effectiveness ratio. Prior to the development of the 
model for cost effectiveness, the following Chapter assesses any costs which might 
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accrue to the women themselves when taking chemoprophylaxis. An analysis of any 
impact on quality of life for women taking long term tamoxifen is also considered. 
149 
Chapter Six 
Indirect Costs of Tamoxifen Chemoprophylaxis 
Women in IBIS: Personal Costs and Quality of Life. 
Introduction 
This chapter sets out to assess the effect of tamoxifen chemoprophylaxis on the 
women themselves. Two main issues are considered. These are the impact on personal 
costs such as taking time off work and travel costs to health facilities for women 
taking tamoxifen chemoprophylaxis and the impact on quality of life. The former 
analysis identifies a range of estimates for personal costs, which are included in the 
sensitivity analysis for the cost effectiveness model in Chapter 7. A decrease or an 
increase in cost due to changes in quality of life is included neither in the baseline 
model or in the sensitivity analysis since there is no evidence in the analysis set out 
below to suggest that women taking long term tamoxifen experience any change in 
quality of life. 
The cost effectiveness of breast cancer chemoprophylaxis will depend on its efficacy 
in preventing incidence and mortality from breast cancer. The acceptability of long 
term drug taking will however bear considerably on the success of the intervention in 
routine health care. Few studies have addressed the indirect costs or benefits 
associated with changes in quality of life or the compromises made by the women 
themselves in terms of personal costs of chemoprevention. This trade-off between 
benefit from life years gained and the costs of potentially lowered quality of life for 
the women themselves is explored further in this section. Costs are examined in terms 
of the personal costs of travel and time spent attending clinic visits. The results are 
discussed in terms of the potential reduced value of breast cancer chemoprophylaxis. 
History of some previous illnesses particularly thrombosis or neoplasm renders 
women ineligible for taking long term tamoxifen. The physical health of women 
recruited to IBIS and indeed of all women likely to be eligible for tamoxifen 
prophylaxis is therefore likely to be equivalent to or better than women of the same 
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age and socio-economic status in the general population. It is possible however that 
there is some psychological morbidity associated with being at high risk for breast 
cancer though it is difficult to discern how this might be affected by tamoxifen 
prophylaxis. Fallowfield15 has suggested that the effects may be bipolar with 
women's anxiety state being either ameliorated or exacerbated by inclusion in a trial 
depending on factors such as level of internal locus of control, personality and recent 
history of stressful life experiences such as bereavement. 
Information on these issues was obtained by means of a questionnaire sent to a sample 
of women recruited to IBIS. The questionnaire had three parts, firstly using a 
standard health status instrument to assess quality of life, secondly a set of questions 
concerned with the personal cost of tamoxifen prophylaxis asking about the cost of 
travel, the cost of time off work and other costs associated with attending clinics and 
finally a set of questions concerned with how women perceive issues concerning 
breast care and breast examination in particular. The third group of questions was 
included by the IBIS co-ordinator to assess the impact of the study on the women's 
approach to personal breast care and are not discussed here. 
Personal costs 
Questions cover the cost and time of travel and any specific costs incurred because of 
attendance at the clinic such as childcare costs and time off work. The aim is to 
estimate the range and significance of personal cost in the overall cost of breast cancer 
chemoprophylaxis. 
This set of questions was also used to assess the value women place on the possibility 
of taking tamoxifen for breast cancer prophylaxis in relation to the benefit they 
perceive from it. Two linked questions were asked: Firstly, about the level of efficacy 
- in terms of breast cancers prevented - at which they would be prepared to take 
tamoxifen. Secondly, the personal costs they might be prepared to incur (in terms of 
distance travelled) in order to receive the service. These questions are indicative of the 
women's perception of risk and benefit from tamoxifen prophylaxis. They provide a 
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basis for quantifying the cost women would be willing to bear in order to receive 
tamoxifen prophylaxis. 
Quality of Life 
The quality of life questionnaire is intended to inform the economic analysis about 
any possible decrement or increment in health status that may represent a cost for 
women taking tamoxifen chemoprophylaxis. Quality of life information is also of 
value in understanding issues such as compliance since changes in health status 
because of tamoxifen use may affect the willingness of otherwise asymptomatic 
women to comply with a long term daily drug regimen. 
After careful consideration, information on quality of life was sought using the SF36 - 
a generic health related quality of life instrument"'. This instrument met a number of 
requirements. Firstly it was considered important to use a measure which had 
demonstrated sensitivity to detecting small variation in the health status of normal 
healthy individuals. Women recruited into IBIS are drawn from the general population 
and are expected to be as healthy. Moreover the objective of treatment with tamoxifen 
in this context is to maintain health. 
Secondly the SF36 has been shown to be better at detecting low levels of ill health 
than other quality of life instruments such as the Nottingham Health Profile 172 . 
Thirdly the reliability, validity, responsiveness and acceptability of the SF36 has been 
demonstrated in a number of settings with both healthy and disease specific 
populations 13. Normative data for the SF36 are available by age and gender for the 
UK population which will allow comparison for women recruited into IBIS with the 
general population14. 
Finally, since a battery of other questions were to be included in the questionnaire it 
was essential that the quality of life instrument be short and acceptable. Many other 
quality of life measures were found to be too long or not to have been validated in 
large samples1'. The SF36 was designed as a self-administered questionnaire16. It 
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contains 36 items and is intended to take about 5 minutes to complete. It measures 
health across 3 main health attributes on eight multi-item dimensions. The attributes 
are: functional status - including dimensions about physical functioning, social 
functioning and role limitations attributed to either physical or emotional problems, 
well being - covering mental health, energy (or fatigue) and pain, and finally an 
overall evaluation of health. This structure allows an assessment of the impact of 
tamoxifen chemoprophylaxis across all aspects of health. In 6 of the 8 dimensions 
respondents are asked to rate their responses on 3 or 6 point scales rather than as yes 
or no as in other questionnaires. For each dimension items are scored, coded and 
summed on a scale from worst health (0) to best health (100). 
Method 
The 3 sets of questions were piloted with a group of women in the study to assess 
acceptability and ease of response. While the women selected are a highly motivated 
group being representatives from each centre there was a 100% response rate from the 
20 questionnaires sent out. Subsequent discussions at a meeting with the women 
suggested that they had experienced few problems completing the questionnaire and 
had welcomed the opportunity to address questions about general health and personal 
costs involved. Information was sought in particular on the understanding of the 
question about the level of effectiveness at which they would be willing to take 
tamoxifen and again understanding was high. None of the questions had been missed 
and most women had spent less than 20 minutes overall in completing the forms. 
The final version of the questionnaire including the 3 sets of questions described 
above comprised: the quality of life instrument including 36 questions, a set of 13 
questions concerned with feelings about breast cancer and breast care including the 
question about the level of effectiveness of tamoxifen prophylaxis at which women 
might be willing to participate in the programme and 5 questions concerning the 
personal cost of IBIS. A question was also added to elicit information about the 
socio-economic status of the women using occupational status from the General 
Household Survey. Information on age of the women and other characteristics could 
153 
be cross matched from their general IBIS record since the women were also asked to 
include their name and study number. The 3 sets of questions were put together into a 
booklet and sent to all women recruited to UK centres. A total of 2,380 
questionnaires were mailed to all women recruited to the study using the address 
database correct at January 1s` 1998 along with a newsletter and other information 
relating to IBIS. Most questionnaires were sent on July 10`h 1998; a further 274 were 
forwarded to women three weeks later. A reminder was sent to all women alongside 
mailing of an information sheet at the beginning of September. 
The covering letter sent with the questionnaire explained the context for the three sets 
of questions and stressed 2 main points. Firstly that the women should offer her 
immediate response to the questions not spending over long completing the 
questionnaire and secondly that there was no expectation at all that the health of 
women in IBIS was likely to be at all different from the general population. 
A form was devised from the questionnaire so that the responses could be entered 
onto a database in oracle and the analysed using STATA. For analysis requiring 
knowledge of the randomisation status of the women the data was separated into 2 
tables Q and L according to the 2 arms of the trial. 
Results 
The analysis is based on 1,557 questionnaires. This is an estimated response rate of 
68.2% returned questionnaires. An error with the mailing machine resulted in the loss 
of around 10% of the questionnaires. The response rate is based on 2,380 
questionnaires known to have been mailed and 1,624 returned. Of those returned 
1,577 were completed and entered. 47 questionnaires were returned though not 
completed. The proportion of questionnaires returned and entered is 66.3%. 
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Costs of chemoprophylaxis to the women themselves 
Costs to the women themselves arising from the cost of travelling to a clinic for 
chemoprevention; the costs of time off work and other costs involved such as 
childcare or maintenance are set out in the tables below. 
1. Mode of transport 
921 women (59%), travel to an IBIS centre using their own means of transport (see 
Table 1). An additional 9% of women use their own transport in combination with 
public transport, a friend's vehicle and either walking or using a taxi. 23% of the 
women use public transport alone with an additional 7% using either their own 
vehicle, a friend's vehicle, a taxi or walking as well. At least 6% of women rely 
solely on a friend to transport them to the centre. Around 11% of women use two or 
more forms of transport. 
Table 1. Mode of transport to IBIS Centres 
Type of Transport Frequency % 
Own 921 59% 
Public 353 23% 
Friend 92 6% 
P&O 60 4% 
O&F 26 2% 
P&W 19 1% 
Walk 17 1% 
P&T 18 1% 
P&F 15 1% 
POW 8 1% 
O&W 7 0% 
Taxi 4 0% 
F&T 2 0% 
F&W 2 0% 
POF 2 0% 
PFT 2 0% 
PFW 1 0% 
OTW 1 0% 
PTW 1 0% 
missing 6 0% 
Total 1557 100% 
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2. Time (m) spent travelling to the Centre 
Table 2 shows that the median frequency for travel time is between 30-60 minutes. 
Almost 75% of the women spend longer than 30 minutes in travelling and half of 
those spend over an hour travelling to the centre. 
Table 2. Travel time (m) to IBIS centres 
Time Frequency % 
<30 minutes 385 25% 
30-60 minutes 573 37% 
>60 minutes 592 38% 
missing 1 7 0% 
Total 1557 100% 
3. Cost (£) of travel to the clinic 
The cost women incur in travelling to IBIS centres are detailed in the Table 3. Over 
half of the women (58%) travel solely by car; a further 7% use the car supplemented 
by some other means of transport as well either public transport (3.5%), other (2.6%), 
public transport and taxi, (1%) or public transport and other, (1%). The mean cost of 
transport by car accounting for the use of petrol only was estimated at £5 per woman. 
Public transport only was used by 379 (24%) of the women and by a further 100 
alongside the car (3.5%), taxi (1.6%), other (, 1%), car and taxi, (1%), car and other 
(<I%), taxi and other, (1%) and car, taxi and other (<I%). The mean cost of public 
transport was estimated at £7.1. Taxis were used by 43(3%) of the women but only 9 
used taxis alone. Almost 10% of women used 2 or more means of transport. Most of 
these used public transport and car or car and taxi or car and other; 16 women used 3 
means of transport and 1 woman used 4 means of transport. 106 women did not 
complete this section. The mean costs overall from the estimates given by the women 
themselves were £6.1. The costs ranged from 60p to £200, the latter for travel by air 
for 1 woman in the study. The range of costs represents the low geographic spread 
of centres available for recruitment to IBIS and the willingness of some women to 
incur considerable travel cost in order to have the opportunity to participate in the 
trial. 
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Table 3. Costs of travel by mode of transport (£) 
Mode of 
transport 
number Sum cost 
(£) 
Mean cost (£) 
Public(P) 379 2697.2 7.12 
Car (C) 906 4543.4 5.0 
Taxi (T) 9 73.5 8.2 
Other(O) 14 40.5 2.9 
P&C 55 804.1 14.6 
P&T 26 378.5 14.6 
P&O 3 54 18.0 
C&O 41 503.8 12.3 
T&O 1 175 175.0 
P, C&T 5 75.9 15.2 
P, C&O 10 153.8 15.4 
P, T&O 1 11.0 11.0 
P, C, T&O 1 0 0.0 
missing 106 0 0.0 
Total 1557 9510.6 
Mean cost 6.1 
4. Time (m) spent at the clinic: first visit 
It is clear that over half of the women in the sample (58%) spend over 41 minutes 
with almost a third spending longer than 60 minutes in the centre; around a third of 
women spend between 21 and 40 minutes in the centre. The median frequency is 
between 41 and 60 minutes. The 5% of women who spend less than 20 minutes on 
their first visit are most likely to have reported on their initial discussion pending 
recruitment to IBIS rather than their first full IBIS visit. The initial recruitment visit 
requires sufficient time for full discussion of the implications of the trial as well as the 
history taking, physical examination, blood test and mammography described earlier. 
Some IBIS centres explain a good deal about the trial process including issues 
concerning randomisation and the background to the study prior to the woman 
deciding to enrol in the study. 5% of women did not complete this section. 
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Table 4. Time (m) spent at first visit. 
Time(minutes) frequency % 
U=20 77 5% 
21-40 496 32% 
41-60 488 31% 
>60 425 27% 
missing 71 5% 
Total 1557 100% 
5. Time (m) spent in follow up visits. 
The median time spent in follow up visits is between 21-40 minutes with 63% 
spending less than 40 minutes in the centre during follow up visits; a fifth spend less 
than 20 minutes. 14% of women did not complete this section. 
Table 5. Time (m) for follow up visits 
Time Frequency % 
</=20minutes 326 21% 
21-40 647 42% 
41-60 252 16% 
61+ 115 7% 
Missing 217 14% 
Total 1557 100% 
6. Other costs 
The women were asked to specify other costs involved in attending an IBIS centre. 
The costs listed are for childcare or for loss of earnings including taking time from 
holiday entitlement in order to attend an IBIS centre. The other category includes 
expenditure on maintenance such as meals and snacks. 1,106 women recorded that no 
additional costs other than travel were incurred. 
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Table 6. Additional costs (£) incurred by women recruited to IBIS 
Type of cost (freq) % Sum cost (£) Mean cost (C) 
Child care(C) 3 0% 35.3 11.8 
Lost pay(LP) 94 6% 2620.6 27.9 
Holiday(H) 91 6% 2944.9 32.4 
Other(O) 128 8% 773.2 6.0 
None(N) 1106 71% 0 0 
C&LP 4 0% 128.5 32.1 
C&H 3 0% 177.0 59.0 
C&O 3 0% 37.0 12.3 
LP&H 3 0% 267.0 89.0 
LP&O 8 1% 467.3 58.4 
H&O 4 0% 119.8 30.0 
C&LP&O 1 0% 15.0 15.0 
LP&H&O 1 0% 114.0 114.0 
Missing 108 7% 7699.5 
Total 1557 
I 
Mean cost(E) 4.94 
_ __ 
I 
i 
Only 343(22%) women reported incurring additional costs other than travel when 
attending IBIS centres. The largest group - 128 women (8%) record `other' costs 
which relate mostly to food and drink purchased while travelling to or attending IBIS 
centres. The mean cost was estimated by these women as £6.0 per women. For the 
106(7%) of women who recorded loss of earnings through attending the clinic the 
mean cost is £27.9 for lost pay alone; 12 women record additional costs either through 
taking holiday entitlement as well (3), other costs (8) or holiday entitlement and other 
costs(1). For the 91 women (6%) who take holiday entitlement in order to attend 
clinics the mean cost estimated by them is £27.9. A very small number of woman 
(1%) incur childcare costs which reflects the age range of women recruited to IBIS; 
most are unlikely to have pre-school age children. 
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7. Main Occupation 
Table 7 shows that a large proportion of the women (62%) are employed either full or 
part-time; a further 8% are self-employed. 14% of the women describe themselves as 
retired and 13% record that they work mainly in the home. Very few (2%) describe 
their main occupation as undertaking charity work and only 2% are unemployed. 
Table 7. Main Occupation 
Occupation Frequency % 
Employed full time 545 35% 
Employed part time 414 27% 
Retired 223 14% 
Work mainly in the home 199 13% 
Self employed 117 8% 
Do charity work 28 2% 
Unemployed 25 2% 
Missing 6 0% 
Total 1557 100% 
8. How women value tamoxifen prophylaxis 
Responses to the questions concerning the value women place on tamoxifen 
prophylaxis (Tables 8&9) suggest that the women recruited to IBIS are highly 
motivated and willing to travel some considerable distance to receive the service. 
All of the women who returned questionnaires completed the section designed to 
assess the value women place on taking tamoxifen prophylaxis in relation to the 
numbers of deaths likely to be prevented per year. Table 8 shows that 60% would be 
willing to take tamoxifen prophylaxis at a relatively low level of absolute risk 
reduction with 1 death prevented per year. A further 17% of women expressed a 
willingness to take tamoxifen at the highest stated level of risk reduction (preventing 5 
deaths per year) with the remaining responses ranged in the middle of the distribution. 
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Table 8. Willingness to take tamoxifen prophylaxis in relation to numbers of 
deaths prevented per year. 
Deaths prevented Frequency % 
>1 933 60% 
>2 123 8% 
>3 163 10% 
>4 44 3% 
>5 264 17% 
Missing 30 2% 
Total 1557 100% 
Table 9 shows how far women would be prepared to travel to receive tamoxifen 
prophylaxis at the level of risk reduction expressed above. 
Table 9. Willingness to travel to receive Tamoxifen prophylaxis 
Travel to: Frequency % 
Local GP 14 1% 
Local hospital 219 14% 
Specialist centre 1311 84% 
Missing 13 1% 
Total 1557 100% 
The responses show a very clear willingness to travel to specialist centres at least 5 
miles away. 
9. Total time and travel costs involved in attending IBIS centres. 
Table 10 is set out as a summary of the per woman personal costs associated with 
recruitment to IBIS. The costs are based on the estimates of travel time and time spent 
at the clinic both for the first and subsequent visits described earlier. The travel time 
and time spent at the clinic has been costed at average hourly earnings for all women. 
Including the wage cost of time spent is in line with the employment status of the 
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women in the study; very few (2%) report themselves as unemployed compared with 
62% who report being in full or part time paid employment. The national earnings 
survey was used to cost time for women in the age groups recruited to IBIS and 
childcare costs were taken as an average of estimates available from the study of 
Employers and Childcare published by Incomes Data Services. The costs of journeys 
to and from the IBIS centres are taken from the cost estimates given by the women 
themselves with the addition of 4% non fuel variable costs for travel. Using a 
reimbursement cost per mile travelled was considered. This would be extremely 
difficult to apply since the kinds. of cars used by the women were not known. 
Weighting the cost in terms of the loss of time involved valued at average earnings 
provides an estimate of the willingness of these women to participate in a trial with 
the opportunity to take tamoxifen prophylaxis. This can be compared with the 
sensitivity analysis also included in the table which values travel times at zero. The 
costs of loss of pay are also taken from the estimates given by the women themselves. 
A sensitivity analysis included in the table values the loss of pay at average earnings 
and loss of holiday entitlement at half-average earnings. 
Table 10. Estimates of personal costs for women recruited to IBIS using time 
costed at zero or alternatively at average hourly earnings. 
Average Costing 
earnings Time@0 
per visit per 5 years Cost(£8.7/hr)' 
Median time spent in travel to the centre (50m) 100 1000 145 0 
Median time spent per woman per 1st visit 50 50 7.25 0 
Time spent per woman per follow up visit 30 270 39.15 0 
Total time 1320 191.4 0 
Mean cost of travel(E)per woman +4% non fuel variable 
cost 
£12.69 126.9 18.3976 18.3976 
Other expenditure per woman " £4.94 49.4 7.163 7.163 
Total cost (E)per 5 years 216.9606 25.5606 
Total cost per woman per year 43.39212 5.11212 
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*Cost of travel estimated by the women in IBIS plus 4% non fuel variable costs 
*Average hourly earnings for women aged 40-59 in full time work. Taken from the 
New Earnings Survey. Part A. ONS published by HMSO. April 1998 
**Average childcare costs. Taken from Employers and Childcare. Study no 633 
published by Incomes Data Services in September 1997 
^ Including loss of pay as loss of average earnings and loss of holiday entitlement as 
loss of half pay assuming 4 hours taken in total changes this estimate to £5.5 
The amount of time spent travelling to or attending clinics over 5 years of taking 
tamoxifen prophylaxis is estimated as 4.4 hours per year. Including the costs of this 
time using the average earnings for women in this age group along with the reported 
costs of travel and other costs involved in attending IBIS clinics gives an estimated 
cost per woman per year of £43.4. The cost assumptions are changed in the 
sensitivity analysis. Firstly assuming that the costs of time are not included (i. e. 
costed at zero) reduces the costs per woman per year to £5. Secondly, the costs of 
loss of earnings or loss of holiday entitlement is included at average annual earnings 
rather than at the level of lost pay reported by the women. This changes the overall 
analysis very little since there is little difference in the costs reported by the women 
and those taken from Incomes Data Services. The cost per woman per year is 
estimated at around £43 or £215 over 5 years. 
10. Visits to GP 
601(39%) report having visited their GP in the last 4 weeks; 956(61%) had not. Of 
those who had, the outcome of the visit is listed in Table 12. For 63% of the women 
the visit resulted in a prescription. For 284(46%) this was for a prescription alone, 39 
(6%) report receiving a referral and a prescription and a further 29 (5%) received a 
referral to the practice nurse or other member of the primary health care team and a 
prescription. A small proportion of women (3%) reported a referral to hospital and to 
the practice nurse as well as receiving a prescription. For 76(12%) the visit had 
resulted in a referral to hospital and 89(14%) had a consultation only with the doctor 
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resulting in neither referral nor prescription. 41(7%) of the women had a referral to 
the practice nurse or other member of the primary care team with an additional 4(1 %) 
being referred to hospital and to the practice nurse or other member of the primary 
health care team. 12 women (2%) did not complete this section though they did state 
they had seen their GP in the last 4 weeks. 16 women stated that they had not visited 
their GP in the last 4 weeks but completed the section on the outcome of the visit: 13 
reported receiving a prescription only, 1 also visited the practice nurse, 1 received a 
referral to hospital 1 had a consultation with the GP only. 
Table 12 Outcome of visits to GP 
Outcome from GP visit frequency % 
Consultation only (C) 89 14% 
Referral to hospital (R) 76 12% 
Prescription only (P) 284 46% 
Appointment with nurse (V) 41 7% 
GP and practice nurse 10 2% 
Referral and prescription 39 6% 
Referral and practice nurse 4 1% 
Prescription and practice nurse 29 5% 
CRP 4 1% 
CPV 12 2% 
RPV 16 3% 
CRPV 2 0% 
Missing data 12 2% 
Total 618 100% 
Of the women who visited their GP in the last 4 weeks a computation was made of 
which study arm they had been randomised to. This was only possible for the 352 
women (65%) who also declared their study number on the survey sheet. The results 
were that 169/352 (48%) were on treatment A and 183/352 (52%) were on treatment 
B. There is no significant difference between the two treatment arms. 
Quality of Life 
Table 13 below shows the results for scores on each of the dimensions of the SF36 
including the missing data in each case. In general proportion of missing data was 
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low. Instructions for the SF36 were followed for dealing with the missing items. This 
was as follows: 
" Physical Functioning is scored from a 10 item question with missing data 
calculated from the answered items; for 11 scores no average could be calculated. 
" Social Functioning is scored from 2, two item questions. Where scores were 
missing the missed score is assumed to be equal to the answered item; there were 
5 missing scores where neither item had been answered. 
" Role Limitation (physical) is scored from 1, four item question; missing responses 
were calculated as the average of answered items 
" Role Limitation (emotional) is calculated from 1, three item question; missing 
responses are calculated as an average of answered items 
" Pain is taken from 2, two item questions; missing scores are assumed to be equal 
to answered items. There were 12 questions where both items were omitted 
" Mental health was scored from 5 items of a single question; missing data were 
calculated as the average of completed items; there were 11 uncompleted 
responses where calculating an average was not possible 
" Energy is calculated from 4 items of a single question, averages are taken to 
calculate missing scores; there were 10 responses were an average could not be 
calculated 
" General Health Perception was calculated from 4 items of a question and a second 
question as a5 item score. Averages across completed items were taken for 
missing items where possible; there were 4 completely missing scores 
9 Change in health status compared with a year ago is scored from a single question; 
there were 14 missing responses 
Table 13. Summary scores for the SF36 for IBIS women compared with results 
from a study of the general population. 
Attribute Physical 
functioning 
Social 
functioning 
Role 
Limitation 
Role 
Limitation 
Pain Mental 
Health 
Energy 
Fatigue 
General 
Health 
IBIS women (physical) (emotional) Perception 
N 1546 1552 1557 1557 1545 1546 1547 1553 
missing data 11 5 0 0 12 11 10 4 
Mean 83 84 80 80 76 74 59 73 
165 
Standard deviation 21.8 22.9 34.7 34.7 24.6 17.1 21 20.1 
Rank 2 1 33 5 6 8 7 
GP Sample(women aged 
45-54)174 
85 87 82 81 77 73 59 73 
N 917 973 960 965 950 957 965 950 
Rank 2 1 34 5 6 8 6 
In general the distribution of scores shows that the women perceive themselves to be 
healthy across the range of dimensions particularly for physical functioning, social 
functioning, role functioning (physical) and role functioning (emotional). The 
perception of general health is also high. The scores for mental health are more 
widely distributed with a mean of 74. For pain, a significant proportion of women 
perceives themselves as having some bodily pain reducing the mean score to 76. 
Women recruited into IBIS perceive energy and fatigue as the lowest scoring health 
dimension; the mean score is 59. 
A comparison with results from a population survey reporting `norms' for health 
status is included in the table (in bold). The results included are for women aged 45- 
64 from a postal survey based on a random sample taken from the computerised 
family health service register in 4 health districts1'. The comparison suggests that the 
health of women recruited to IBIS does not differ from that of women of the same 
age in the general population. The ranking of scores for the IBIS group and for the 
general population sample is similar. Physical and social functioning rank highest in 
both the general population sample and the IBIS group with mental health pain scores 
and scores for general health lower. Energy and fatigue is the lowest ranked score in 
both groups. 
A final question asked within the SF36 is concerned with change in health status over 
the last 12 months. Scores are much lower in this section because a score of 100% 
would mean much better health and of 0% would be much worse health. The mean 
score was 51.9 % (SD=14.8) which suggests that women recruited to IBIS report the 
same or improved health compared with the previous year. 
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Differences in the 2 arms of the trial 
Table 14 below shows the means and standard deviations from the SF36 for each of 
the health dimensions separated for women in the 2 arms of the trial notionally 
referred to as Q and L. The results from t tests for each health dimension are also 
included. 
Table 14. SF36 summary scores and t-test for women allocated to either Q or L 
representing the 2 arms of the trial. 
Q L 
Physical functioning mean(n) 83.7(511) 85.1(471) 
std dev 21.1 20.1 
t -1.082 
pt 0.279 
Social functioning mean(n) 83.8(513) 85.5(474) 
std dev 23 22.3 
t -1.157 
pt 0.2472 
Role Limitation mean(n) 81.9(513) 82.7(478) 
(physical) std dev 33.7 32.9 
t -0.409 
pt 0.682 
Role Limitation mean(n) 81.3(513) 81.4(478) 
(social) std dev 33.9 33.6 
t -0.763 
pt 0.9392 
Pain mean(n) 75.9(512) 77.9(475) 
std dev 23.9 24.4 
t -1.302 
pt 0.193 
Mental 
health 
mean(n) 74.1(511) 75.5(473) 
std dev 17.2 17 
t -1.285 
pt 0.198 
Energy mean(n) 58.9(513) 60.7(473) 
std dev 21.3 21.4 
t -1.278 
pt 0.201 
General Health mean(n) 72.4(513) 73.7(475) 
std dev 20.2 20.4 
t -0.951 
pt 0.342 
Change from mean(n) 52.0(512) 51.6(468) 
1 year ago s td dev 1 4.5 1 4 
It 0 . 432 
p >t 0 . 6658 
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None of the results suggest that women in the 2 arms of the trial are different in 
respect of any aspect of health status. There are clearly no adverse effects on general 
quality of life for women taking tamoxifen prophylaxis. Neither do women in one arm 
or the other consider their health to have deteriorated over the last year. 
Discussion 
The personal costs for women in IBIS range from £20 to £30 per year of recruitment 
depending on whether time spent travelling to or during clinic visits is included at 
zero base or costed at average hourly earnings for women in this age group. The 
impact of these costs on the overall cost effectiveness of tamoxifen chemoprophylaxis 
is discussed in Chapter 7. 
Responses from the questionnaire show that a high proportion of women recruited to 
IBIS are car owners who spend between £5-7 on their journeys to IBIS centres. Most 
of the women have either full or part time employment although only 14% of the 
women claim to lose money through attending an IBIS clinic. There may be some 
underestimation of these costs since women may disregard there own personal 
expenditure when undertaking health care. In particular, women recruited to IBIS 
are self selected and the motivation to seek recruitment to a trial may lead them to 
place relatively low value on the cost of time spent, travel or other incidental 
expenditure. 
Less than 1% of the women say they have responsibilities for children that would 
cause them to incur additional cost while they are attending the centre. The wide 
range of travel costs reported includes over 75% of journeys lasting 30-60m or more 
than 60 minutes; 10% of women use 2 or 3 different forms of transport. This finding 
of a willingness to travel to distant sites in order to participate in a trial with the 
chance of receiving tamoxifen is supported by the responses showing a high value 
placed on receiving tamoxifen even at the lowest stated level of absolute risk 
reduction despite the need to travel to specialist centres. 
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The extent to which travel costs including the time spent travelling would be incurred 
outside the trial setting will depend on the terms of any possible extension given to 
the license for use of tamoxifen following completion of the UK trial. If licensing is 
extended to include prophylactic use then access through GP practices might be 
possible which would reduce travel time and personal costs for women seeking this 
service. Under such a model of care it is possible that time spent in follow up would 
reduce though an initial referral to a specialist breast unit may continue to be needed 
to secure eligibility for long term treatment with tamoxifen. Time spent during visits 
to IBIS is higher on the first than on subsequent visits with a mean of 40-60 minutes 
for the first appointment compared with 20-40 minutes for follow up. 
The impact of quality of life effects from tamoxifen prophylaxis has been recognised 
by study investigators for both the UK and USA trials though to date there are no 
published reports available from these studies. The economic consequences of 
changes in health status are likely to be threefold. Anxiety among women at high risk 
for breast cancer may have consequences for counselling needs which should be 
addressed within the health service. This would be particularly important if there was 
a profound increase in anxiety among women taking tamoxifen prophylaxis. Changed 
anxiety or other effects of tamoxifen prophylaxis on quality of life may also affect 
compliance with the drug regimen and with appointment keeping. 
The similar ranking and level of scores for most of the health dimensions for the SF36 
Quality of Life instrument in the IBIS population in comparison with a general 
population sample does however suggest that there is little or no effect on quality of 
life for women recruited to IBIS. Low scores for pain recorded in both IBIS women 
and the general population sample have also been observed in other general health 
surveys for women of this age. The high ranking of mental health scores for women 
in IBIS compared with the general population is interesting. While this result is not 
significant it does suggest that recruitment to the trial does not have an adverse effect. 
Fallowfield has suggested that for women at high risk for breast cancer the possibility 
of participation in a prevention trial may improve their quality of life by raising their 
locus of control and reducing anxiety. 
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The results for t-tests between the 2 arms of the trial shows that no adverse effects of 
quality of life occur for women taking tamoxifen, neither has health changed over the 
last year for women taking tamoxifen or for those in the control arm. These results 
may be biased by a possible tendency of women likely to have a high quality of life 
and health status being most willing to put themselves forward for trial entry. It is 
noticeable that the score for physical health for women in the study remains high 
suggesting no adverse effects of symptoms or side effects from taking tamoxifen 
affect these women. Mental health remains close to the scores for the general 
population shown in Table 13 for women in both arms of the study suggesting no 
adverse effects on mental health for women in either group. Indeed women's health in 
both groups is no different than for women of a similar age in the general population. 
Costs in terms of any possible decrement on quality of life for women taking 
tamoxifen are minimal These results suggest that no adjustment would be needed to 
calculate quality adjusted life years gained for women willing to undertake this kind 
of treatment. 
Other issues concerning biases in this study should be considered. The response rate 
to the questionnaire was less than 70%. This may have been a low estimate since the 
precise number of questionnaires mailed was unknown due to an error with the 
mailing machine. It does however raise questions about the possible characteristics of 
women failing to complete or not receiving the form. An undertaking was given to the 
women both in the covering letter forwarded with the questionnaire and the reminder 
letter that completion was entirely voluntary. In the interests of meeting this 
commitment and not compromising possible continuance of any women with the 
study it was not possible to seek further information from the women failing to 
respond. 
Biases associated with volunteers are also relevant in this context and may result in a 
more positive health report among those responding. Volunteer bias documented for 
example in screening programmes suggests that people who choose to participate are 
likely to differ from the general population in a number of ways that may affect 
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reported health. In general volunteers tend to have better health and lower mortality 
rates than the general population and are more likely to adhere to prescribed regimen. 
On the other hand those who volunteer for IBIS may have an increased risk of 
mortality or morbidity than the general population. Such individuals may be more 
likely to score lower for aspects of quality of life than the general population. The 
direction and magnitude of this bias is difficult to predict though will be considered in 
further follow up. 
In more general terms, it could be argued that asymmetry may also exist in the sample 
because of a differential drop out rate between the 2 arms of the trial. Those women 
most likely to suffer adverse consequences on quality of life as a result of taking 
tamoxifen may be more likely to drop out of the study than those experiencing no 
effects or indeed net benefits. As a consequence, decrements in general health and 
well being will have been underrepresented in the sample taken. In addition the 
results presented here do not, of course, include longer term effects. Further research 
is needed to assess the extent to which women involved in the trial are representative 
of all those who may be eligible for tamoxifen prophylaxis. 
Summary and Conclusions 
Costs to the women themselves are measured in order to assess any possible reduction 
in the value of breast cancer chemoprophylaxis caused by unreasonable personal costs 
for the women involved. This includes both the cost of work lost due to clinic visits, 
costs of travel to the clinics or other costs associated with clinic visits and possible 
decrements in quality of life for women taking tamoxifen prophylaxis. 
Due to the eligibility criteria for IBIS the women recruited might be expected to be as 
healthy if not healthier than women of the same age in the general population with the 
possible exception of possible psychological morbidity due to being at high risk for 
breast cancer. Compliance with a long term drug regimen will rely on the trade off 
women are prepared to make balancing a possible future benefit against possible side 
effects or reduced quality of life. 
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Personal costs and quality of life were assessed by means of a questionnaire piloted 
and then sent to all women in the study (as at January 1S` 1998). Two main sets of 
questions were included. The first set dealt with travel cost, the cost of time lost, 
work lost and other specific costs such as the cost of childcare. The second set 
concerned with quality of life and health status used the SF 36, a specific instrument 
validated in populations with low levels of ill health. Normative data have been 
published for the SF36 and it is a short and acceptable form to complete. The response 
rate was 68% though not all forms were completed; the analysis is based on 66% of 
the forms. 
A large proportion of women recruited to IBIS report themselves to be in part time or 
full time work (62%) although few women report loss of earnings due to an IBIS visit 
(7%). Personal car use is the most frequent form of transport to the centre involving 
over 70% of journeys and 75% of journeys are longer than 30 minutes with half of 
these being over 1 hour. 
The women are characterised by their willingness to travel. A question concerning 
the value they place of tamoxifen prophylaxis suggests that over 60 % would wish to 
take it at a low level of absolute benefit (1 death prevented per year) and that 84% of 
women would be happy to travel to a specialist centre to receive tamoxifen. The costs 
used for travel are those reported by the women themselves with a 4% non-fuel 
variable cost. The National Earnings Survey was used to cost time off work. 
Sensitivity analysis included time lost, costed at average earnings and at zero cost. 
The costs of travel range from 60p to £200; the mean costs of travel are £6.1. The 
total mean cost summarised across all costs including the cost of travel, time spent 
and other costs is an estimated £217/ 5 woman years when time is included at average 
earnings and £25.56/ 5 woman years when time is costed at zero. 
A question was included about recent visits to the GP in order to assess any 
differences between the 2 arms of the trial in use of primary care. 39% of the women 
overall reported a visit to the GP in the last 4 weeks; 63% of these visits had resulted 
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in a prescription. There was no difference in the pattern of use of primary care 
between the 2 arms of the trial. 
Responses to the SF36 show that women recruited to IBIS have the same pattern of 
health as women in the general population across all of the health dimensions 
including physical functioning, role limitation (includes both physical and emotional), 
social functioning, pain, mental health energy/fatigue and general health perception. 
Energy and fatigue has the lowest score for both groups. There is also no significant 
difference in any of the health dimensions between the 2 arms of the trial. There 
appear to be no adverse effects on quality of life for women taking long team 
tamoxifen prophylaxis and no adjustment for quality of life is needed in assessing cost 
effectiveness. 
The impact of personal costs to the women themselves on cost effectiveness of 
tamoxifen chemoprophylaxis are discussed further in Chapter 7. The estimates 
derived from the analysis discussed above are included in the sensitivity analysis for 
cost effectiveness. The range of estimates used identifies the level at which personal 
costs begin to bear adversely on the cost effectiveness ratio. 
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Chapter Seven 
Economics of Tamoxifen Chemoprophylaxis for Reducing Mortality and 
Morbidity from Breast Cancer. 
The following section sets out a population based cost effectiveness analysis for 
prophylaxis of breast cancer with the drug tamoxifen. The data were collected from 
women enrolled in the International Breast Cancer Intervention Study (IBIS); costs 
directly related to research in the trial are not included. The design is based on a 
decision model assessing the health and economic outcomes of chemoprophylaxis for 
women at different levels of risk for breast cancer compared with no 
chemoprophylaxis. 
Assumptions used in both the baseline model and in the sensitivity analysis are based 
on the data presented in previous chapters. This includes summary data from the 
analysis of service delivery for tamoxifen chemoprophylaxis reported in chapter 3, the 
possible range of costs associated with changes in morbidity reported in chapter 4 for 
the rate of use of hospital visits by women in the 2 arms of the trial and in chapter 5 
for the use of medications. A range of assumptions for costs associated with travel to 
the centres and the loss of earnings for the women themselves are included based on 
the analysis presented in chapter 6. Costs associated with changes in quality of life are 
not included since the analysis also shown in chapter 6 found no evidence of 
differences in health status and quality of life between women in the 2 arms of IBIS. 
Cost associated with the risk of adverse events includes only the increased risk of 
endometrial cancer since information based on the literature review in Chapter 2 
minimises the likelihood of other major mortality risks. The estimate for the cost of 
breast cancer included in the model is taken from the analysis developed below. 
The determinants for cost effectiveness are derived from modelling the impact of 
tamoxifen chemoprophylaxis on a district health authority population. The outcome - 
cost per breast cancer prevented - is assessed against alternative assumptions for cost 
and for efficacy of chemoprophylaxis. More detailed analysis for the cost per life 
year gained for women taking tamoxifen chemoprophylaxis is modelled on a cohort 
of women at high risk (an incidence of breast cancer of 6.76/1000) with estimates for 
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risk reduction taken from the NSABP P-1 study2. This model includes estimates for 
cost effectiveness with different assumptions about the duration of the protective 
effect of tamoxifen in reducing the risk of breast cancer. This approach is further 
developed to produce an estimate of the likely extreme difference in cost per life year 
gained depending on the lowest or highest assumptions associated with the costs of 
service delivery, costs associated with morbidity and with the women's personal 
costs. 
Core Assumptions 
In the baseline case, a decision model is prepared to compare the health and economic 
outcomes of breast cancer chemoprophylaxis for women in an average district health 
authority with a population of one million. The average population risk of breast 
cancer is used to set the predicted numbers of cases. It is estimated that 7% of the 
women in each of four, five year age bands (45 - 64) have at least a two fold increased 
risk of breast cancer (this risk is distributed as 5% at two fold relative risk, 1% at five 
fold relative risk and 1% at 10 fold relative risk) and would be eligible for tamoxifen 
chemoprophylaxis. The baseline incidence in the population for each age band in the 
model is taken from the Public Health Common Data Set for England and Wales. 
Efficacy is estimated at 50% reduction in incidence of breast cancer for women taking 
tamoxifen chemoprophylaxis based on the finding from the North American NSABP 
P-12, though the impact of a lower estimate of efficacy on the cost effectiveness ratio 
is determined in the sensitivity analysis. The efficacy of prophylaxis is assumed to be 
equivalent for women across all levels of risk. Core assumptions about the model of 
service delivery is of specialist hospital based care with significant involvement of 
specialist nurses. Other models of care considered in the sensitivity analysis are a 
service based in primary care; the impact on cost effectiveness of assumptions about 
the costs of service delivery included in IBIS is also assessed. 
Outcome estimates for the analysis set out below are made from the predicted 
endpoints for women involved in IBIS and for changes in breast cancer incidence 
from those reported in the NSABP P-I chemoprevention trial referred to earlier. The 
potential impact of tamoxifen chemoprophylaxis on morbidity is discussed even 
though there were no significant findings from the blinded subgroup analysis of 
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reported morbidity in the 2 arms of IBIS presented earlier (Chapters 4 and 5). 
Specifically there are 2 scenarios that seem feasible based on current evidence. These 
are the costs associated with the use of betablockers and the costs associated with 
changes in the rate of hospital visits for benign breast disease. 
Breast cancer treatment costs are derived from an audit of diagnosis and management 
of 1,779 breast cancer cases from 17 different hospital Trusts carried out by the 
Thames Cancer Registry (TCR) 17. This is described in detail below. The 17 Trusts 
included in the TCR breast cancer audit database all provide complete and 
comparable data. The patients represent 48% of the total of North Thames Region's 
activity of 3039 new cases of breast cancer diagnosed between January 1St 1996 and 
December 30 1996 7. 
In the model, the marginal cost of chemoprophylaxis compared with no 
chemoprophylaxis is expressed as the cost per breast cancer prevented and per year of 
life gained. Projections are also included about the potential for years of life gained 
based on survival estimates. The marginal cost effectiveness is the additional cost of 
prophylaxis minus any cost savings due to the use of prophylaxis (savings from breast 
cancers prevented and any other beneficial health effects) divided by the number of 
cases of breast cancer (under 65) averted. Cost per life year gained is based on 
average expectations of survival for women in each age band. Economic outcomes are 
the cost of prophylaxis and the changed cost of treating breast cancer. Estimates with 
discounting of both costs and benefits are included. 
Costs of breast cancer 
The cost of breast cancer averted is taken from the Thames Cancer Registry Audit of 
New Cases of Breast Cancer. The audit was used because it is more likely to provide 
estimates of the true cost of breast cancer treatment than a protocol based cost study. 
A number of studies have shown that there are wide variations in the quality of care in 
relation to published standards. The audit was however carried out at a time when 
there was widespread discussion in the medical press about the importance of 
implementing an agreed protocol for management of breast cancer and nationally 
agreed guidelines had been published. It is likely therefore that the variations in 
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estimate of £200 per woman available to clinics participating in IBIS. Developments 
in the model also look at the potential impact of costs or savings which may arise 
from changes in the morbidity experience for women taking long term tamoxifen 
particularly the cost of treatment for symptoms of benign breast disease or for changes 
in the cost of beta blockers prescribed for the vascular symptoms such as hot flushes 
which are commonly associated with tamoxifen. Variations are also proposed in the 
numbers of women eligible for prophylaxis including targeting only women at very 
high risk of breast cancer and the possibility that all women over 55 might be eligible. 
Finally, the impact of the costs to the women themselves is included by using two 
different assumptions about the value of the time spent by women in travelling to and 
attending clinics. These are time valued at average hourly earnings for women of the 
same age or with time valued at zero. Other personal costs such as childcare are 
reviewed. 
Cost of breast cancer 
The frequency of each of the procedures for women diagnosed with breast cancer 
noted during the TCR audit and the costs based on charges is set out in Table 1. The 
procedures appearing with the highest frequency in the audit are for clinical 
assessment (91%), mammography (74%) and cytology (80%). This is in line with 
NHS guidance from the Clinical Outcomes Group40 which states that a definitive 
diagnosis on the majority of women presenting with a breast lump (95%) should be 
made on the basis of triple assessment by clinical assessment, breast imaging and 
cytology by fine needle aspiration or core biopsy. In general the use of frozen section 
histology should only be needed in a small proportion of cases. Trucut biopsy was 
used in 23% of cases in the TCR sample. This is likely to have been used in addition 
to cytology by fine needle aspiration in some cases. 
The use of mammography seems rather low. In general, patients receive full blood 
count, urea and electrolytes, liver function tests and chest X ray as a baseline to 
surgery. Blood counts, urea and electrolytes are not listed in the TCR sample though 
are assumed to be included in the charges associated with surgery. The use of liver 
function tests and chest X-ray does seem to be low in the sample given that 80% of 
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women receive surgery. This may be due to variations in the local protocol for care 
among the different hospitals included or in underreporting. The cost of these 
interventions is small in relation to the overall cost and variations in practice are 
unlikely to affect the overall cost of care. Other tests such as bone scan and liver 
ultrasound are not routinely indicated since they do not have a high yield in 
asymptomatic patients with operable breast cancer and there is no evidence that there 
use improves survival or quality of life1. 84 
The radiotherapy regimen proposed by the Royal College of Radiologists suggests a 
rather higher frequency of use than the 50% recorded in the TCR audit. The 
difference may well be explained by variations in mastectomy rates around the North 
Thames Region and the local policy in relation to radiotherapy. Although 
radiotherapy has been shown to reduce local recurrence in patients undergoing local 
excision of a breast lump, there is still no conclusive evidence on the value of 
radiotherapy in improving local control following mastectomy. Current conclusions 
from overviews of randomised trials suggest that there is no survival benefit from 
radiotherapy and that deaths from other causes may increase with radiotherapy 
following mastectomy180' 186. An ongoing trial (START) presently still recruiting 
patients will provide more detailed information to resolve this issue. Until the 
completion of the START trial, rates of radiotherapy are likely to vary according to 
local policy. At just under £1500 per patient the overall cost of radiotherapy is 24% of 
the total charges for breast cancer care -a surprising proportion considering the 
paucity of research evidence to guide practice. It is interesting to note also that the 
cost of treating advanced disease with high cost chemotherapy amounts to a small 
proportion of the total cost (<0.6%) while these treatments remain accessible to only a 
small proportion of the population. 
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Table 1. Charges for breast cancer care 
Costs of new cases of breast cancer 
Procedure Price % Cost(f) Note 
clinical assessment 147 91 133.77 1 
mammogram 28 74 20.72 1 
ultrasound 30 30 9 1 
cytology 8 80 6.4 1 
trucut biopsy 20 23 4.6 1 
chest X ray 12 38 4.56 1 
bone scan 138 19 26.22 1 
liver ultrasound 30 20 6 1 
liver function tests 5 28 1.4 1 
women undergoing surgery 80 0 
excision biopsy 562 19 106.78 2 
wide local excision 661 45 297.45 3 
repeat excision 562 4 22.48 2 
mastectomy 1472 28 412.16 4 
cavity wall biopsy 562 3 16.86 2 
reconstruction 1,472 3 44.16 5 
women prescribed tamoxifen 120 77 92.4 6 
ovarian ablation 1914 2 38.28 7 
chemotherapy 754 21 158.34 8 
lymphoedema 147 2 2.94 9 
Radiotherapy 48 10 4.8 10 
following lumpectomy 3000 80(45%) 1080 
f ollowing mastectomy 2250 60(45%) 378 
Advanced Disease 0 
5 year follow up 3540 8 02 832 11 
% advanced disease 1 20 
%non anthracyclines 1 60 3 4 .8 
% anthracyclines 1 648 7 .. 5 
1 23.544 
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Care 
Notes 
1 Hospital outpatient cost of test 
2 HRG (j07)'59 
3 HRG (j04) 
4 HRG(j02) 
5 HRG (j02) 
6 Non proprietary cost of prescribing tamoxifen(20mg 
tabs) 16 
@ £2.95 for 30 tabs)/yr 
17 HRG (m03) 
Cost of triple combination of cyclophosphamide16 
methotrexate and 5-flouracil(CMF)8 cycles. 
General surgery outpatient cost for management of lymphoedema's 
110 Radiotherapy costs taken from Mount Vernon Cancer Centre 
11 1 Mytomycin C: dosc of 12mg/m2, doxorubicin: dose of 65mg/m2, paclitaxel: 
dose of16 
Costs of 10 outpatient oncology visits also included 
12 Cost of palliative care/patient 
12 
Costs for endometrial cancer 
The estimated increase in the incidence of endometrial cancer for women taking long 
term tamoxifen is taken from the relative risk for women taking tamoxifen found in 
the NSABP P-1 chemoprevention trial. An overall annual average rate of 2.3 per 
1000 women in the tamoxifen arm compared with 0.91 in the placebo group this is a 
relative risk of 2.53 (95% CI = 1.53 - 4.97). This information is used in the model to 
estimate the expected increase in the incidence of endometrial cancer for the baseline 
case and for varying assumptions about the efficacy of treatment. The baseline rates 
for endometrial cancer are estimated at 3 per 10,000 for women in England and 
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Wales. Background rates in the USA are considerably higher. The cost of 
endometrial cancer is estimated as £2,261 per woman. 
Baseline case (core assumptions) 
The cost effectiveness of tarnoxifen chemoprophylaxis is based on information 
presented in Tables 2 and 3. Table 2, presents the baseline model for the estimated 
numbers and cost of breast cancer in an average English District Health Authority 
with a million population including a total of 120,140 women in the eligible age group 
for tamoxifen prophylaxis (45 - 64). The expected incidence of breast cancer for 
these women is shown by age group. Seven percent of the women in this population 
(8,410) are estimated as having at least a two fold relative risk of breast cancer 
because of family history and to be eligible to receive prophylaxis. The table 
approximates the number of cases per year likely both for women at average 
population risk (188) and for those at increased risk (28). The cost of breast cancer 
care for the total number of new cases (216.49) is just over a million pounds 
(£1,320,994) per year. 
Table 2. The expected number (and cost) of cases of breast cancer for a health 
district (population of 1,000,0000 with 120,000 women aged 45-64) 
Women at least 2 fold risk cost of 
Incidence increased risk 2Xrr baseline risk total breast cancer 
(£) 
Age Number Rate/100,00 
0 
number (7%) Incidence cases/year cases/year cases/year 6102 
45-49 35,100 125 2457 250 6.14 40.80 46.95 286,466 
50-54 34,240 134 2396.8 268 6.42 42.67 49.09 299,567 
55-59 26,060 185.5 1824.2 371 6.77 44.96 51.73 315,627 
60-64 24,740 259.6 1731.8 519.2 8.99 59.73 68.72 419,334 
Total 120,140 8,409.8 1,408.2 28.33 188.16 216.49 1,320,994 
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In the baseline case for tamoxifen chemoprophylaxis, shown in the first column of 
Table 3, it is assumed that efficacy is a 50% reduction in breast cancer incidence per 
year for the 5 years duration of tamoxifen use for women with at least a two fold risk 
of breast cancer. It is assumed that all women at high risk (8,410) comply with a 
regimen of daily tamoxifen for five years. The estimated cost effectiveness is £57,558 
per breast cancer prevented. 
Sensitivity Analysis 
1. Changes in assumptions about efficacy and eligibility 
Table 3 compares the results for the cost per breast cancer prevented in the baseline 
case with results for changes in assumptions about efficacy of tamoxifen 
chemoprophylaxis and for a scenario where all women over age 55 are eligible for 
chemoprevention with 50% uptake. 
Table 3. Cost per breast cancer prevented in the baseline case (Risk Reduction 
(RR) =0.50) and with a series of alternative assumptions about Risk Reduction. 
Risk Reduction (RR) 
Baseline case 
RR=0.50 n RR=0.45 In RR=0.33 In RR=0.5 n 
Cost of chemoprevention 50%55+ 
Cost of delivery £4,499,243 8409.8 £4,499,243 8,409.8 £4,499,243 8409.8 £1,713,7013 32031.8 
Cost of adverse events £8,727.7 3.9 £8727.7 3.9 £8,727.7 3.9 £54964.9 24.3 
Total(cost) £4,507,970.7 £4,507,970.7 £4,507,970.7 £17191977.9 
Savings from 
chemoprevention 
Breast cancers 
prevented/year 
£86,420.2 14.2 £77,778.2 12.7 £57,728.7 9.5 £247314.1 40.5 
Breast cancers prevented (5 
years) 
£432,101.1 70.8 £388,891.0 63.7 £288,643.5 47.3 £1236570.3 202.7 
I Total(savings) £432101.1 £388891.0 £288643.5 £1236570.3 
Cost per breast 
cancer prevented 
£57,558.2 £64,631.5 £89,197.7 £78,733.8 
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The cost of delivering a service for tamoxifen chemoprophylaxis using the estimate of 
£535 per woman in a specialist hospital based service (from Chapter 3) for 8,410 
eligible women is £4,499.243. This cost remains the same when varying the 
assumption about efficacy since the same numbers of women are treated in each case. 
For the scenario where women can opt into the programme once over age 55, the cost 
of delivering chemoprevention increases by around 3 fold in order to treat around 
32,000 women in addition to those at high risk for reasons other than age. The cost of 
treating the 21 additional cases of endometrial cancer which might be expected to 
arise with such a large number of additional women taking prophylactic tamoxifen 
outweighs the savings in cost terms from the 26 additional breast cancers prevented. 
Estimates for the cost effectiveness (cost per breast cancer prevented) of tamoxifen 
prophylaxis shown in Table 3 increases by over 50% when efficacy is estimated at 
only 0.33 reduction in risk of breast cancer. The cost effectiveness does not improve 
when increasing the numbers of women taking tamoxifen with eligibility determined 
by age since the cost of service delivery rises at a greater rate than the numbers of 
breast cancers prevented. In the same way, the impact of adverse events on overall 
costs remains the same. Despite a relatively low unit cost for service provision in 
comparison with many other health care interventions the overall costs are high. This 
is because a large number of women must be treated in order to prevent one breast 
cancer. The absolute risk reduction in this Health Authority population model is 
0.007. The numbers of women who would need to receive tamoxifen in order to 
prevent one breast cancer is 142. 
2. Alternative means of service delivery: Model based on the budget available to 
participating centres in the International Breast cancer Intervention Study (IBIS) 
Table 4 sets out the estimates for tamoxifen prophylaxis based on the expenditure 
assumptions used in IBIS. The expenditure is set at £200 per woman recruited. The 
cost per breast cancer prevented is £17,773.4 for the baseline case with an assumed 
relative risk reduction of 0.5. This estimate rises to £29,639.6 for the lowest 
assumption of relative risk reduction at 0.33 and is £20,426.2 at 0.45. 
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Table 4. Cost effectiveness (Cost per breast cancer prevented) of 
chemoprevention based on the expenditure assumptions in IBIS with a series of 
assumptions of relative risk reduction. 
Risk Reduction (RR) 
RR=0.50 n RR=0.45 n RR=0.33 n RR=0.5 n 
Cost of chemoprevention 50%55+ 
Cost of delivery £1,681,960.0 8,410 £1,681,960 8,410 JE1,681,960.0 
0 8,410 
JE6,406,360. 32,031.8 
Cost of adverse events £8,727.7 3.9 £8727.7 3.86 £8727.7 
3.86 
£54,964.9 24.3 
Total(cost) £1,690,687.7 £1,690,688 £1,690,687.7 £6,461,324.9 
Savings from 
chemoprevention 
Breast cancers preventedlyear £86,420.2 14.2 £77778.2 12.75 £57728.7 9.46 £247,314.1 40.5 
Breast cancers prevented (5 
years) 
£432,101.1 70.8 £388891.0 63.7 J E288643.5 47.30 J 
31 
E1236570.3- 202.7 
Total(savings) £432,101.1 £388891.0 £288643.5 £1236570.3 
Cost per breast cancer 
prevented 
£17,773.4 £20,426.2 £29,639.6 £25,782.2 
Table 5 shows the equivalent data for the service delivery option of offering 
tamoxifen prophylaxis in primary care. The most cost effective option of £42,713.1 
per breast cancer prevented is seen with a risk reduction of 50% for a service based in 
primary care. This model would include consultation with specialists only at the first 
and final visits. 
Table 5. Cost effectiveness of chemoprevention based on the expenditure 
assumptions in a GP led model in a primary care setting with a series of 
assumptions of relative risk reduction. 
Risk Reduction (RR) 
RR=0.50 n RR=0.45 n RR=0.33 n RR=0.5 n 
Cost of chemoprevention 50%55+ 
Cost of delivery £3,448,018 8409.8 £3,448,018 8409.8 £3,448,018 8409. 
8 
£1,313,3038 £32,031.8 
Cost of adverse events £8727.7 3.9 £8727.7 3.9 £8727.7 3.9 £54964.9 24.3 
Total(cost) £3,456,745.7 £3,456,745.7 £3,456,745.7 £13,188,002.9 
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Savings from 
chemoprevention 
Breast cancers £86,420.2 14.2 £77,778.2 12.7 £57,728.7 9.5 £24,7314.1 40.5 
prevented/year 
1 
Breast cancers prevented £432101.1 70.8 £388891.0 63.7 £288643.5 47.3 £1236570.3 202.7 
(5 years) 
Total(savings) £432,101.1 £388,891.0 £288,643.5 £1,236,570.3 
Cost per breast cancer £42,713.1 £48,137.0 £66,974.5 £58,975.7 
prevented 
Impact of risk 
Table 6 uses a simple model to illustrate the impact of risk in the population on cost 
effectiveness of prophylaxis (Cost per breast cancer prevented). Using the same 
parameters as for the model above in the tables above, changes in cost effectiveness 
are calculated for a population of 1,000 women at three different levels of risk of 
breast cancer (two fold, five fold and ten fold of baseline risk) with the three different 
estimates for efficacy described above (risk reduction of 0.33,0.45 and 0.5). 
Table 6. Impact on cost effectiveness (cost per breast cancer prevented) of the 
relative risk of breast cancer in the targeted population 
Cost per breast cancer prevented (£) 
Relative risk 
Risk reduction Vold 5foid 10foid 
0.33 89,197.7 36,899.5 17,839.5 
0.45 64,631.54 27,073.0 12,926.3 
0.5 57,558.2 24,243.7 11,511.6 
The cost effectiveness estimate ranges from £89,197.7 to £ 11,511.6 for women at two 
fold increased risk with a reduction in the incidence of breast cancer of 0.33 to women 
at ten fold increased risk with a reduction in risk of 0.5 respectively. The costs are . 
primarily determined by the numbers of women receiving tamoxifen. The cost 
effectiveness is lowest for groups of women at very high risk for breast cancer as 
increasing numbers of breast cancers are prevented. 
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3. Impact of changes in morbidity 
The possible impact of changes in morbidity for women taking tamoxifen included 
here are based on results from women enrolled in IBIS discussed earlier. Although, in 
general, there were few apparent differences in hospital visits or in use of prescribed 
medications - the proxy measures used for morbidity - for women in either of the two 
arms of the trial, the results did suggest a need for continued review with increasing 
accrual to the trial. In particular from the hospital visit data there was a non 
significant trend indicating the possibility of changes in symptoms of benign breast 
disease requiring specialist advice and/or hospital treatment and from the medications 
data, changes in the use of beta blockers. 
The relative risk reduction for benign breast disease for women taking tamoxifen was 
calculated for women enrolled in IBIS using the hospital visits data which suggested 
that there was a non significant difference of about 5% in the numbers of women 
having hospital visits resulting in a procedure, between the 2 arms of the trial. 
Moreover the visits in one arm of the trial tend to be lower cost than in the other arm 
(a mean of £650.35 compared with £827.16). The baseline rate of hospital visits by 
women in the relevant age group was taken as around 17% from the NHS hospital 
episode system per yeart67. For the baseline District Health Authority model where 
8,410 women are receiving tamoxifen this might result in a difference in the cost of 
hospital visits of £32-£4l per woman per year receiving tamoxifen. Since the trial has 
not yet concluded it is necessary to assess these effects as a difference between the 
two arms of the trial. This is a cost - or a saving - on the overall cost of delivering 
tamoxifen chemoprophylaxis per woman of between 30 and 38%. 
For possible changes in the use of betablockers the impact is smaller. The rate of use 
of betablockers in the general population was estimated as 5.6% of a general practice 
population aged 45-64 (87/1,565). The relative risk between the 2 anus of the trial 
was 0.67. Assuming that the frequently used drug, Atenolol, is prescribed at 50 
mg/day at a cost of £1/month the cost or saving from tamoxifen prophylaxis would be 
an estimated £7 per woman. This is less than 0.2% of the total cost of tamoxifen 
chemoprophylaxis.. 
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The impact of changes in morbidity are considered for cost effectiveness (Cost per 
breast cancer prevented) in Table 8. 
4. Impact of personal costs to the women themselves 
The analysis in Chapter 6 found a range of personal costs per woman per year from £5 
to £43 depending on whether or not the time spent by women in travelling to and 
attending clinics is included at average earnings or at zero. Table 7 shows the effect 
on the cost per breast cancer prevented for the baseline case in the District Health 
Authority model with an assumption of 0.50 reduction in incidence of breast cancer 
based on a population where women at 2 fold increased risk of breast cancer are 
eligible to take tamoxifen. Table 7 shows both personal cost estimates. 
Table 7. Cost effectiveness (Cost per breast cancer prevented) of tamoxifen 
chemoprophylaxis including two assumptions about the women's personal costs 
Risk 
reduction=0.5 
0 
n 
Cost of chemoprevention £ 
Cost of delivery 4,499,243.00 8,410 
Cost of adverse events 8,727.68 3.8600982 
Women's personal 
costs 
@ £5 42,049.00 
@ £43 361,621.40 
Total(cost) @ £5 4,550,019.68 
£43 4,869,592.08 
Savings from chemoprevention 
Breast cancers prevented/year 86,420.22 14.16 
Breast cancers prevented (5 years) 432,101.10 70.8 
1 Total(savings) 432,101.10 
Cost per breast cancer prevented ©£5 58,151.99 
Cost per breast cancer prevented @ £43 62,664.89 
The cost per breast cancer prevented increases by between 1% and 8% compared with 
the baseline estimate of £57,558.2 shown in Table 3. 
188 
5. Consolidated estimate for cost per breast cancer prevented 
Table 8 sets out a summary cost effectiveness for tamoxifen chemoprophylaxis for 
breast cancer based on the analysis in Table 12. In this summary it is assumed that the 
protective effect of tamoxifen endures only during the period of active intervention. 
Estimates for cost effectiveness would of course improve were there to be a longer 
term protective effect. Alternative estimates for the impact of findings for morbidity 
and for personal costs to the women themselves are included. For the latter, both 
estimates of £5 and £43 per woman per year in the nurse led and IBIS model are 
included. In the GP model of service delivery the personal costs are included either as 
£5 or at zero cost. This latter assumption is based on the expectation that most care 
will take place in the GP practice with minimal cost to the woman herself. Under this 
model, a single visit to the specialist centre may occur once during the 5 year period 
and the £5 personal cost assumption represents a high estimate for the cost women 
may have to bear for a hospital visit. 
The table shows that the highest estimate for cost per breast cancer prevented is 
£40,645 in a nurse led service when the highest estimate of personal cost for the 
women and themselves is included and when assuming that costs accrue because of 
tamoxifen use due to increased incidence of benign breast disease and increased use 
of beta blockers. In the scenario with costs for beta blockers accruing to 
chemoprophylaxis but with a reduction in the rate of benign breast disease the cost per 
breast cancer prevented is £14,423.5. The lowest cost per breast cancer prevented is 
obtained where the cost of service delivery approximates to the budget available to 
participating IBIS centres of £200 per woman and where personal costs to the women 
are set at £5 per woman. 
In the GP led service which, based on available information may be a feasible 
approach a negative value for cost effectiveness of - £3990.83 is obtained where 
tamoxifen use is considered to reduce the rate of benign breast disease and increase 
the use of beta blockers. This suggests that benefits exceed costs and arises partly 
because it is assumed in the GP led service that there will be no or few personal costs 
to the women themselves. The cost effectiveness is £12,426.19 when both aspects of 
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morbidity accrue as costs. These results demonstrate the impact of both personal 
costs and the possible impact of morbidity on overall cost effectiveness. 
Table 8. Summary estimates for cost effectiveness of tamoxifen prophylaxis for 
breast cancer for hospital based, GP led or IBIS cost for service delivery 
including or excluding estimates of impact of morbidity (benign breast disease or 
use of beta blockers) and personal costs for women at £5 or £43 per woman for 
the nurse led and IBIS service models and £5 or £0 personal cost for woman in 
the GP model of service. 
Service delivery & personal cost Morbidity Assumptions 
assumptions 
plus benign minus benign plus benign minus benign 
breast disease breast disease breast disease breast disease 
plus beta minus beta minus beta plus beta 
blockers blockers blockers blockers 
Cost effectiveness for nurse led 40,644.60 24,083.64 40,534.93 24,193.31 
service(£535twoman) assuming £43 
personal cost per woman. 
Cost effectiveness for nurse led 30,874.78 14,313.82 30,765.10 14,423.49 
service(£535/woman) assuming £5 
personal cost per woman. 
Cost effectiveness for GP led 12,426.19 (4,100.51) 12,350.78 (3,990.83) 
service(£410/woman) 
assuming £0 personal cost per woman. 
Cost effectiveness for GP led service 24,468.13 7,919.95 24,371.24 8,029.63 
(£4101woman) assuming £5 personal cost 
per woman. 
Cost effectiveness for IBIS model 23,474.78 6,948.09 23,399.38 7,057.76 
(£200/woman) 
assuming £43 personal cost per woman. 
Cost effectiveness assuming IBIS 12,681.94 ( 3,844.75) 12,606.54 ( 3,735.08) 
costs (£200) 
and £5 personal cost per woman 
190 
6. Cost per life years gained 
Table 9 shows the years of life gained for women taking tamoxifen prophylaxis. The 
model in this case is based on the annual incidence of breast cancer found in the 
NSABP P-1 Breast Cancer Prevention Trial. The results were monitored over six 
years. Mortality from all causes of 324.6 per 100,000 is taken from age specific 
mortality for women aged 35-64 in England and Wales included in the Public Health 
Common Data set for 1998 based on data for 1995-7. Women in the placebo arm of 
the trial had an average incidence of breast cancer of 6.76 per 1000 for women. 
The model assumes that there is no further protection from tamoxifen beyond the 6 
year monitoring period and the incidence of breast cancer reverts to that of the control 
population. In Table 8 different assumptions for the length of the protective effect are 
included. Under three different possible outcomes of an additional 5,10 or 15 years 
continuous protective effect it is assumed that women in the tamoxifen arm retain a 
relative risk of reduction in incidence of breast cancer of 0.5. 
Table 9. Net reduction in incidence of breast cancer. The core assumption in 
this table is of no further protective effect beyond year 6. The average rate of 
breast cancer is 6.76/1000. Deaths from all causes are assumed to be an average 
mortality rate of 324 per 100,000 woman years. 
Year Breast cancer Incidence Deaths 
from all 
causes 
Breast cancer free 
population surviving 
Net 
reduction 
in 
incidence 
control tam RR multiplier control tam control tam 
0.0067 0.00324 100,000 100,000 0 
1 670 448.9 0.33 0.67 324 324 99,006.0 99,227.1 221 
2 663.3 298.5 0.55 0.45 320.8 320.8 98,021.9 98,607.8 365 
3 656.7 400.6 0.39 0.61 317.6 317.6 97,047.5 97,889.6 256 
4 650.2 331.6 0.49 0.51 314.4 314.4 96,082.9 97,243.6 319 
5 643.8 199.6 669 0.31 311.3 311.3 95,127.8 96,732.7 444 
6 637.4 286.8 0.55 0.45 308.2 308.2 94,182.3 96,137.7 351 
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7 631.0 305.2 93,246.1 631 
8 624.7 302.1 92,319.2 625 
9 618.5 299.1 91,401.6 619 
10 612.4 296.1 90,493.0 612 
11 606.3 293.2 89,593.5 606 
12 600.3 290.3 88,703.0 600 
13 594.3 287.4 87,821.3 594 
14 588.4 284.5 86,948.3 588 
15 582.6 281.7 86,084.1 583 
16 576.8 278.9 85,228.4 577 
17 571.0 276.1 84,381.2 571 
18 565.4 273.4 83,542.5 565 
19 559.7 270.7 82,712.0 560 
20 554.2 268.0 81,889.9 554 
21 548.7 265.3 81,075.9 549 
Total 12755.7 Total 10,790 
Net 1966.0 
reduction 
in 
incidence 
The result for the assumption of no further protection beyond year 6 is a net reduction 
of breast cancer incidence of 1966 at year 21,15.4% of the total number of cases of 
breast cancer (12,755.7) overall in this high risk population during the time period. 
Using the same approach the results for three alternative assumptions in the duration 
of the effect, an additional 5,10 or 15 years of protection, yields a reduction of 3,513, 
4,984 and 6,383 cases of breast cancer respectively. These estimates are used in 
Table 10 to assess the impact of the duration of the protective effect on the marginal 
cost effectiveness. 
Table 10. Cost per breast cancer prevented and per additional breast cancer free 
life year gained with a series of assumptions about the duration of the protective 
effect of chemoprevention for 100,000 women at high risk (6.76 per 1000) for 
breast cancer. The table is based on hospital based service delivery (£535/woman). 
Protective effect (duration in years) beyond year 6 
Cost 0 5 10 15 
Cost of delivery at £535 per 
woman 
£53,500,000. 
0 
Cost of adverse events £103,779.9 
192 
For each possible outcome of an additional 5,10 or 15 years in the duration of the 
protective effect, Table 10 shows the cost effectiveness of tamoxifen 
chemoprophylaxis. For an additional 5 years gained the estimate for cost per breast 
cancer prevented decreases by over 60% to £9,156.7. Gaining an additional 10 or 15 
years of protection results in a cost per breast cancer prevented of £4,653.2 and 
£2,295.9 respectively. 
The calculation of cost per life year gained also shown in Table 10, assumes that 
women with no protective effect beyond year 6 have gained 5 years of life during the 
first protective phase. Women who gain an additional 5,10 or 15 years have a net 
gain of 10,15 and 20 years respectively. The cost per life year gained is £4,235.5. for 
the base case with no additional years gained beyond year 6. Cost effectiveness 
estimates range from £915.7 to £114.8 per life year gained for gains of 10 to 20 years 
duration of the protective effect. 
Discounted cost effectiveness is shown in Table 11. Costs and benefits are discounted 
to net present value at 5% per year using the public sector discount rate. Costs are 
discounted at 5% over 5 years and the benefits are discounted at 5% over 5,10,15 
and 20 years according to the additional years of the protective effect (0,5,10,15 years 
respectively). Thus a breast cancer prevented was valued more highly in year 1 than in 
later years and the costs of tamoxifen prophylaxis are considered more expensive in 
the early than later years. Results in Table 9 are shown for the hospital based model of 
service delivery at £535 per woman. Results for a GP led model at £410 per woman 
are summarised in Italics. 
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Table 11. Discounted cost per breast cancer prevented and per additional life 
year gained with a series of assumptions about the duration of the protective 
effect of chemoprevention for 100,000 women at high risk (6.76 per 1000) for 
breast cancer. Costs are discounted at 5% over 5 years and savings are discounted at 
5% over 5,10,15and 20 years respectively according to the years of protective effect 
(0,5,10, and 15years respectively). The table is based on hospital based service 
delivery at £535/woman. Results for a primary care led service at £410 per woman are 
included in italics. 
Additional Protective Effect (years) 
Costs 0 5 10 15 
Cost of delivery at £535 £53,500,000 £41,917,250.0 £41,917,250.0 E41,917,250.0 £41,917,250.0 
.0 
J 
Cost of adverse events £103,779.9 £81,311.6 £81,311.6 £81,311.6 £81,311.6 
Total cost £53,603,779 £41,998,561.6 £41,998,561.6 £41,998,561.6 £41,998,561.6 
.9 
Savings from breast cancer £9,394,501.9 £13,159,760.5 £14,628,349.0 £14,679,903.0 
Net reduction in breast 1540.4 2156.6 2397.3 2405.8 
cancer (discounted) 
Cost per breast cancer £21,166.5 £13,372.2 £11,417.1 £11,355.6 
prevented (14,808.4) (8,831.0) (7,331.8) (7,284.4) 
Life years gained 7697.9 21566.3 35959.6 48115.1 
Cost per life years gained £4,235.5 £1,337.2 £761.1 £567.8 
(specialist based service 
delivery) 
Cost per life years gained £2,963.2 £883.1 £488.8 £364.2 
(primary care led service 
delivery) 
The (discounted) marginal cost per breast cancer prevented is £13,372.2 for 5 years 
additional benefit beyond year 6 and a marginal cost per breast cancer prevented of 
£11,355.6 per breast cancer prevented for a protective effect continuing for 15 years. 
The discounted marginal cost per life year gained is £567.80 with a protective 
duration of 15 years. 
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7. A high and low cost scenario for cost effectiveness 
Table 12 shows a number of estimates for cost effectiveness of tamoxifen 
chemoprophylaxis using contrasting assumptions to determine the extent of the 
extreme difference between a high and low cost scenario. For the high cost scenario 
the model of service delivery is assumed to be a specialist hospital based model. 
Morbidity is considered to accrue to the cost of service delivery both for benign breast 
disease and for use of beta blockers. The personal costs to the women associated with 
the hospital based model are £43/woman. The results are expressed as the cost per 
breast cancer prevented and per life year gained for the assumption of either a5 or 10 
year duration of protective effect. The low cost scenario is based on a GP model of 
service delivery and assumes that there are morbidity benefits for women taking 
tamoxifen prophylaxis resulting in both reduced use of beta blockers and hospital 
visits for benign breast disease. The low estimate for personal costs to the women 
themselves of £5/woman is included. For both scenarios the costs are discounted over 
5 years and the savings over 5 or 10 years respectively. 
Table 12: Cost effectiveness of tamoxifen chemoprophylaxis. A high and low cost 
scenario (based on the net incidence estimates set out in Table 9). 
(a) Scenario 1: Highest Cost 
Duration of Protective effect 
5 (baseline case) 10 
Costs (discounted) 
Service delivery (at 
£535/woman) 
£41,917,250.0 £41,917,250.0 
Adverse events £81,311.6 £81,311.6 
Beta Blockers 
(£7/woman) 
£548,450.0 £548,450.0 
Benign Breast Disease 
(£41 /woman) 
£3,212,350.0 £3,212,351.0 
Personal costs 
(£43/woman) 
£3,369,050.0 £3,369,050.0 
Total cost £45,759,361.6 
£45,759,361 
Savings 
Breast cancer prevented £9,394,501.9 
£5,795,089.5 
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No. s of breast cancers 1966 3513 
prevented 
Discounted breast cancers 1540.4 2156.6 
prevented 
Cost per breast cancer £18,496.9 £11,376.1 
prevented 
Discounted years of life 7697.9 21,566.3 
gained 
Cost per year of life £4,724.0 £1,853.1 
gained 
(b) Scenario 2: Lowest Cost 
Duration of protective effect 
5 (baseline case) 10 
Costs 
Service Delivery 
(410/woman) 
£32,123,500.0 £32,123,500.0 
Adverse events £81,311.6 £81,311.6 
Personal costs 
(£5/woman) 
£391,750.0 £391,750.0 
Total cost £32,596,561.6 £32,596,561.6 
Savings 
Beta Blockers 
(£7/woman) 
£548,450.0 £429,730.0 
Benign breast disease 
(£41 /woman) 
£3,212,350.0 £2,516,990.0 
Breast cancer prevented £9,399,282.8 £ 13,159,760.5 
Total savings £12,611,632.8 £15,676,750.5 
Nos. of breast cancers 
prevented 
1966 3513 
Discounted breast cancers 
prevented 
7697.9 21566.3 
Cost per breast cancer 
prevented 
£ 10,165 £4,816 
Discounted years of life 
gained 
9825 25130 
Cost per year of life 
gained 
£2,034.1 £481.6 
The results for the cost per breast cancer prevented range between £18,496.9 and 
£10,165.3 per breast cancer prevented for the high and low cost scenario respectively 
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assuming a5 year duration of protective effect. This is an extreme difference of 
£8,331.6. Where the duration of protection is for 10 years the cost per breast cancer 
prevented is £11,376.1 and £4,816.3 for the high and low cost scenario respectively. 
This is an extreme difference of £6,559.8. For cost per life year gained, the extreme 
difference between the high and low cost model for a 5-year duration of protective 
effect is £2,127.8 from £4,724.0 and £2,596.2 per life year gained respectively. For a 
10-year duration of protective effect the difference is £1,068.6 from £1,853.1 per year 
of life gained to £784,5 per year of life gained respectively. These results suggest that 
there is only a small impact of morbidity and indeed of women's personal costs on the 
cost per life year gained. The main cost drivers are the cost of service delivery and the 
risk status of the women involved. The differences found between the 5 and the 10- 
year duration of protective effect are reduced by the process of discounting the 
benefits of chemoprophylaxis. Since this is a preventive intervention it could be 
argued that the benefits should not be discounted. Without discounting the benefits 
(years of life gained) the extreme differences between the low and high cost scenarios 
are lower particularly for duration of effect for 10 years. The extreme differences are 
£1667.2 per life year gained for a 5-year duration of protective effect and £656 for a 
10 year duration. 
Discussion 
Chemoprophylaxis for breast cancer is targeted at a group of women at extremely 
high lifetime risk of breast cancer for whom few effective treatment strategies are 
available. Two different approaches are taken in developing estimates of cost 
effectiveness. Both yield similar results and provide complementary information 
about the factors affecting cost and cost effectiveness. Firstly, the decision analysis 
based on an average District Health Authority population of a million people provides 
an assessment of the importance of the risk status of the population. Where the 
absolute benefits of chemoprevention are low, high costs will accrue from the need to 
treat large numbers of women in order to prevent or delay a single breast cancer. 
Moreover in an average District Health Authority population the proportion of women 
at high risk will be relatively small. Secondly in the assessment from a cohort of 
women using results from NSABP P-12 it is clear that the cost effectiveness of 
tamoxifen chemoprophylaxis is favourable in comparison with many other health care 
197 
interventions when targeted at high risk women and providing that the protective 
effect continues beyond the period of active treatment. 
Estimates of cost effectiveness based on the results from the NSABP P-1 study are 
more likely to represent the true magnitude for cost effectiveness since the population 
targeted is at high risk for breast cancer and the incidence in both the treated and 
control population was monitored assiduously over a number of years. The risk 
factors defining eligibility for the study and indeed those underpinning IBIS are a 
useful basis for defining a target population for tamoxifen prophylaxis in health 
policy. The cost effectiveness range is within the range of many routine treatments in 
the NHS and low for those concerned with preventing early mortality. 
There are however a number of limitations to this analysis including a number of 
assumption used in the estimates for cost effectiveness. The results for cost 
effectiveness can only be expressed in terms of breast cancer incidence since to date 
there is no information about the possible effects on mortality. There is also no 
evidence to address the question of whether the results for incidence represent a delay 
in the development of cancers or a permanent benefit. There has been some 
speculation of an increase in the proportion of aggressive breast cancers owing to the 
selection of tamoxifen resistant tumours. The effectiveness of adjuvant tamoxifen for 
women taking tamoxifen at the time of diagnosis is not known and the mortality rate 
for these women may be high. Long term adverse effects of prolonged tamoxifen use 
will be monitored by ongoing follow-up in the UK and USA studies though only the 
known increase in risk of endometrial cancer has been included. 
Fixed costs for any of the interventions discussed are not included since they are 
integrated within the charges used to derive cost estimates. Given the small numbers 
of women who might be eligible for chemoprophylaxis within the average health 
district it is likely that any increased demand would be absorbed within present breast 
cancer services or indeed in general practice. Moreover fixed costs would vary 
considerably in different centres and the emphasis here is on determining the main 
factors affecting cost effectiveness. Where implementation of a service for tamoxifen 
chemoprophylaxis was considered the fixed costs would bear on the start up costs. In 
deriving the estimates for cost effectiveness compliance is assumed to be 100% which 
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has not been the case in any of the chemoprevention studies to date. Reduced 
compliance may not affect the cost of service delivery, though will reduce the efficacy 
of the intervention. The precise impact of reduced compliance has not been 
calculated though is arguably likely to be comparable to the effect found for changes 
in efficacy seen in Table 6. 
It is likely that a reduction in compliance would have its main effect on cost 
effectiveness through reducing the numbers of breast cancers prevented. Based on the 
figures shown in Table 10 a reduction in compliance to 70% would reduce the cost 
per breast cancer prevented to £32,854 (assuming that the savings from 30% fewer 
breast cancers prevented would be £8,396,352 instead of £11,990,430). This would 
change the cost per breast cancer prevented to £32,854 instead of £21,166.5 shown in 
the table -a difference of just over 50%. The impact on the difference in cost per year 
of life saved would be a change from £4,235.5 to £6,570.85. The effect of reduced 
compliance may be less were the cost of service delivery and the cost of adverse 
events also to be reduced. The effect of the former is however likely to be small 
especially if women continued to attend clinic sessions for checks but were not 
complying with appropriate ingestion of tamoxifen on a daily basis. The impact on 
adverse events may also be small since the costs associated with adverse events are 
relatively low in comparison with the cost of breast cancers prevented. 
The cost of delivering tamoxifen prophylaxis per women is relatively low in 
comparison with many other health care interventions yet the overall cost 
effectiveness estimates are substantially influenced by the numbers of women who 
would need to be treated in order to prevent one breast cancer because of the level of 
absolute risk reduction. For women at moderate or low absolute risk of breast cancer 
this number is relatively high in comparison with the numbers of breast cancers 
prevented. 
Cost effectiveness decreases with. increasing risk of the women involved and 
measured over the six year period of the NSABP P-1 where the average risk in the 
population treated was 6.76 per 1000 becomes an estimated discounted cost per breast 
cancer prevented of £21,166.5 in a hospital based service (see Table 10). This 
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assumes that there are no additional benefits beyond the period of the active 
intervention and that all visits by the women are to specialist centres. 
At a discounted cost per breast cancer prevented of £14,808.4 offering prophylaxis 
through general practice would be more cost effective than a hospital based service 
albeit nurse led with specialist support. Such an approach might be possible with only 
1 visit to a specialist at the initiation of tamoxifen prophylaxis and anticipating a 
reduced number of follow up visits. It could be argued that mammography would be 
needed only to check eligibility for tamoxifen and that routine mammograms for a 
service which is intended to reduce the risk of breast cancer is an inappropriate 
intervention and an unnecessary expense outwith the routine NHS Breast Screening 
Programme. The IBIS estimate for cost effectiveness approximates the lowest 
estimate found for a GP based model of service delivery. It is likely however that the 
research costs for IBIS underestimate the true cost of the intervention with some 
subsidy from the host breast care services in the NHS. 
Using the results from Table 12 the cost effectiveness of tamoxifen chemoprophylaxis 
appears to lie between £4,724 and £784.5 per life year gained. The former assumes a 
specialist hospital based model of service delivery with costs of morbidity for benign 
breast disease and beta blockers both accruing to overall costs and with the personal 
costs to the women themselves at the high estimate of £43 per woman. The estimate is 
based on the assumption that the duration of the protective effect for tamoxifen 
prophylaxis is 5 years beyond the active period of treatment. By contrast, the low 
estimate includes only £5 per woman for personal costs. Morbidity is assumed to be a 
net benefit to a woman taking tamoxifen for both benign breast disease and for use of 
beta blockers. The duration of the protective effect is 10 years. Although there is a 
three fold difference between the high and low estimates the cost per life gained 
appears to lie within a feasible range for a new health technology though would of 
course depend on the importance of defining and successfully targeting a high risk 
population. 
There is some debate about the appropriateness of discounting in the context of 
prevention19. The effect is to reduce the value of future benefits undermining the 
relative value of prevention over therapeutic interventions. The consequence of 
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discounting is to increase the cost per life year gained particularly once costs have 
become more distant and benefits extend to an additional 15 years of protective effect 
Morbidity arising from tamoxifen prophylaxis appears to be low with little overall 
impact on cost effectiveness. To date, no comparable estimates have been published 
in other chemoprevention trials. Recent reports about the impact of the main adverse 
events of tamoxifen chemoprophylaxis particularly an increased risk of endometrial 
cancer suggest that the extent of the risk and the clinical impact have been 
exaggerated. 
Developing the model for chemoprevention within the context of a district health 
authority population has the advantage of identifying the impact on the costs of breast 
cancer care overall. For an average District Health Authority population the impact 
on breast cancer incidence would be small. This is mostly because the proportion of 
the population with levels of risk of breast cancer high enough to become eligible for 
chemoprophylaxis are small. Where a programme for prophylaxis was developed 
eligibility criteria would be need to be strictly enforced in order to ensure that only 
high risk women were targeted. Failure to achieve a high risk population may result 
in expenditure on chemoprevention at the expense of more cost effective means of 
reducing mortality and morbidity from breast cancer. 
Of importance in targeting tamoxifen chemoprophylaxis are findings from the 
NSABP P-12 trial that a benefit from tamoxifen was identified for women across the 
spectrum of risk factors and levels of risk. The trial was not designed to assess 
whether findings for high risk women could be generalised to all women and the main 
effect - of almost 50% reduction in risk of breast cancer occurs for a population of 
women at high risk. The study did however provide evidence that women with a 
history of LCIS or atypical hyperplasia were more likely to develop invasive cancer 
than had been previously expected and that tamoxifen chemoprophylaxis could reduce 
the risk. The authors conclude that eligibility should be extended to three main groups 
of women: women with a history of atypical hyperplasia or LCIS, the group of 
women under 50 with sufficient risk to warrant eligibility to the NSABP P-1 trial and 
postmenopausal women at high risk for breast cancer who have had a hysterectomy. 
201 
Since women in these categories are likely to have an average relative risk of at least 
3 fold relative risk they may be appropriate criteria for targeting women in the UK. 
The cost effectiveness estimates can be compared with other means of reducing breast 
cancer incidence although there are problems of comparability particularly in 
estimating the savings from the cost of breast cancer prevented. Boer and de 
Koning187 published cost effectiveness estimates for the current NHS Breast 
Screening Programme of £25,142 per death prevented and £24,205 or £27,865 for 
extending the age range to 65 or reducing the interval to two years respectively. The 
estimates for tamoxifen prophylaxis are likely to fall well below this range providing 
that the intervention is targeted at women at high risk for breast cancer (at least 3 fold 
relative risk) delivered in general practice and that the effect of risk reduction 
translates into a mortality benefit. 
The cost effectiveness of early treatment for breast cancer to year 10 of between 
£10,625 ($17,000) per death prevented for women at all ages in the highest risk 
categories to £31,250 ($50,000) for women at any age at a lower risk of death is lower 
than that found for breast screening. The effectiveness of early treatment for breast 
cancer may be considered comparable to the findings from NSABP P-1 since 
interventions are concerned with women at increased risk of death from breast cancer 
rather than with women at average population risk. 
There is insufficient information on the present management of women at high risk 
for breast cancer to compare with the costs estimated for chemoprophylaxis of breast 
cancer. Bilateral prophylactic mastectomy has been a treatment choice for some 
women though there are few routine data available to assess the frequency of use of 
this approach, its survival advantage or cost effectiveness". Annual mammography 
has also been suggested for women in high risk categories though there are no data at 
present to assess the efficacy of this approach. 
Summary and Conclusions 
Modelling cost effectiveness for tamoxifen chemoprophylaxis based on both a district 
health authority population and on the results from NSABP P-1 highlights the 
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importance of the cost of service delivery in calculating overall cost effectiveness. 
Estimates of the costs of service delivery and the possible costs of morbidity included 
in the model are taken from analysis of women recruited to the International Breast 
Cancer Intervention Study and presented in previous chapters. The baseline case is 
taken as a consultant based service in a hospital setting with specialist nurse 
involvement costing overall £535 per woman. This model of service delivery requires 
women to travel to specialist centres for treatment but restricts consultant input to an 
initial visit to determine eligibility and to exclude the possibility of breast cancer. 
Measures of efficacy are taken from outcome data published from the NSABP P-1. 
The costs of breast cancer have been developed from analysis of an audit carried out 
by the Thames Cancer Registry (TCR). Other costs such as for endometrial cancer 
are based on HRGs currently in use for costing procedures in the NHS. 
Few studies have been published on which to base cost estimates for the treatment of 
early breast cancer. The TCR audit used here is based on 1,779 cases of breast cancer 
in 17 different hospital trusts in the Thames region. The cost of breast cancer is 
estimated at £6,102 per woman and includes estimated costs for advanced disease and 
for palliative care taken from the published literature. A large proportion of the 
overall cost is for radiotherapy (24%); the cost of chemotherapy for advanced disease 
is a small proportion of the total cost (<I%). Estimates for cost effectiveness of 
prophylactic tamoxifen is based on a district health authority population with a1 
million population and 120,000 women aged 45-64. It is assumed that around 7% of 
women are at increased risk of breast cancer and would be eligible for 
chemoprevention with tamoxifen. The estimated cost of breast cancer for this 
population is about 1.5 million per year. The cost of delivering tamoxifen prophylaxis 
to the eligible population would be around £100 per woman year. 
The main adverse effect included is the cost of endometrial cancer (£2,261). At 3 per 
10,000, the baseline rate of endometrial cancer is low in the UK compared with the 
USA. The relative risk of endometrial cancer with prolonged tamoxifen use is 
insufficient to have a significant effect on overall cost effectiveness. 
The cost effectiveness derived from estimating the incidence of breast cancer in a 
cohort of women taking tamoxifen over 6 years using the results from NSABP P-1 
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may be between £4,274 and £784.5 per life year gained depending on whether a high 
cost or low cost scenario is used. This covers the possible effects of long term 
tamoxifen use on morbidity, the inclusion or exclusion of personal costs to the women 
themselves and assumes a5 or 10 year protective effect respectively for tamoxifen in 
reducing breast cancer risk. 
The sensitivity analysis explores alternative means of service delivery including a GP 
based service and the expenditure assumptions within the research protocol for IBIS. 
Also included in the sensitivity analysis is the impact of morbidity on cost 
effectiveness. Earlier work (chapters 4 &5) found no significant differences between 
the two arms of the trial for morbidity assessed either as rate of hospital use or use of 
medications. There were however non-significant differences in the rate of use of 
hospital visits for benign breast disease and for the use of beta blockers which merit 
further analysis with increasing accrual and duration of the study. 
The costs of care set out within the GP led service, in keeping with other forms of 
chemoprophylaxis such as hormone replacement therapy for osteoporosis, could 
possibly be reduced from the £410 per woman included here. Lower cost might be 
achieved if, for example, the level of specialist involvement were targeted only 
towards problems or difficult cases. Current thinking within IBIS does however 
suggest that specialist input would be recommended. In general practice the personal 
costs for the women themselves would be low. 
For developing health policy in relation to tamoxifen chemoprophylaxis the level of 
risk of the target population is clearly of considerable importance in terms of cost 
effectiveness. For women at very high risk (10-fold risk) the cost effectiveness is 
around five times lower than for woman at 2 fold increased risk of breast cancer. The 
eligibility criteria used for entry to the NSABP P-1 and to IBIS provide a useful basis 
for deciding access to tamoxifen chemoprophylaxis within the NHS since they have 
achieved a high-risk population in both studies. Developing referral criteria on this 
basis would provide support for GPs in advising women and ensure cost-effective use 
of resources available for care and prevention of breast cancer. 
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Appendix 1: The range of cost effectiveness estimates for alternative costs of 
service delivery and including or excluding costs of morbidity at either £5 or 
£43 personal costs per woman. 
1. Cost effectiveness for nurse led service (E535/woman) assuming £5 personal cost per 
woman. 
Morbidity scenario 
Cost (£) Plus benign 
breast disease 
plus beta 
blockers 
Minus benign 
breast disease 
minus 
beta blockers 
Plus benign 
breast disease 
minus beta 
blockers 
Minus benign 
breast disease 
plus beta 
blockers 
Cost of service delivery 53,603,779.9 53,603,779.9 53,603,779.9 53,603,779.9 
Morbidity 
benign breast disease 16,081,133.97 16,081,133.97 16,081,133.97 16,081,133.97 
beta blockers 107,207.5598 107,207.5598 107,207.5598 107,207.5598 
Personal cost 
@£5 2,500,000 2,500,000 2,500,000 2,500,000 
Total Cost 72,292,121.43 39,915,438.37 72,077,706.31 40,129,853.49 
Savings (breast cancer) 11,931,927.74 11,931,927.74 11,931,927.74 11,931,927.74 
Cost per breast cancer 
prevented 
30,874.78 14,313.82 30,765.10 14,423.49 
2. Cost effectiveness for GP led service (£410/woman) 
Assuming £5 personal cost per woman. 
Cost (£) 
Plus benign 
breast disease 
plus beta 
blockers 
Minus benign 
breast disease 
minus 
beta blockers 
Plus benign 
breast disease 
minus beta 
blockers 
Minus benign 
breast disease 
plus beta 
blockers 
Cost of service delivery 41,103,779.9 41,103,779.9 41,103,779.9 41,103,779.9 
Morbidity 
benign breast disease 16,081,133.97 16,081,133.97 16,081,133.97 16,081,133.97 
beta blockers 82,207.5598 107,207.5598 107,207.5598 107,207.5598 
Personal cost 
@ £5 2,500,000 2,500,000 2,500,000 2,500,000 
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Total Cost 59,767,121.43 27,415,438.37 59,577,706.31 27,629,853.49 
Savings (breast cancer) 11,931,927.74 11,931,927.74 11,931,927.74 11,931,927.74 
Cost per breast cancer 24,468.13 7,919.95 24,371.24 8,029.63 
prevented 
3. Cost effectiveness assuming 
per woman 
Cost 
Plus benign 
breast disease 
plus beta 
blockers 
Minus benign 
breast disease 
minus 
beta blockers 
Plus benign 
breast disease 
minus beta 
blockers 
Minus benign 
breast disease 
plus beta 
blockers 
Cost of service delivery 20,103,779.9 20,103,779.9 20,103,779.9 20,103,779.9 
Morbidity 
benign breast disease 16,081,133.97 16,081,133.97 16,081,133.97 16,081,133.97 
beta blockers 40,207.56 107,207.56 107,207.56 107,207.56 
Personal cost 
@ £5 2,500,000 2,500,000 2,500,000 2,500,000 
Total Cost 38,725,121.43 6,415,438.37 38,577,706.31 66,29,853.49 
Savings (breast cancer) 11,931,927.74 11,931,927.74 11,931,927.74 11,931,927.74 
Cost per breast cancer 13,704.96 - 2,821.73 13,629.55 -2,712.06 
prevented 
4. Cost effectiveness for nurse led service(E535/woman) 
Assuming £43 personal cost per woman. 
Cost 
Plus benign 
breast disease 
plus beta 
blockers 
Minus benign 
breast disease 
minus 
beta blockers 
Plus benign 
breast disease 
minus beta 
blockers 
Minus benign 
breast disease 
plus beta 
blockers 
Cost of service delivery 53,603,779.9 53,603,779.9 53,603,779.9 53,603,779.9 
Morbidity 
benign breast disease 16,081,133.97 16,081,133.97 16,081,133.97 16081,133.97 
beta blockers 107,207.56 107,207.56 107,207.56 107,207.56 
Personal cost 
@£43 21,600,000 21,600,000 21,600,000 21,600,000 
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Total Cost 91,392,121.43 59,015,438.37 91,177,706.31 59,229,853.49 
Savings (breast cancer) 11,931,927.74 11,931,927.74 11,931,927.74 11,931,927.74 
Cost per breast cancer 40,644.60 24,083.64 40,534.92 24,193.312 
prevented 
5. Cost effectiveness for IBIS model (E200/woman) 
assuming £43 personal cost per woman. 
Cost 
Plus benign Minus benign 
breast disease breast disease 
plus beta minus 
blockers beta blockers 
Plus benign 
breast disease 
minus beta 
blockers 
Minus benign 
breast disease 
plus beta 
blockers 
Cost of service delivery 20,103,779.9 20,103,779.9 20,103,779.9 20,103,779.9 
Morbidity 
benign breast disease 16,081,133.97 16,081,133.97 16,081,133.97 16,081,133.97 
beta blockers 40,207.56 107,207.56 107,207.56 107,207.56 
Personal cost 
@£43 21,600,000 21,600,000 21,600,000 21,600,000 
1 
Total Cost 57,825,121.43 25,515,438.37 57,677,706.31 25,729,853.49 
Savings (breast cancer) 11,931,927.74 11,931,927.74 11,931,927.74 11,931,927.74 
Cost per breast cancer 23,474.78 6,948.09 23,399.37 7,057.76 
prevented 
6. Cost effectiveness for GP led service(£410/woman) 
Assuming £0 personal cost per woman. 
Cost 
Plus benign 
breast disease 
plus beta 
blockers 
Minus benign 
breast disease 
minus 
beta blockers 
Plus benign 
breast disease 
minus beta 
blockers 
Minus benign 
breast disease 
plus beta 
blockers 
Cost of service delivery 20,103,779.9 20,103,779.9 20,103,779.9 20,103,779.9 
Morbidity 
benign breast disease 16,081,134.0 16,081,134.0 16,081,134.0 16,081,134.0 
beta blockers 40,207.6 107,207.6 107,207.6 107,207.6 
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Personal cost 
£0 
Total Cost 36,225,121.4 3,915,438.4 36,077,706.3 4,129,853.5 
Savings (breast cancer) 11,931,927.7 11,931,927.7 11,931,927.7 11,931,927.7 
Cost per breast cancer 12,426.2 -4,100.5 12,350.8 -3,990.8 
prevented 
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Recommendations 
1. Where tamoxifen chemoprophylaxis for breast cancer is introduced into routine 
health care, protocols for ensuring that eligibility criteria are met will be needed in 
order to maximise cost effectiveness. Consideration should be given to restricting 
eligibility for tamoxifen chemoprophylaxis to the groups of women eligible for 
NSABP P1 or IBIS. This would include broadly three main groups of women 1) 
women with a history of atypical hyperplasia or LCIS 2) a group of women eligible 
because of a combination of age and family history - following the principle that 
younger women would need a higher level of family involvement to be risk 
equivalent and postmenopausal women at high risk for breast cancer who have had a 
hysterectomy. The priority would be to secure a group of women with at least 3 fold 
relative risk. 
2. The level of specialist support for tamoxifen chemoprophylaxis for breast cancer 
should be established with the aim of avoiding unnecessary investigations and follow- 
up. Service delivery in primary care with referral into routine breast services for 
consultant or specialist nurse advice when needed is feasible given the likely level of 
demand within health districts and should be fully evaluated.. 
3. Decisions regarding the availability of mammography screening for women taking 
tamoxifen will need to be made in the light of findings from research addressing the 
value of more frequent mammography for women at high risk for breast cancer. Any 
protocol for service delivery will need to ensure integration with the NHS Breast 
Screening Programme in order to avoid duplication and wasted resources. 
4. Further research is needed to: 
> Monitor the long term consequences of tamoxifen use on the general health and 
morbidity of women. Long term breast cancer adjuvant studies are useful in 
providing information on the safety of trials for tamoxifen prophylaxis but more 
detailed studies are needed to assess the effect of long term exposure to tamoxifen 
for chemoprevention of breast cancer in healthy asymptomatic women. In 
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addition, small changes in the use of hospital services or prescribed medications 
for the age group targeted in prevention trials could have a significant impact on 
the overall cost of tamoxifen chemoprophylaxis because of the potentially large 
numbers of women involved. The long term impact on vascular symptoms and on 
benign breast disease in particular is unclear and will require further research to 
establish fully. 
¢ Further assessments of well being and quality of life are also needed since the 
women studied here are self selected women and likely to be highly motivated 
with a positive attitude towards the prospect for chemoprevention. 
¢ Assess whether the reduction in incidence of breast cancer found in the NSABP P- 
1 study will act to delay the onset of disease or will reduce mortality. The precise 
duration of the effect after cessation of the period of active intervention with 
tamoxifen treatment is also uncertain. 
¢ Clarify the impact of age on efficacy of the intervention in order to understand 
fully the value of chemoprophylaxis for women at high risk for breast cancer by 
virtue of age. 
¢ In general research on alternative means of preventing mortality and morbidity 
from breast cancer should be pursued. For example, an understanding of the 
biological plausibility of casual link between dietary fat and breast cancer 
discussed in this study cannot exclude the possible importance of diet at key 
development stages. In particular, the relationship with onset of menarche and 
early adolescence where the impact of diet on breast carcinogenesis may be 
profound. A number of randomised controlled trials are underway in the USA 
although these are focussing only on the recruitment of adult women. Further 
studies on the use of other chemopreventive agents are also underway. 
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Conclusions 
Findings from this study suggest that the cost effectiveness of tamoxifen 
chemoprophylaxis for breast cancer could realistically be set in the range between 
£4,724.0 and £2,596.2 per life year gained with a5 year duration of protective effect. 
The upper and lower limits are defined by putting together high or low estimates for 
key elements of cost. The high cost scenario includes 
"A service based on a specialist hospital model at £535 per woman 
" The cost of excess morbidity from long term tamoxifen use 
" Personal costs to the woman due to clinic visits of £43 per person over the 5 year 
period of active intervention. 
The low cost scenario includes 
"A service model based in primary care 
No excess costs due to morbidity arising from tamoxifen use 
" Health benefits reducing the cost of general health care in addition to reducing the 
risk of breast cancer for women taking tamoxifen 
" Personal costs to the woman due to clinic visits of £5 per person or less over the 5 
year period of active intervention 
The study found that the cost of delivering breast cancer chemoprevention per women 
is relatively low in comparison with many other health care interventions. Yet the 
overall cost effectiveness is sensitive to a number of factors including the baseline 
risk of the women and the magnitude and duration of the protective effect. Changing 
the risk status of eligible women from 2 fold to 5 fold average population risk results 
in a 50% improvement in the cost effectiveness estimate. For women at moderate or 
low absolute risk of breast cancer the number who need to take tamoxifen to prevent 
one breast cancer is relatively high in comparison with the numbers of breast cancers 
prevented. Even where a high risk population can be successfully targeted a large 
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proportion of the cost lies in the number of women who need to be treated in order to 
prevent one breast cancer. 
Introducing tamoxifen chemoprophylaxis for breast cancer into the NHS will rely on 
effective means of targeting women at high risk and of ensuring lowest possible costs 
of service delivery. Given the small numbers of women who might be eligible for 
chemoprophylaxis within the average health district it is likely that any increased 
demand would be absorbed within present breast cancer services or indeed in general 
practice. 
Chemoprevention trials have not been designed to assess whether findings for high 
risk women can be generalised to all women. The outcome found in the NSABP P1 - 
of almost 50% reduction in risk of breast cancer is for a population of women at 
around 3 fold baseline risk. The NSABP P1 trial did however provide evidence that 
women with a history of LCIS or atypical hyperplasia were more likely to develop 
invasive cancer than had been previously expected and that tamoxifen 
chemoprophylaxis could reduce the risk. Introducing tamoxifen chemoprophylaxis 
into the NHS will require consideration of the appropriate level of service based on 
criteria for referral and precise assessment of the need for specialist support and the 
importance of integration with the NHS Breast Screening Programme. Delivering 
tamoxifen chemoprophylaxis through primary care does however seem feasible. 
Despite the frequency of visits to clinic settings for women enrolled into IBIS 
specialist clinical input at consultant level is minimal and mainly focussed on the 
initial visit. A reduced number of visits to hospital is possible providing the woman 
has access to her GP for follow up. Referral for mammography could also be reduced 
to the initial visit. More frequent mammography may be inappropriate for a health 
intervention targeted towards reducing the risk of breast cancer. 
Eligibility for tamoxifen chemoprophylaxis could cover three main groups of women: 
women with a history of atypical hyperplasia or LCIS, the group of women under 50 
with sufficient risk to warrant eligibility to the NSABP Pltrial and postmenopausal 
women at high risk for breast cancer who have had a hysterectomy. Since women in 
these categories are likely to have an average relative risk of at least 3 fold relative 
risk these may well be appropriate criteria for targeting women in the UK. 
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Interest in the possible use of the drug tamoxifen for chemoprophylaxis of breast 
cancer came about as a result of findings of a 35% reduction in the risk of breast 
cancer in the contralateral breast for women taking tamoxifen. This could potentially 
have substantial public health significance if applicable to prevention for women 
without diagnosed disease - potentially reducing the death rate to around 40 per 
100,000 per year preventing more than 5000 deaths per year. Even where a 
prophylactic application may be verified empirically such a broad scale improvement 
is unlikely from tamoxifen chemoprophylaxis since the intervention is aimed at high 
risk women in the age range 40-65 while over 60% of breast cancer deaths are in 
women aged 65 and over. 6 Moreover costs are highest where the risk status of the 
women involved is equivalent to that in the general population. 
Recent evidence suggest that there is a reverse in the previously rising trend of 
incidence and mortality from breast cancer in the UK. Analysis of trends in mortality 
in birth cohorts since the 1930 presented here support the view that the decline is most 
likely to be due to the assiduous application of effective therapeutic regimen. There 
may also be a role for changes in the distribution of risk in birth cohorts or period 
effects. The effect cannot be attributed to the NHS Breast Screening Programme. 
Background figures for incidence, with which to compare a preventive intervention, 
are difficult to ascertain because of the impact of the NHS Breast Screening 
Programme on the rate for registration of breast cancer. Since the introduction of the 
NHS Breast Screening Programme the lifetime probability of acquiring breast cancer 
for a woman aged 30 (with a life expectancy of 83) was 1 in 11 in 1982 and 1 in 9 in 
1992. The breast-screening programme was introduced in 1988. Mortality endpoints 
are most desirable in assessing the efficacy of chemoprevention since the prospect 
that tamoxifen modifies the rate of or blocks carcinogenesis rather than inhibiting the 
inset of disease cannot be ruled out. Nevertheless possible effects of chemo 
prevention in risk reduction, compressing or delaying the development of breast 
cancer may be beneficial. Cost effectiveness will depend on the duration and 
magnitude of the effect and the absolute risk reduction in the treated population. 
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Hitherto, efforts to reduce mortality and morbidity from breast cancer have focussed 
on secondary prevention through the NHS Breast Screening Programme and treatment 
of disease through appropriate application of adjuvant therapy. Estimates of the likely 
reduction in risk of death from breast cancer with chemoprevention have been 
predicted from adjuvant studies where a review of long term follow up has shown a 
consistent improvement of around 50% in ten year survival with use of tamoxifen 
after surgical resection of disease. Consistent with this finding, a recent report from 
the NSABP Breast Cancer Prevention Trial found a 49% reduction in risk of invasive 
breast cancer in healthy women taking tamoxifen. This has not been confirmed by the 
publication of two further preliminary reports from chemoprevention studies. 
Differences in the study populations may however may be responsible for these 
contrary findings. 
The screening trials have proposed a relative risk reduction in mortality of around 
24% - for screened women. Results from international regression analysis for the 
effect of dietary fat reduction on population mortality from breast cancer suggest a 
possible 24% reduction with a low fat dietary intervention. A review of 
epidemiological evidence for the relationship between diet and breast cancer however 
cannot confirm these findings. Better designed studies are able to control for family 
history or reproductive risk factors, but none has sufficient heterogeneity in fat intake 
to detect adequately the effect of a reduction in mortality of anything near the 24% 
seen in international regression analysis. 
This study shows that the cost effectiveness of tamoxifen chemoprophylaxis of breast 
cancer is within acceptable limits for implementation in comparison with the present 
programme for care and prevention of breast cancer providing certain conditions are 
met. For an average district health authority population of 250,000 people with about 
100 deaths from breast cancer per year full implementation of effective adjuvant 
therapy may prevent around 30-40 deaths, the screening programme may prevent 10- 
15 deaths. For preventive interventions the scope for dietary effects though far from 
proven may have the potential of saving 20-25 deaths; with tamoxifen 
chemoprophylaxis targeted only at say the 10% high risk women in the population 
would prevent only 5-10 deaths. 
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There are few other studies available with which to compare the validity of the 
approach used in seeking to understand the likely impact of long term tamoxifen 
chemoprophylaxis on the changed morbidity experience of women. The use of 
hospital services is frequently cited in studies of needs assessment as a proxy for 
morbidity in the population 187,188,189 and a linear relationship might be expected. 
Where the relationship is less than perfect it is possible that the methodology may 
have underestimated the true impact on morbidity. The study does however review 
other possible means by which morbidity may have been expressed either through 
changes in the quality of life of the women involved or through changes in the use of 
primary care services - reported visits to general practice. Neither of these showed 
any significant changes in reported morbidity or in decrements in quality of life 
though attention should be given to this issue in further follow up. 
Efforts were made to ensure accuracy and completeness of reports from the women 
through hand searching of records. Validation of the approach was sought through 
reference to routine sources of information. In the case of hospital resource use 
validation of the information on reasons for use of health services including diagnosis 
and procedures undertaken was sought through comparison with the rate of 
admissions to hospital by women in the general population reported in the Hospital 
Episode Statistics. For the rate of use of medications further information with which 
to validate the approach was sought through comparison with the National Morbidity 
Survey and through review of data for women of the same age registered with a large 
general practice. 
There were no significant findings in this study to suggest that long term tamoxifen 
use in the context of chemoprevention affects morbidity. There were no significant 
differences for women allocated to tamoxifen or placebo in the self reported rate of 
use of hospital services or use of prescribed medications. Further recruitment to IBIS 
or indeed detailed analysis of morbidity trends in other prevention studies is needed to 
explore this further since confirmation of the non significant trend that did emerge in 
changed use of hospital visits for benign breast disease may change the costs of breast 
cancer chemoprevention by between 30 and 38%. By contrast, confirmation of a non 
significant trend of increased use of beta blockers for the relief of menopausal 
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symptoms as often experienced by women taking tamoxifen would affect the cost by 
less than 1 %. 
In terms of the distribution of cost a small number of women do account for a large 
proportion of the overall costs. This finding suggests that it will be the impact of 
tamoxifen chemoprophylaxis on increasing or reducing the incidence of high cost 
procedures, which determines the cost impact from morbidity. Adjuvant studies report 
that acute toxicity of tamoxifen is low and prolonged exposure in adjuvant studies 
does not appear to result in adverse effects on coronary heart disease or bone mineral 
density despite its anti - oestrogenic properties. In fact, where serum levels of lipids 
and lipoproteins have been monitored tamoxifen appears to have an oestrogenic effect 
improving the lipid profile. There are concerns about an increase in the relative risk of 
endometrial cancer for women taking adjuvant tamoxifen. This effect appears to be 
dose and duration dependent. For women receiving adjuvant tamoxifen at a dose of 
20mg per day the relative risk appears to be between two and three fold . Estimates 
from chemoprevention studies are now as high as a five-fold increase although the 
absolute numbers are low. The median cumulative dose of tamoxifen needed before 
diagnosis of endometrial cancer estimated from the Stockholm Trial was 29g. This 
level would be reached after four years of treatment with a daily intake of 20mg as 
given in IBIS. 
There is both clinical and biochemical evidence of an increased risk of 
thromboembolic events in women taking tamoxifen. The effect is clearly complex 
and multifactorial influenced also in adjuvant studies by the presence of disease and 
the impact of chemotherapy. The relative risk for women taking tamoxifen alone 
either as an adjuvant therapy or for prophylaxis may be between three and five fold 
although was less than two for all thromboembolic disease in the NSABP Breast 
Cancer Prevention Trial. The relative risk appears to increase when tamoxifen is 
taken in combination with chemotherapy with implications for treatment options; the 
effect is greater in postmenopausal women. 
The impact of long term exposure to tamoxifen on cardiac health may be at least as 
important as the end point of primary breast cancer reduction. Consistent findings of 
an effect on lipid lowering may give rise to a relative protective effect of tamoxifen 
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on mortality from myocardial infarction of around 2.0 though the recent updated 
overview of randomised trials of adjuvant therapy among women with early breast 
cancer showed no significant difference in the aggregate of all cardiac or vascular 
deaths after about five years of tamoxifen. The long term impact on cardiac 
morbidity in general is unclear and will require further research to establish fully. The 
precise duration of the effect after cessation of tamoxifen treatment is also uncertain. 
The impact of tamoxifen on bone mineral density in postmenopausal women seems to 
be an increase primarily in the lumbar spine and hip by an annual increment of around 
1.5% though this increase appears to occur only during the early years of tamoxifen 
use. Some evidence also suggests that the protective effect on BMD may be lost after 
cessation of use and similar effects on radial bones appear doubtful. Larger studies 
are needed to confirm the reduction in bone mineral density in premenopausal women 
suggested in results from the Royal Marsden prevention pilot and to assess both the 
duration of this effect and the clinical significance. 
The overall cost for delivering tamoxifen prophylaxis within the context of IBIS is 
estimated at £1,116 per woman per 5 years. The largest proportion of cost (57%) is in 
staff time. The cost of Doctor time is the largest element; the amount of time spent by 
the Doctor explains the difference in cost between the centres. Tests and 
investigations account for a further 23% of the cost and provision of the drug 
tamoxifen for 14% of the cost. Costs of administration make up the remainder of the 
cost (6%). 
The main time element in the provision of tamoxifen chemoprophylaxis is in 
discussing the concept to the women and the protocol for consent to enter the trial 
While the time element in `consenting' woman may translate into time spent 
discussing the evidence base and side effects of tamoxifen prophylaxis if the approach 
was adopted in routine practice some savings could be made. Two scenarios for 
service delivery are used in the cost effectiveness analysis. These are £535 for a 
specialist nurse led hospital based service or £410 for a service run in general 
practice. The nurse led service is used as the baseline approach for the model 
developed in chapter 7 and the GP run service is explored through the sensitivity 
analysis. Both approaches would rely on minimal input from a consultant surgeon or 
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equivalent with only 1 visit included for the 5-year period. The frequency of 
mammography would be a maximum of 3 times in the 5-year period of active 
intervention. Both scenarios exclude the costs attributable to the research trial 
particularly the need for annual mammography, the taking and processing of blood 
and time spent recruiting women to the study. 
The costs borne by women using a service for tamoxifen chemoprophylaxis based on 
women recruited to IBIS range from £20 to £30 per year of recruitment depending on 
whether time spent travelling to or during clinic visits is excluded or costed at average 
hourly earnings for women in this age group. This includes both the cost of work lost 
due to clinic visits, costs of travel to the clinics or other costs associated with clinic 
visits. Women recruited to IBIS are willing to travel long distances to receive the 
chance of taking tamoxifen chemoprophylaxis. 75% of journeys are longer than 30 
minutes with half of these being over 1 hour. Over 60 % of women sampled reported 
that they would wish to take tamoxifen at even a low level of absolute benefit (1 death 
prevented per year); 84% of the women would be happy to travel to a specialist centre 
to receive tamoxifen. There was no difference in the pattern of use of primary care 
between the 2 arms of the trial. 
Including the personal costs to the women themselves in the cost effectiveness 
analysis increases the cost by between 1% and 8% depending on whether an 
allowance is made for the cost of time spent in travelling to or attending clinic visits. 
Where the service was made available in primary care this cost would be minimal. 
Health status of women recruited to IBIS was measured using the SF36. This proved 
to be a practical and acceptable instrument for use in a postal questionnaire. 
Responses to the SF36 show that women recruited to IBIS have the same pattern of 
health as women in the general population across all of the health dimensions 
including physical functioning, role limitation (includes both physical and emotional), 
social functioning, pain, mental health energy/fatigue and general health perception. 
Energy and fatigue has the lowest score for both groups. There is also no significant 
difference in any of the health dimensions between the 2 arms of the trial. There 
appear to be no adverse effects on quality of life for women taking long teen 
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tamoxifen prophylaxis and no adjustment for quality of life is needed in assessing cost 
effectiveness. 
The cost effectiveness of tamoxifen chemoprophylaxis can be compared with other 
means of reducing breast cancer incidence although there are problems of 
comparability particularly in estimating the savings from the cost of breast cancer 
prevented. Boer and de Koning 12 published cost effectiveness estimates for the 
current programme of £25,142 per death prevented and £24,205 or £27,865 for 
extending the age range to 65 or reducing the interval to two years respectively. The 
estimates for cost effectiveness of tamoxifen prophylaxis fall below this range 
providing that the effect of risk reduction translates into a mortality benefit. Further 
assessment of whether the results for reduction in incidence found in the NSABP P1 
represent a delay in the development of cancers or a permanent benefit is also an 
important priority for further research. Estimates for the cost effectiveness of early 
treatment for breast cancer to year 10 of between £10,625 ($17,000) per death 
prevented for women at all ages in the highest risk categories to £31,250 ($50,000) for 
women at any age at a lower risk of death are substantially more favourable than for 
breast screening outcomes though may be considered comparable to the range of cost 
effectiveness reported here for tamoxifen chemoprophylaxis. 
There is insufficient information on the present management of women at high risk 
for breast cancer to compare with the costs estimated for chemoprophylaxis of breast 
cancer. Bilateral prophylactic mastectomy has been a treatment choice for some 
women though there are few routine data available to assess the frequency of use of 
this approach, its survival advantage or cost effectiveness. ' 3 Annual mammography 
has also been suggested for women in high-risk categories though there are no data at 
present to assess the efficacy or cost effectiveness of this approach. 
To date no other cost effectiveness studies of breast cancer chemoprevention have 
been published. Yet a complete understanding of the value of chemoprophylaxis of 
breast cancer will rely on the impact of long term drug use on morbidity and on the 
quality of life and the well being of the women as well as the cost of service delivery. 
Further research is needed to 
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" Monitor the long term consequences of tamoxifen use on the general health and 
morbidity of women. Small changes in the use of hospital services or prescribed 
medications for the age group targeted in prevention trials could have a significant 
impact on the overall cost of tamoxifen chemoprophylaxis because of the 
potentially large numbers of women involved. 
" Further work is needed to assess whether the effects found in the NSABP P1 study 
measure a delay in breast cancer mortality rather than prevention. 
In general research on alternative means of reducing mortality and morbidity from 
breast cancer should be pursued. An understanding of the biological plausibility of 
causal link between dietary fat and breast cancer discussed in this study cannot 
exclude the possible importance of diet at key development stages. In particular, the 
relationship with onset of menarche and early adolescence where the impact of diet on 
breast carcinogenesis may be profound. Further research is needed to address this 
issue. A number of randomised controlled trials are underway in the USA although 
these are focussing only on the recruitment of adult women. There are difficulties in 
undertaking prevention trials because of the concerns raised by ethics committees 
about the recruitment of healthy women and because of the numbers of women 
involved. 
Long term breast cancer adjuvant studies are useful in providing information on the 
safety of trials for tamoxifen prophylaxis but more detailed studies are needed to 
assess the effect of long term exposure to tamoxifen for chemoprevention of breast 
cancer in healthy asymptomatic women. 
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